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Résumé 
Les facteurs de risque des maladies cardiovasculaires, telle, que la détérioration du 
profil lipidique, deviennent plus prononcés après la ménopause, ce qui fait de la maladie 
coronarienne, l’une des principales causes de décès chez les femmes ménopausées. Une 
proportion importante de femmes prennent du poids après la ménopause en particulier dans 
la région abdominale entraînant par conséquent des perturbations métaboliques. Des 
données récentes suggèrent également que l’absence des œstrogènes observée à la 
ménopause favorise le développement de la stéatose hépatique. Cette dernière a été 
incriminée pour incriminée dans le développement de la résistance à l'insuline, et est de ce 
fait considérée comme une composante hépatique du syndrome métabolique. Il est 
impératif d'établir des stratégies visant à contrecarrer l'accumulation de graisse dans le foie 
et l’accroissement du tissu adipeux chez les femmes ménopausées, en tenant compte que 
l'utilisation de l'hormonothérapie substitutive est de nos jours moins soutenue. Les quatre 
études de la présente thèse ont été conduites pour tenter de fournir des informations sur le 
traitement et la prévention de l’augmentation de la masse graisseuse et de la stéatose 
hépatique qu’entraîne la suppression des œstrogènes, à travers les modifications du mode 
de vie (diète et exercice physique) chez la rate ovariectomizée (Ovx); un modèle animal de 
la ménopause. 
Dans les deux premières études nous nous sommes concentrés sur l’augmentation 
de la masse graisseuse et sa reprise suite à une perte de poids. Dans la première étude, nous 
avons montré que les rates Ovx qui ont suivi un programme de restriction alimentaire (FR) 
ont diminué significativement (P < 0.01) leur poids corporel, leur contenu en graisses intra-
abdominales ainsi que leurs triacylglycérols (TAG) hépatiques, comparativement aux rates 
Ovx nourries à la diète normale. De plus, l’entraînement en résistance (RT) a prévenu la 
reprise de poids corporel ainsi que l’accroissement du tissu adipeux et l’accumulation de 
lipides dans le foie des rates Ovx, après l’arrêt du régime amaigrissant. Les résultats de la 
deuxième étude ont confirmé l'efficacité de la restriction alimentaire associée à 
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l’entraînement en résistance (FR + RT) dans la réduction du poids corporel, des lipides 
dans le foie et le tissu adipeux chez les rates Ovx. Tenant compte des résultats de notre 
première étude, l’entraînement en résistance seulement a constitué un atout pour atténuer le 
poids corporel et la masse grasse reprise par les rates Ovx suite à un programme de perte de 
poids (FR + RT); bien que l'impact ait été moindre comparé au maintien seul de la 
restriction alimentaire. De la même manière que la supplémentation en œstrogènes, les 
résultats de la troisième étude indiquent que l'entraînement en endurance mené 
concurremment avec l’ovariectomie a significativement atténué l'accumulation de lipides 
dans le foie ainsi que dans le tissu adipeux. Toutefois, l’entraînement en endurance effectué 
avant l'ovariectomie n'a pas protégé contre l'accumulation des graisses qu’entraîne 
l'ovariectomie, si celui-ci est interrompu après l'ovariectomie. Enfin, pour compléter les 
résultats antérieurs, nous avons montré dans la quatrième étude que l’expression des gènes 
impliqués dans la synthèse de lipide; SREBP-1c, SCD-1, ChREBP, et ACC dans le foie a 
augmenté après le retrait des œstrogènes, tandis qu’une diminution (P < 0.01) des niveaux 
d'ARNm de PPAR-α a été observée.  De plus, l'expression hépatique des gènes des 
cytokines pro-inflammatoires incluant IKKβ, IL-6 ainsi que le contenu protéinique de NF-
кB étaient augmentés (P < 0.01) chez les rates Ovx par rapport aux rates ayant subi une 
Ovx simulée (Sham). Toutes ces perturbations ont été améliorées avec la supplémentation 
en œstrogènes seulement, ainsi qu'avec l'entraînement en endurance seulement.  
Dans l'ensemble, nos résultats indiquent que l'exercice physique (en résistance ou en 
endurance) a un impact significatif sur la réduction de l'accumulation des lipides dans le 
foie et dans le tissu adipeux des rates Ovx. De plus, chez les rates Ovx, l’entraînement en 
endurance mimerait les effets des œstrogènes sur l'expression des gènes impliqués dans 
l'accumulation de lipides et l’inflammation préclinique dans le foie.  
 
Mots-clés : Œstrogènes, Obésité ménopausique, Reprise de poids et de graisse, Foie gras, 
Restriction alimentaire, Entraînement en résistance, Entraînement en endurance, Bio-
marqueurs de l'inflammation, Ovariectomie (Ovx), Rat 
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Abstract 
Cardiovascular disease risk factors, such as lipid profile deterioration, become more 
pronounced after menopause making coronary heart disease a leading cause of death among 
postmenopausal women. A large proportion of women after menopause gain weight 
especially in the abdominal region resulting in several metabolic disturbances. Recent 
evidence also suggests that loss of estrogen function in menopause is associated with the 
development of a state of hepatic steatosis. Excessive fat accumulation in hepatocytes has 
been shown to play an important role in the development of insulin resistance and is even 
considered as a hepatic component of the metabolic syndrome. There is an important need 
to establish strategies to counteract fat accumulation in adipocyte and liver in 
postmenopausal women specifically considering the fact that utilization of hormone 
replacement therapy is now less supported. The four studies of the present thesis have been 
conducted in an attempt to provide information on the treatment and prevention of estrogen 
withdrawal-induced fat mass and hepatic steatosis via lifestyle modifications (diet and 
exercise training) in an ovariectomized (Ovx) rat model of menopause.  
In the first two studies we focused on fat mass gain and regain following weight 
loss. In study 1, we showed that food restriction program (FR) decreased (P < 0.01) body 
mass, intra-abdominal fat pad weight, and liver triacylglycerol (TAG) levels as compared to 
normally fed Ovx rats. Moreover, resistance training program (RT) was useful in 
preventing body weight as well as adipose tissue and liver fat regain in Ovx rats, following 
diet-induced weight loss. Results of study 2 confirmed the efficiency of the FR + RT 
program in reducing body weight as well as liver and adipocytes fat accretion in Ovx rats. 
In line with the findings of our first study, continuation of only RT constituted an asset to 
attenuate body weight and fat mass regain in Ovx rats following a FR + RT weight loss 
program, although the impact was less than maintaining FR alone. Similar to estrogen 
supplementation, results of study 3 indicated that endurance exercise training conducted 
concurrently with the induction of ovariectomy significantly attenuated liver and adipocyte 
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fat accumulation. However, an endurance exercise training state acquired before 
ovariectomy did not provide any protective effects against ovariectomy-induced fat 
accumulation if exercise is discontinued after the ovariectomy. Finally, complementing 
previous findings we showed in study 4 that liver gene expressions of transcription factors 
SREBP-1c and ChREBP along with downstream lipogenic enzymes SCD-1 and ACC were 
increased with estrogens withdrawal conversely to reduced PPAR-α mRNA levels (P < 
0.01). Furthermore, gene expressions of pro-inflammatory cytokines including IKKβ and 
IL-6 as well as protein content of NF-кB were higher (P < 0.01) in the liver of Ovx than in 
Sham animals. All of these responses were corrected with estrogen supplementation alone 
as well as with endurance exercise training alone in Ovx rats.  
On the whole, our results indicate that exercise training (resistance or endurance) 
has a significant impact on reducing fat accumulation in liver and adipocytes in Ovx rats. In 
addition, it seems that endurance exercise training in Ovx rats stimulates estrogenic-like 
effects on the expression of genes involved in lipid accumulation and sub-clinical 
inflammation in the liver. 
 
Keywords: Estrogen, Menopausal obesity, Weight and fat regain, Hepatic steatosis, Food 
restriction, Resistance training, Endurance exercise training, Inflammatory bio-markers, 
Ovariectomy (Ovx), Rat 
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 Introduction 
One of the subpopulations in which the prevalence of obesity and overweight is 
growing rapidly is postmenopausal women. Although it is not yet clear whether the 
menopausal transition itself leads to weight gain, it is known that the physiological 
withdrawal of estrogen brings about changes in fat distribution that increase the risk for the 
metabolic syndrome, diabetes, and cardiovascular disease [Dubnov-Raz, Pines et al. 2007]. 
In fact, with arrival of menopause, women experience an increase in body weight and 
alterations in body composition, with a tendency for intra-abdominal (visceral or central) 
fat accumulation [Brochu, Starling et al. 2000]. Increased intra-abdominal fat is strongly 
associated with insulin resistance and cardiovascular complications, while the same amount 
of lower body fat seems to have a protective effect [Kopelman 2000; Okura, Nakata et al. 
2004]. Remarkably, postmenopausal women tend to accumulate fat outside the adipose 
tissue (mainly in the liver) referred to as ectopic lipid deposition, which may be the cause 
of deleterious metabolic complications [Volzke, Schwarz et al. 2007; Kotronen and Yki-
Jarvinen 2008]. On the other hand, there is growing evidence of the metabolic and 
cardiovascular impact of liver lipid infiltration [Johnson, Sachinwalla et al. 2009] and 
interventions which reduce hepatic fat concentration are often accompanied with significant 
improvements in metabolic function such as insulin resistance and cardiovascular metabolic 
disturbances [Petersen, Dufour et al. 2005]. These observations highlight the importance of 
understanding the molecular and physiological mechanisms that underlie menopause-
associated obesity and metabolic dysregulation. Therefore, it is relevant to investigate 
possible strategies and their underlying mechanisms for the prevention/treatment of 
adipocyte and liver fat accumulation in the estrogen-deficient state. 
The four studies presented in this thesis have been conducted in an attempt to 
provide information on the treatment and prevention of estrogen withdrawal-induced fat 
mass increase and hepatic steatosis by lifestyle modifications (diet and exercise training) in 
ovariectomized (Ovx) rat model of menopause. Rodent ovariectomy is one approach to 
modeling human menopause and studying the metabolic consequences of loss of ovarian 
function. Studies in rodents consistently demonstrate that Ovx promotes obesity and its 
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metabolic complications. Using the Ovx model, we addressed several questions regarding 
regulation of adipocytes and liver fat accumulation.  
In the first study, we tested the hypothesis that substituting food restriction (FR) by 
resistance training (RT) after a period of weight loss would maintain the decrease in fat 
accumulation in liver and adipose tissue that occurs with weight loss in Ovx rats. In line 
with this approach, the second study investigated the effect of maintaining RT or FR on 
body weight regain, fat mass, and liver lipid infiltration in estrogen deficient animals 
previously submitted to a FR + RT weight loss program. An interesting question related to 
exercise and estrogen withdrawal is whether women who exercise regularly during their 
reproductive period are protected against the deleterious metabolic effects of menopause. 
Therefore, in the third study, we addressed this question using an animal model that 
allowed us to test a complete design of trained and untrained animals before and after 
withdrawal of estrogens. In continuation with our third study, the aim of the fourth study 
was to test the hypothesis that exercise training reduces the expression of key molecules 
involved in lipid synthesis while favoring the expression of molecules involved in fat 
oxidation. The second objective of this last study was to investigate the effects of 
ovariectomy and exercise training on gene expression of inflammatory markers in the liver. 
This thesis comprised seven chapters. The first section of chapter 1 presents a 
review of literature on the emergence of metabolic syndrome (intra-abdominal fat) and 
hepatic steatosis in the postmenopausal hormonal state, and their treatment and prevention 
by lifestyle modifications (exercise training). In the second part, a review on the pathogenic 
role of sub-acute inflammation in obesity and insulin resistance is presented. Chapters 2-5 
introduce the experimental studies of this thesis that are presented according to the format 
required by the journals in which they are published or have been submitted to and have the 
references provided at the end of each study. Finally, chapter 6 presents a general 
discussion and conclusion on the studies presented in this dissertation. Chapter 7 presents 
thesis references. 
  
Chapter 1: Review of literature 
 
Emergence of metabolic syndrome and hepatic steatosis in 
menopausal hormonal state: treatment and prevention by 
exercise training 
 
Cardiovascular disease in postmenopausal women 
Gender differences in the development of cardiovascular disease (CVD) are well 
documented. Female gender is comparatively protected against CVD in the reproductive 
age range [Loria, Lonardo et al. 2008]. However, coronary heart disease (CHD) is a main 
and leading cause of death in women [Wingo, Calle et al. 2000]. Early epidemiological 
studies indicated higher incidence of the disease in postmenopausal women compared to 
women of reproductive age [Gordon, Kannel et al. 1978; Rosenberg, Hennekens et al. 
1981; Colditz, Willett et al. 1987; Matthews, Meilahn et al. 1989]. Accordingly, 
cardiovascular diseases are more prevalent in men than in premenopausal women, but the 
incidence increases sharply in postmenopausal women [Wenger, Speroff et al. 1993]. 
Menopause is characterized by the progressive reduction of estrogens resulting to cessation 
of menses [Mastorakos, Valsamakis et al. 2010]. Strategies to prevent CVD in this 
population should therefore be a principal objective for healthcare providers. 
Based on above evidence, the hypothesis that estrogens have protective effect 
against atherosclerosis has been put forward. Studies that have investigated the role of age 
at menarche and the calculated total lifetime exposure to endogenous estrogen, indicate that 
endogenous estrogens appear to play a protective role for the cardiovascular system [de 
Kleijn, van der Schouw et al. 2002; Jansen, Temme et al. 2002; Saltiki, Doukas et al. 2006]. 
These studies conclude that shorter lifetime exposure to endogenous estrogens is an 
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important risk factor for the presence and the severity of coronary heart disease. It is known 
that estrogens exert several protective effects on the cardiovascular system such as 
favorably modifying the lipid profile by increasing high density lipoprotein (HDL) and 
lowering low density lipoprotein (LDL) while also improving endothelial function 
[Lieberman, Gerhard et al. 1994]. The lack of these estrogenic effects at the time of 
menopause results in deleterious metabolic changes that not only negatively affect lipids 
but also fat redistribution and insulin resistance [Seed 2002]. Therefore, although we have 
to be careful on the effect of age, menopause can be considered a risk factor for CVD 
because estrogen withdrawal has a negative effect on cardiovascular functions and 
metabolism. Menopause negatively impacts upon many traditional risk factors for CVD, 
including changes in body fat distribution from a gynoid to an android pattern, reduced 
glucose tolerance, abnormal plasma lipids, increased blood pressure, endothelial 
dysfunction and vascular inflammation [Rosano, Vitale et al. 2007]. Based on these data, 
hormone replacement therapy in postmenopausal women was the first line prescription by 
physicians for many years and numerous observational studies suggested a cardiovascular 
benefit in women taking postmenopausal hormone replacement therapy [Psaty, Heckbert et 
al. 1994; Sidney, Petitti et al. 1997; Grodstein, Manson et al. 2000].  However, in recent 
years, large prospective and randomized trial studies such as the Women’s Health Initiative 
(WHI) reported no CHD benefit by hormone replacement therapy and even suggested a 
possible increased incidence of CVD [Rossouw, Anderson et al. 2002]. Although no 
specific mechanism has yet fully explained this paradox, several potential adverse 
consequences from estrogen therapy relative to CHD risk have been proposed, such as 
elevations in TAGs and C-reactive protein (CRP) along with increased likelihood of 
thrombus formation; all of which have been implicated in increasing CHD risk in women 
[Welty 2001; Alexander and Clearfield 2006]. Moreover, from a clinical standpoint, the 
protection conferred by initiating hormone replacement therapy soon after the menopause is 
small [2006]. Therefore, it seems that prevention of CVD or CHD in postmenopausal 
women have to mostly rely on well-established interventions such as diet and exercise 
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which should be vigorously emphasized by health care providers at the time of menopause 
[2006; Alexander and Clearfield 2006].  
 
Menopausal obesity and the emergence of metabolic syndrome 
The prevalence of obesity and type 2 diabetes mellitus (T2DM) is rapidly increasing 
worldwide. The public health consequences of this situation are devastating and recognized 
by practically every major international health organization. Obesity is first and foremost a 
problem of energy imbalance (energy intake exceeds energy expenditure); and 
unfortunately, women who can expect to live almost more than a third of their lives after 
menopause; are disproportionately affected by obesity and its co-morbidities such as 
aforementioned CVD. Review of the relevant literature and results from recent clinical trial 
studies indicate that 60% of postmenopausal women are considered overweight and obese 
and 43% present the metabolic syndrome [Ford, Giles et al. 2002]. In addition, 
postmenopausal status is associated with a 60% increased risk of the metabolic syndrome, 
even after adjusting for confounding variables, such as age, body mass index, household 
income, and physical inactivity [Park, Zhu et al. 2003]. Menopausal obesity-related CVD 
become a leading cause of morbidity and mortality in women after fifty years of age 
[Simoncig-Netjasov, Vujovic et al. 2008]. In parallel there is an increased prevalence of 
cardiometabolic abnormalities in the transition from pre- to postmenopause such as 
increased central (intra-abdominal/visceral/abdominal) body fat, a shift toward a more 
atherogenic lipid profile, increased blood pressure, and glucose intolerance along with 
reduced insulin sensitivity and high prevalence of nonalcoholic fatty liver disease 
(NAFLD); elucidating the noticeable increase of rate in CVD after menopause [Carr 2003; 
Clark 2006]. It has been suggested that there is a metabolic syndrome resulting from the 
menopause due to estrogen deficiency, as many of the risk factors are more prevalent in 
postmenopausal women [Kaaja 2008]. Eshtiaghi et al. recently reported that menopause 
can be a predictor of metabolic syndrome independent of age [Eshtiaghi, Esteghamati et al. 
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2010]. The features of the metabolic syndrome include the accretion of visceral adiposity, 
insulin resistance, hypertension, and dyslipidemia (hypertriglyceridemia, reduced HDL, and 
increased small dense LDL particles) (Table 1) [Despres 1993]. The emergence of these 
risk factors may be a direct consequence of ovarian failure or alternatively, an indirect result 
of the metabolic cost of central fat redistribution with estrogen deficiency [Carr 2003]. 
Nevertheless, the exact mechanism linking menopausal hormonal context and its resulting 
visceral adiposity to the downstream metabolic diseases remains unclear.  
 
Menopause, weight gain and fat redistribution 
The rate of weight gain during the menopausal period is not consistent between 
studies [Panotopoulos, Raison et al. 1997]. While it is still unclear whether the menopause 
transition itself brings about weight gain [Crawford, Casey et al. 2000; Dubnov-Raz, Pines 
et al. 2007], there is good evidence that menopause is associated with weight gain and 
changes in fat distribution that increase the risk of cardiovascular diseases [Astrup 1999; 
Milewicz, Demissie et al. 2003; Genazzani and Gambacciani 2006]. Rosano et al. reported 
that postmenopausal women tend to gain weight from the first year of menopause and 
experience a redistribution of body fat from a gynoid to an android pattern [Rosano, Vitale 
et al. 2007]. There are two patterns of fat distribution: accumulation of fat centrally as intra-
abdominal fat (named android or apple shape); and accumulation of fat peripherally in the 
gluteo-femoral region (named gynoid or pear shape). Apple shape/android/intra-
abdominal/central/visceral fat deposition is associated with a higher risk of 
hypertriglyceridemia, insulin resistance, diabetes, and CVD, independently of overall 
obesity [Kannel, Cupples et al. 1991; Despres 1993]. It seems that estrogen promotes the 
accumulation of gluteo-femoral fat [Krotkiewski, Bjorntorp et al. 1983]. This may, at least 
partially, explains that fluctuations in reproductive hormone concentrations throughout 
women’s lives uniquely predispose them to excess weight gain. For example, menopause is  
  
 
7
Table 1. Taken from [Despres 1993] Features of the metabolic syndrome. 
 
 
1. Central obesity 
2. Insulin resistance 
3. Dyslipidemia 
a. Elevated TG 
b. Small dense LDL particles 
c. Reduced HDL 
4. High blood pressure  
5. Hypercoaguable state 
6. Pro-inflammatory state 
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one of the critical periods of a woman’s life during which weight gain and onset or 
worsening of obesity is favored [Pavon de Paz, Alameda Hernando et al. 2006]. 
Longitudinal and review of cross-sectional studies support the notion that the menopause 
transition, independently of aging process and total body fatness, is associated with an 
increase in abdominal and visceral adipose tissue accumulation [Tchernof, Calles-Escandon 
et al. 1998]. Alterations in regional adipose tissue metabolism along with positive energy 
imbalance resulting from hormonal changes of the menopause transition may be potential 
mechanisms for the menopause related acceleration in abdominal fat accumulation 
[Guthrie, Dennerstein et al. 2003] (Figure 1). Moreover, Lovejoy et al. in their recent 
observational-longitudinal study with annual measurements for 4 years reported that 
menopause onset is associated with reduced energy expenditure (both basal and physical 
activity) and fat oxidation that can predispose to obesity (total and visceral abdominal fat) if 
lifestyle changes are not made [Lovejoy, Champagne et al. 2008]. A menopause related 
decline in fat-free mass (muscle) is also reported which may be responsible for a decrease 
in energy expenditure [Colombel and Charbonnel 1997; Panotopoulos, Raison et al. 1997]. 
Intra-abdominal adipose tissue is thought to be the most important determinant for the 
constellation of metabolic disturbances, termed metabolic syndrome. Women with high 
amounts of visceral fat have an excess of cardiovascular mortality and associated metabolic 
abnormalities [Lapidus, Bengtsson et al. 1984]. Therefore, it is not surprising that review of 
the relevant literature and results from recent clinical trials indicate that metabolic 
syndrome may occur in at least 40% of postmenopausal women, which is largely 
determined by overweight status and obesity [Lobo 2008]. The prime emphasis in 
management of the metabolic syndrome and the prevention of CVD is to reduce underlying 
modifiable risk factors through lifestyle changes [Kaaja 2008]. Consequently, almost all 
concerned review studies support the importance of focusing on postmenopausal women, 
with the goal of weight reduction, increasing physical activity and encouraging healthy 
dietary choices to prevent weight and visceral fat gain in menopause transition [Sowers, 
Zheng et al. 2007; Kaaja 2008; Lobo 2008; Lovejoy, Champagne et al. 2008]. 
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Figure 1. Potential mechanisms explaining menopause-related increases in abdominal and 
intra-abdominal adiposity.   
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Menopause and hepatic steatosis 
Non-alcoholic fatty liver disease (NAFLD) 
Liver lies below the diaphragm in the thoracic region of the abdomen. This organ 
plays a major role in metabolism and has a wide range of functions including production of 
biochemicals necessary for digestion, glycogen storage, decomposition of red blood cells, 
protein synthesis, hormone production, and detoxification [Maton, Hopkins et al. 1993]. 
Liver is particularly vulnerable to ectopic fat accumulation [Bruce and Byrne 2009] that 
could result in NAFLD characterized by hepatic lipid accumulation in the absence of 
significant alcohol consumption. NAFLD is the most frequent chronic liver disease in 
Western countries [Angulo 2002] and its incidence in both adults and children is rapidly 
rising in conjunction with the burgeoning epidemics of obesity and T2DM [Stein, Dong et 
al. 2009]. NAFLD is defined as fatty infiltration of the liver exceeding 5 to 10% by weight 
[Salt 2004]. It includes a wide spectrum of disorders ranging from simple steatosis 
described by hepatic lipid accumulation in the form of triglyceride (TG) to nonalcoholic 
steatohepatitis (NASH) described by the association of lipid accumulation with evidence of 
hepatocyte injury, inflammation and different degrees of fibrosis [Brunt and Tiniakos 
2005]. NASH can also progress to cirrhosis and hepatocellular carcinoma. NAFLD is now 
considered the hepatic manifestation of metabolic syndrome and has insulin resistance as its 
feature [Musso, Gambino et al. 2003; Musso, Gambino et al. 2008]. Moreover, new 
evidence suggests that NAFLD is becoming a risk factor for diabetes and CVD; 
independently of insulin resistance, metabolic syndrome, plasma lipid levels, and other 
usual risk factors [Chitturi and Farrell 2007; Alkhouri, Tamimi et al. 2009]. It was reported 
that hepatic steatosis by itself is associated with a pro-atherogenic lipid profile [Cali, Zern 
et al. 2007] and increased production of pro-inflammatory markers [Wieckowska, 
Papouchado et al. 2008]. In support of this, recent epidemiological studies suggest that 
NAFLD may be dynamically involved in the pathogenesis of CVD, potentially through the 
increased release of pro-atherogenic markers from liver mainly inflammatory cytokines 
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[Targher, Marra et al. 2008]. Loria and et al. showed that many well-defined metabolic, 
haemodynamic, hormonal, pro-thrombotic and pro-inflammatory CVD risk factors play a 
major role in the complex pathophysiology of NAFLD (Table 2) [Loria, Lonardo et al. 
2008]. Moreover, they conclude that lipotoxicity derived from NAFLD represents a 
potential biological mechanism accounting for increased CVD risk, and there appears to be 
a close link between deranged energy homeostasis, inflammatory changes in adipose and 
liver tissues and molecular mediators of atherogenesis.  
On the other hand, NAFLD is involved in whole-body insulin resistance and 
dyslipidemia, although whether insulin resistance is a consequence of liver ectopic fat 
deposition or vice versa remains an unanswered question [Bruce and Byrne 2009]. Some 
researchers have proposed that with insulin resistance, the combination of increased plasma 
glucose and free fatty acids concentrations promote hepatic fatty acid synthesis and impair 
β-oxidation leading to hepatic steatosis [Marchesini, Brizi et al. 1999; Sanyal, Campbell-
Sargent et al. 2001]. On the contrary, other investigators have projected that liver fat 
accumulation and hepatic insulin resistance can happen without the development of 
peripheral insulin resistance [Kraegen, Clark et al. 1991; Kim, Fillmore et al. 2001]. 
However, when considerable hepatic steatosis occurs, liver becomes insulin resistant and 
overproduces both glucose and very low density lipoprotein (VLDL) leading to 
hyperglycemia, hypertriglyceridaemia, and decreased HDL concentrations [Kotronen and 
Yki-Jarvinen 2008]. Moreover, the results of Samuel et al. support the hypothesis that 
hepatic steatosis leads to hepatic insulin resistance by stimulating gluconeogenesis and 
activating protein kinase C-ε (PKC-ε) and c-Jun N-terminal protein kinase 1 (JNK1), which 
may interfere with tyrosine phosphorylation of insulin receptor substrate 1 and 2 (IRS-1 
and IRS-2) and impair the ability of insulin to activate glycogen synthase [Samuel, Liu et 
al. 2004]. 
The exact pathogenesis of hepatic lipid accumulation seems to be very complex and 
only partially understood. Nevertheless, it is a condition usually associated with obesity 
(particularly central abdominal obesity), diabetes, and insulin resistance. On the whole, the  
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Table 2. Taken from [Loria, Lonardo et al. 2008] Possible pathophysiological bases for an 
association between NAFLD and accelerated atherosclerosis. 
 
  
 
13
The left-hand column lists the widely accepted genetic and environmental risk factors for 
atherosclerosis. Interestingly, evidence is mounting that the same factors also play a role in 
the development of NAFLD. LDL, low density lipoprotein; VLDL, very-LDL; HDL, high 
density lipoprotein; ALT, alanine aminotransferase; HCV, hepatitis C virus; T2DM, type 2 
diabetes mellitus; PAI-1, plasminogen activator inhibitor-1; CRP, C-reactive protein.  
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general mechanism of liver fat accumulation involves an imbalance between lipid 
availability (from circulating lipid uptake or de novo lipogenesis) and lipid disposal 
(through fat oxidation or triglyceride-rich lipoprotein secretion) [Musso, Gambino et al. 
2009]. Excessive fat accumulation in the liver can occur as a result of: (i) increased fat 
delivery into the liver (dietary fatty acids and plasma non-esterified fatty acids derived from 
adipose tissue), (ii) increased fat synthesis in liver, (iii) reduced fat oxidation, and (iv) 
reduced fat export in the form of VLDL (see Figure 2 for an overview). Considering the 
complexity and heterogeneity of the mechanisms involved, it is quite difficult to imagine 
that it would be possible to identify a single gene variation as the single cause of the disease 
[Petta, Muratore et al. 2009]. Therefore many genes, related not only to fat accumulation 
but also to different mechanisms implicated in the disease progression, have been 
evaluated, and some polymorphisms capable of increasing the severity of the disease have 
been identified (Table 3) [Wilfred de Alwis and Day 2007]. 
According to Petta et al. [Petta, Muratore et al. 2009] body fat, insulin resistance, 
oxidative stress and mitochondrial dysfunction, cytokine/adipokine interplay, and apoptosis 
are risk factors of NAFLD. Most interestingly, recent data indicates that intra-abdominal 
(visceral) fat likely plays a pivotal role in the pathogenesis of NAFLD [Thomas, Hamilton 
et al. 2005] affecting all above mentioned risk factors. In effect, visceral fat acts as an 
endocrine storage organ, secreting different molecular mediators such as FFA, adiponectin, 
leptin, TNF, IL-6, etc; and participating directly in NAFLD pathogenesis in different ways, 
dependently or independently of insulin resistance, therefore contributing to liver fat 
accumulation [Ronti, Lupattelli et al. 2006]. To date, the most effective treatments of 
NAFLD are lifestyle changes (diet, weight reduction, and exercise) [Williams, Sander et al. 
2006]. However, the front-line therapy with lifestyle modifications resulting in weight loss 
through decreased caloric intake and exercise is often difficult to maintain on a long term 
basis [Stein, Dong et al. 2009]. Therefore, information regarding fat accumulation in liver 
and adipocytes is needed to establish the most effective strategies to prevent and treat 
NAFLD and to counteract the deleterious metabolic effects of NAFLD. 
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Figure 2. Taken from [Lavoie and Gauthier 2006] Overview of the four main pathways 
involved in the development of nonalcoholic hepatic steatosis, and their regulatory factors. 
Nonalcoholic hepatic steatosis is characterized by (1) an increase in the uptake of lipids by 
the liver, (2) an increase in hepatic de novo lipogenesis (DNL), and an insufficient 
elimination of excess liver triacylglycerols (TAGs) by means of (3) hepatic lipid oxidation 
and (4) very low density lipoprotein (VLDL) assembly and secretion. HSL, hormone-
sensitive lipase; LPL, lipoprotein lipase; FAT/CD36, fatty acid translocase/cluster of 
differentiation 36; SREBP-1c, sterol-regulatory-element-binding protein 1c; ChREBP, 
carbohydrate-response-element-binding protein; LXR, liver X receptors; PPAR, 
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peroxisomal proliferator-activated receptors; SCD-1, stearoyl-CoA desaturase-1; AMPK, 
AMP-activated protein kinase; PGC-1α, peroxisome proliferator-activated receptor gamma 
coactivator-1 alpha; MTP, microsomal transfer protein; DGAT, diacyglycerol 
acyltransferase; ARF-1, ADP-ribosylation factor 1; ApoB, apolipoprotein B.  
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Table 3. Taken from [Wilfred de Alwis and Day 2007] Genes potentially involved in the 
pathogenesis of nonalcoholic fatty liver disease (NAFLD). 
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RXR, retinoid X receptor; LXR, liver X receptor; SREBP, sterol responsive element 
binding protein; ChREBP, carbohydrate responsive element binding protein; MTP, 
microsomal triglyceride transfer protein; PPARα, peroxisome proliferator-activated 
receptor α; PPARγ, peroxisome proliferator-activated receptor γ; RBP4, retinol binding 
protein 4; TNFα, tumor necrosis factor α; IL-6, interleukin-6; SOCS, suppressor of 
cytokine signaling; PPA2, protein phosphatase A2; SOD, superoxide dismutase; GST, 
glutathione transferase; GSH, glutathione peroxidase; TLR, Toll-like receptor; MnSOD, 
manganese superoxide dismutase; MAO, monoamine oxidase; AFABP, adipocyte fatty 
acid binding protein; IL-10, interleukin-10; MCP1, monocyte chemoattractant protein-1; 
TNFR, tumor necrosis factor receptor; KLF6, Kupper-like factor 6; CTGF, connective 
tissue growth factor; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of matrix 
metalloproteinase.  
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NAFLD in postmenopausal women 
Gender may influence the incidence and severity of NAFLD. Women are protected 
from the occurrence of CVD and NAFLD [Isidori, Giannetta et al. 2005; Lonardo, Carani 
et al. 2006]; however, similarly to CVD and atherosclerosis, the estrogen-related hepato-
protective effect disappears after menopause [Carulli, Lonardo et al. 2006].  Population-
based studies showed that nonalcoholic hepatic steatosis is more common in men than in 
women; however, following the menopause there is a reversal in gender distribution so that 
NAFLD is more common in females [Park, Jeon et al. 2006]. In fact, nonalcoholic hepatic 
steatosis is twice as common in postmenopausal compared to premenopausal women 
[Hagymasi, Reismann et al. 2009]. It seems that endogenous estrogens play a protective 
role against the hepatic steatosis. Basic and clinical studies support the hypothesis that 
estrogens might protect from the development of NAFLD [Carulli, Lonardo et al. 2006; 
Lonardo, Carani et al. 2006]. For instance, anti-estrogens increase the risk of nonalcoholic 
steatohepatisis [Bruno, Maisonneuve et al. 2005]. In addition, alterations in body 
composition, fat distribution and/or hormonal or metabolic changes that occur following 
menopause may influence the development and progression of NAFLD [Suzuki and 
Abdelmalek 2009]. Therefore, it is logical that several studies indicated that menopause as 
a natural state of estrogen deficiency is associated with hepatic steatosis [Clark, Brancati et 
al. 2002; Park, Jeon et al. 2006; Volzke, Schwarz et al. 2007]. The importance of this 
phenomenon is enlightened by the fact that excessive fat accumulation in liver plays an 
important role in the development of insulin resistance [Kadowaki, Hara et al. 2003]. 
Furtheremore, there is a widespread agreement that NAFLD predicts CVD [Bataller, 
Sancho-Bru et al. 2003]. Increased fat accumulation in the liver is accompanied by 
atherosclerosis and the metabolic syndrome [Brea, Mosquera et al. 2005; Villanova, 
Moscatiello et al. 2005; Targher, Bertolini et al. 2006; Targher, Bertolini et al. 2007; 
Tolman, Fonseca et al. 2007], even independently of intra-abdominal visceral adiposity 
[Nguyen-Duy, Nichaman et al. 2003; Thamer, Machann et al. 2007]. New findings even 
indicate that ectopic fat in liver may be more important than visceral fat in characterization 
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of metabolically benign obesity in humans with which and atherosclerosis has been 
proposed to exist [Stefan, Kantartzis et al. 2008; Messier, Karelis et al. 2010].  Moreover, 
Tarantino et al. claim that “hepatocytes are the last cells to be involved in the progressive 
chain of fat accumulation and probably the first cells to tell us that something is wrong” 
[Tarantino, Pizza et al. 2009]. While it is not completely clear yet, the general association 
between NAFLD and CVD has just been established by the fact that the liver is involved in 
regulating/secreting numerous CVD risk factors, notably a cytokine tumor necrosis factor-
alpha (TNF-α), an acute-phase protein CRP, glucose, lipoproteins, coagulation factors 
(plasminogen activator inhibitor-1) and a substance which increases blood pressure 
(angiotensin II) [Tarantino, Pizza et al. 2009]. Therefore, due to the increasing prevalence 
and association with other metabolic disorders in postmenopausal women, it is important 
that clinicians gain a deep understanding of NAFLD and its clinical presentation as well as 
therapeutic options in the absence of ovarian secretions. Consequently, information relative 
to cellular and molecular mechanisms involved in the development of hepatic steatosis in 
menopausal status has clinical importance. It seems that hormone replacement therapy 
decreases the risk of steatosis [Hagymasi, Reismann et al. 2009] and the prevalence of 
NAFLD is lower in postmenopausal women taking hormone replacement therapy than in 
women not taking it [Clark, Brancati et al. 2002]. Nevertheless, although hormone 
replacement therapy appears safe in NAFLD, it is not recommended for liver protection 
because of the increased risk of cardiovascular events [Rossouw, Anderson et al. 2002; 
McKenzie, Fisher et al. 2006]. A recent review on NAFLD in older women reported that at 
present, there are no specific or effective pharmacological treatments available; and 
lifestyle modifications with weight loss and exercise are regarded as first line treatments 
[Frith and Newton 2010]; as this is the case for the management of metabolic syndrome. 
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General mechanisms of adipocyte fat accumulation and hepatic steatosis in rat model 
of menopause 
Among the several endocrine factors that are accountable for the development of 
obesity, female ovarian hormones have been shown to play a major role [Picard, Deshaies 
et al. 2000]. Animal models and molecular markers are precious research tools to 
understand the process leading to adipocyte and liver fat accumulation in a postmenopausal 
hormonal context. The Ovariectomized (Ovx) rat model of menopause is a model 
resembling the decline in estrogen levels in postmenopausal women, which is at least 
partially responsible for the increase in osteoporotic fractures and cardiovascular diseases 
[Gallo, Zannoni et al. 2005]. In addition, the Ovx rat model may be considered as an 
experimental model of postmenopausal obesity that may also resemble the characteristic 
features of a metabolic syndrome occurring in menopause; therefore, Ovx rats can be used 
as models to reflect the lipid pathogenic changes in perimenopausal or postmenopausal 
women [Wang, Guo et al. 2004]. This will help to investigate possible lifestyle intervention 
or new pharmacological treatments. 
It is now well established that in animals, Ovx leads to increased food intake and 
body weight [Latour, Shinoda et al. 2001] thus resulting in increased adipose tissue and 
liver fat accretion [Deshaies, Dagnault et al. 1997; Picard, Deshaies et al. 2000]. Data from 
observational and clinical trials evidently show that estrogens possess favorable metabolic 
effects and estrogen treatment has been shown to decrease body weight gain and fat 
accumulation in both animals and humans [Tchernof, Calles-Escandon et al. 1998; 
Seidlova-Wuttke, Hesse et al. 2003; Seidlova-Wuttke, Jarry et al. 2003]. Although hard to 
separate specifically, estrogens act through two general actions regarding the pathogenesis 
of Ovx induced fat gain: central effects of estrogens withdrawal (increased food intake and 
decreased energy expenditure resulting in adipocyte fat gain preferably in intra-abdominal 
region; since our focus is on hepatic fat accumulation, in our research work we call it 
‘‘extra-hepatic effects of estrogens’’) and ectopic effects of estrogens withdrawal (or intra-
hepatic: affecting ectopic tissue of liver at molecular level resulting in ectopic fat 
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accumulation). There might be interactions between two effects of estrogens in terms of 
adipocyte and ectopic fat accumulation. For example, central effects are indirectly involved 
in liver fat accumulation via increased fatty acid flow into the liver from circulation (arising 
from increased food intake and higher intra-abdominal fat depositions). 
  
Mechanisms of estrogen action in brief 
It is now well recognized that the effects of estrogens are not limited to the female 
reproductive system and almost all tissues are under estrogenic influence in both men and 
women [Ciocca and Roig 1995; Matthews and Gustafsson 2003]. Epidemiological and 
clinical evidence strongly suggest that estrogens, in particular 17β-estradiol (E2) the most 
potent and dominant estrogen in mammals, play an important regulatory role in the 
metabolism and regional distribution of adipose tissue [Wade and Gray 1978; Ohlsson, 
Hellberg et al. 2000; Mayes and Watson 2004]. Estrogen deficiency leads to increased fat, 
preferentially in visceral fat, which would link obesity to the susceptibility of related 
disorders [Pallottini, Bulzomi et al. 2008]. Estrogens promote subcutaneous fat depot after 
sexual maturation [Ohlsson, Hellberg et al. 2000]. Conversely, in postmenopausal women 
abdominal fat increases [Sjostrom, Smith et al. 1972]. It seems that E2 controls fat 
distribution by changing the lipolytic response into the two fat depots differentially, thus 
favoring fat accumulation in peripheral depots at the expense of the visceral depot 
[Pallottini, Bulzomi et al. 2008]. Estrogens also regulate activity of lipoprotein lipase 
(LPL), a major lipogenic enzyme in adipose tissue [Hamosh and Hamosh 1975]. It has been 
shown in several studies that ovariectomy in female rats results in increased LPL, while 
estrogen replacement decreased the LPL activity [Mayes and Watson 2004]. 
Moreover, in recent years it has become evident that estrogens’ role in adipose 
tissue biology and lipid metabolism may be broader and more complex than initially 
appreciated. It seems that active metabolic tissues, such as the liver, are particularly 
sensible to estrogen effects in terms of different functions including lipid metabolism. The 
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molecular and biological mechanisms underlying the metabolic actions of estrogen in liver 
are poorly understood. Estrogen is a steroid hormone mainly produced by ovaries. Its 
actions are predominantly mediated by genomic mechanisms through its nuclear receptors 
(ER) α or β [Bjornstrom and Sjoberg 2005]. ERs are ligand-activated transcription factors 
that mediate estrogens’ biological actions in liver and it was shown that ER diminishes 
sharply at postmenopause [Shimizu 2003; Meza-Munoz, Fajardo et al. 2006]. Outstanding 
advancements in recent years suggested that estrogens action in vivo is complex and often 
involves activation of cytoplasmic signaling cascades in addition to genomic actions 
mediated directly through estrogen receptors α and β; and might simultaneously activate 
distinct signaling cascades that function as networks to coordinate tissue responses to 
estrogen [Segars and Driggers 2002]. These orchestrating distinct signaling pathways 
which involves specific complexes of cytoplasmic proteins might supplement or augment 
genomic effects of estrogen that are attributable to transcriptional activation by bound 
receptors [Driggers and Segars 2002]. Therefore, it is not surprising that E2 has been shown 
to exert rapid non-genomic biological actions through membrane bound subpopulations of 
ER [Kelly and Levin 2001; Evinger and Levin 2005; Revankar, Cimino et al. 2005]. 
Interestingly, D’Eon et al. reported novel genomic and non-genomic actions of E2 that 
promote leanness in Ovx animals independently of reduced energy intake [D'Eon, Souza et 
al. 2005]. Moreover, it has been suggested that E2 reduces adiposity by promoting the use 
of lipid as fuel which is recognized by the stimulation of pathways that promote fat 
oxidation in muscle, by inhibition of lipogenesis in adipose tissue, liver, and muscle; and by 
improved rates of adipocyte lipolysis [Pallottini, Bulzomi et al. 2008]. 
 
Central (extra-hepatic) effects of estrogen withdrawal 
Obesity results from an imbalance between energy intake and expenditure. Since 
hyperphagia is a well known response to Ovx and is prevented if estradiol is replaced, 
many of the effects attributed to estradiol may be explained primarily by changes in food 
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intake [Richard 1986]. In fact, one view of Ovx-induced obesity is that estrogen removal 
leads to a marked increase in body energy stores of the rat (via increased energy intake and 
food efficiency along with decreased energy expenditure), which leads to increased 
energetic efficiency [Picard, Deshaies et al. 2000; Lemieux, Picard et al. 2003]. This 
contributes to weight gain, especially as visceral or intra-abdominal fat, that has been 
reported in both Ovx animals [Paquette, Shinoda et al. 2007] and women during and after 
menopause [Simkin-Silverman and Wing 2000]. Consequently, determinants of lipid 
metabolism such as liver triacylglycerol (an index of long-term hepatic lipid accumulation) 
and adipose tissue lipoprotein lipase activity (the enzyme which hydrolyzes lipoprotein-
bound triglycerides and favors tissue uptake of so released fatty acids) are altered in 
correspondence with increased energy flux [Lemieux, Picard et al. 2003]. In other words, 
Ovx-induced increased energy efficiency is accompanied by concomitant adaptations of 
peripheral lipid metabolism that include the induction of pathways implicated in fat 
accumulation [Deshaies, Dagnault et al. 1997]. Therefore, the central effects of estrogen 
withdrawal indirectly (i.e. via food intake and changes in insulin levels and its efficiency of 
action) affect liver fat accumulation in Ovx animals [Picard, Deshaies et al. 2000]. Briefly, 
central effects of estrogen supplementation in Ovx rats have been shown to lower food 
intake [Gray and Wade 1981; Pedersen, Bruun et al. 2001], decrease adipose tissue 
lipoprotein lipase (LPL) activity [Gray and Greenwood 1984], increase adipose tissue 
lipolysis [Darimont, Delansorne et al. 1997], increase spontaneous physical activity [Roy 
and Wade 1975], and increase energy expenditure [Heine, Taylor et al. 2000; Pedersen, 
Bruun et al. 2001]. In regard to central effects of estrogen, Picard et al. state that Ovx 
induces obesity by removing the catabolic actions of estrogens, which act upon as yet 
poorly defined central neuropeptidergic pathways that regulate energy balance [Picard, 
Deshaies et al. 2000]. For example, estrogen has been reported to have negative effects on 
feeding and energy expenditure through direct actions on the hypothalamus and/or through 
indirect actions by regulating adipose hormones such as leptin, adiponectin, and resistin 
[Cooke and Naaz 2004].  
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Intra-hepatic effects of estrogen withdrawal 
Several conditions promote liver TAG accumulation among which an estrogen-
deficient state is considerable [Paquette, Shinoda et al. 2007; Barsalani, Pighon et al. 2008; 
Corriveau, Paquette et al. 2008]. For instance, hepatic steatosis was reported to become 
evident in an aromatase-deficient mouse (which lacks the intrinsic ability to produce 
estrogen) and was diminished in animals after treatment with estradiol [Nemoto, Toda et al. 
2000]. In addition, visceral obesity, metabolic syndrome with insulin resistance, and 
hepatic steatosis are the main features of the aromatase knockout (ArKO) mouse phenotype 
[Simpson, Jones et al. 2005]. Although many of the effects attributed to estrogens in the 
pathogenesis of Ovx-induced fat gain may be explained primarily by the central effects of 
estrogens mostly via changes in food intake, D’Eon et al. demonstrated that estrogen 
reduced adiposity in Ovx rodents which is not confounded by differences in food intake 
[D'Eon, Souza et al. 2005]. Their data are consistent with the phenotypes of both estrogen 
receptors-α (ERKO) knock-out and aromatase (and thus estrogen)-deficient mice, both of 
which exhibit increased adiposity with no reported differences in food intake [Heine, 
Taylor et al. 2000; Jones, Thorburn et al. 2000; Jones, Thorburn et al. 2001; Misso, Murata 
et al. 2003]. Moreover, the results of Beckett et al. suggest that estradiol regulates substrate 
metabolism in ectopic tissues such as skeletal muscles independent of changes in food 
intake [Beckett, Tchernof et al. 2002]. Taken together, these data show that the ovarian 
hormonal status has important ectopic effects at the molecular level in peripheral tissues 
such as the liver rather than only central effects of diet (amount or type) and energy 
expenditure [Barsalani, Pighon et al. 2008]. Fisher et al. reported that despite a similar food 
intake, Ovx-pair fed animals gained markedly more weight than did Sham animals and 
nearly as much as Ovx-ad libitum animals [Fisher, Kohrt et al. 2000]. Likewise, 
unpublished data from our lab indicate that pair-feeding in Ovx rats does not completely 
prevent liver fat accretion in rats. Therefore, there must be factors other than food intake in 
the pathogenesis of liver fat accumulation in estrogen-deficient states.  
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Some pathways leading to liver lipid infiltration in estrogen deprived states have 
been investigated. Increased lipid uptake by liver because of increased fatty acid flow from 
circulation coming from intra-abdominal fat deposition, attributed to the increased food 
intake after estrogen withdrawal, can primarily and partially explain hepatic fat 
accumulation. The portal/fatty acid flux theory suggests that visceral fat, via its unique 
location and enhanced lipolytic activity, releases toxic free fatty acids, which are delivered 
in high concentrations directly to the liver [Malavazos, Gobbo et al. 2009]. This leads to the 
accumulation and storage of hepatic fat and the development of hepatic insulin resistance 
[Xu, Barnes et al. 2003]. However, the portal/fatty acid flux theory has been questioned 
with the observation that the bulk of portal vein FFAs originate from subcutaneous adipose 
tissue in overnight-fasted obese individuals [Klein 2004]. Nevertheless, other mechanisms 
and pathways leading to hepatic steatosis in postmenopausal state need to be considered. 
Unfortunately, studies on the expression of lipid metabolism-related genes in the liver Ovx 
rats are limited.  
Enhanced uptake mechanisms of lipids by the liver resulting from estrogen 
deficiency could also play a role yet to be explored. As estrogen levels decline, there may 
be increased lipogenesis and reduced fatty acid oxidation within the liver [Suzuki and 
Abdelmalek 2009]. Thus, another possible pathway leading to hepatic steatosis is de novo 
lipogenesis. Liver synthesizes fatty acids de novo through a complex cytosolic 
polymerization in which acetyl-coenzyme A is converted to malonyl-CoA by ACC and 
undergoes several cycles of metabolic reactions to form one palmitate molecule [Fabbrini, 
Sullivan et al. 2010]. Liver de novo fatty acid synthesis is mostly regulated by three known 
transcription factors: SREBP-1c, ChREBP, and PPAR-γ [Hashimoto, Cook et al. 2000; 
Bugianesi, Leone et al. 2002; Matsusue, Haluzik et al. 2003; Evans, Barish et al. 2004]. 
SREBP1-c activates FAS and SCD-1 genes that are responsible for lipogenesis in the liver 
[Reddy and Rao 2006]. D’Eon et al. investigated the expression of several genes involved 
in the regulation of lipogenesis in the liver of Ovx-control and Ovx-estrogen (E2) 
replacement mice [D'Eon, Souza et al. 2005]. Similar to their observations in adipose 
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tissue, estrogen supplementation in Ovx rats decreased hepatic expression of the lipogenic 
gene SREBP-1c, and its downstream targets ACC-1 and FAS compared to Ovx-control 
rats. Similarly, in another study from our lab, increased lipogenesis in liver of Ovx rats has 
been reported by changes in the expression and protein levels of lipogenic molecules such 
as SREBP-1c and SCD-1 [Paquette, Wang et al. 2008]. In addition, suppression of hepatic 
gene expressions involved in lipid oxidation such as PPAR-α was also reported in these 
Ovx rats. PPAR-α is a receptor for peroxisome proliferators that functions as a sensor for 
fatty acids (lipid sensor), and ineffective PPAR-α sensing can lead to reduced energy 
burning resulting in hepatic steatosis [Reddy and Rao 2006]. Moreover, very recently it has 
been reported that estrogen removal decreased the rate of fatty acid oxidation by 34% in 
liver tissue of Ovx rats [Paquette, Chapados et al. 2009]. Furthermore, Na et al. reported 
that estrogen deficiency in the liver of Ovx rats (high-fat fed) raises lipogenesis by 
increasing mRNA expression of FAS and PPAR-γ, while diminishing lipolysis by 
decreasing the expression of HSL and PPAR-α mRNAs [Na, Ezaki et al. 2008]. In line with 
this observation, in a very recent study of Rogers et al., liver from Ovx mice displayed 
visible steatosis even in a state of pair-feeding that was coincident with a remarkable 
elevation in hepatic PPAR-γ expression which is known to stimulate a program increasing 
lipogenic gene expression [Rogers, Perfield et al. 2009]. Accordingly, higher expression of 
two genes involved in lipogenesis; FAS and ACC was observed in this study. To confirm 
the role of estrogens in the regulation of hepatic lipid metabolism, it has been shown that 
17β-estradiol (E2) replacement in an animal model completely prevented the accumulation 
of lipids in the liver of Ovx rats and normalized the disturbed lipogenesis and lipid 
oxidation in liver [Paquette, Wang et al. 2008; Paquette, Chapados et al. 2009].  
Moreover, to our knowledge, the VLDL-TG production and secretion system under 
low estrogenic condition is not well established. However, very recent data (unpublished) 
from our laboratory revealed declined VLDL-TG production in Ovx rats [Barsalani, 
Chapados et al. 2010 submitted paper].  
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Despite growing number of evidences relating to menopause-associated metabolic 
disturbances; there are few studies with reference to the underlying pathways of estrogen-
deficiency induced hepatic steatosis. Taken together, estrogen withdrawal can have direct 
effects on hepatocytes and cellular constituents of liver tissue (intra-hepatic effects), as well 
as central effects on food consumption, energy expenditure, and adipose deposition that 
contribute to the overall effects on liver fat accretion (Table 4). 
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Table 4. Effects of estrogen withdrawal on liver fat accumulation. 
Central Effects  Intra-hepatic Effects 
CNS/hypothalamic effects 
• Food consumption 
• Leptin secretion 
• Activity and energy 
expenditure 
 
Lipid profile and adipose tissue effects 
• Absence of estrogen causes 
fat redistribution/gain 
particularly increased intra-
abdominal fat and altered 
lipid homeostasis 
(portal/fatty acid flux theory) 
 
 
 Lipid uptake  
• Unknown (possible mechanism 
of down-regulation of fatty acid 
uptake via estrogen-dependent 
pathways, yet to be explored) 
 
Lipogenesis  
• SREBP-1c 
• SCD-1 
• FAS  
• ACC 
• PPAR-γ 
 
Lipid oxidation 
• PPAR-α  
• HSL 
• Fatty acid β-oxidation 
 
VLDL-TG production and secretion system 
• VLDL-TG production in Ovx 
rats 
 
 
 
Effects of estrogen withdrawal on liver lipid accumulation (hepatic steatosis) may be direct 
by affecting lipid uptake, de novo lipogeneis, lipid oxidation, and liver VLDL-TG 
production and secretion in liver; or secondary to its effects on the central nervous system 
(CNS) or fat gain, particularly intra-abdominal (visceral) fat accretion.  
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       Prevention/treatment of adipose tissue and liver fat accumulation in 
menopausal hormonal state 
More than 60% of American postmenopausal women are overweight or obese 
[Mokdad, Serdula et al. 1999] and as mentioned earlier, it is well established that 
menopause is associated with weight gain, unfavorable alteration in body composition 
(elevated visceral fat deposition), and a state of hepatic steatosis [Astrup 1999; Faria, 
Ribeiro Filho et al. 2002; Volzke, Schwarz et al. 2007]. It seems that hormone replacement 
therapy (HRT) alleviates these symptoms of menopause [Hassager and Christiansen 1989; 
Arabi, Garnero et al. 2003; Green, Stanforth et al. 2004]. However, research on the safety 
of HRT is conflicting. The Women’s Health Initiative in the United States in 2002 and the 
Million Women Study in the UK in 2003 reported the evidence of increased risk of heart 
disease, stroke, venous thromboembolism, and breast cancer with HRT in postmenopausal 
women [Rossouw, Anderson et al. 2002; Beral 2003]. In general, although short-term use 
of HRT remains beneficial for severe menopausal symptoms, the uncertainty with the 
risks/benefits of HRT along with the well-publicized results of above two large-scale HRT 
trials, have led to the conclusion that HRT will not protect future health in postmenopausal 
women [McPherson 2004; Wegge, Roberts et al. 2004]. Therefore, it seems that the 
justification for HRT can no longer be applied for disease prevention or treatment, thus 
women continue to seek alternative options to improve their quality of life and reduce the 
risk of heart disease, osteoporosis, and breast cancer during postmenopause time [Cassidy 
2005]. 
Interestingly, the most research recommended prevention/treatment for weight gain, 
elevated visceral fat deposition, and hepatic steatosis is identical which is weight loss 
through lifestyle interventions including exercise and/or diet. These lifestyle modifications 
can constitute an important alternative (or complementary) strategy to HRT in 
postmenopausal women to alleviate concerned disorders. Moreover, very recently Zanesco 
and Zaros in their review paper reported that in an attempt to reduce the incidence of CVD 
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in postmenopausal women, a variety of approaches have been used but the results are 
conflicting and changes in lifestyle have been proposed as a most effective preventive 
action [Zanesco and Zaros 2009]. It seems there is no substitute for an appropriate lifestyle 
[Dubnov-Raz, Pines et al. 2007]. Moreover, Hagey and Warren suggested that exercise and 
nutrition play important roles in the prevention and treatment of obesity, diabetes, and CVD 
in postmenopausal women [Hagey and Warren 2008]. Data from a 5-year randomized 
clinical trial known as the Women’s Healthy Lifestyle Project, demonstrated that weight 
gain and increased waist circumference during the peri- to postmenopause can be prevented 
by a long-term lifestyle dietary and physical activity intervention [Simkin-Silverman, Wing 
et al. 2003].  
One of the most important components of lifestyle relates to physical activity which 
for a long time has been known to be a powerful low-risk means for the promotion of all 
aspects of human health including postmenopausal women [Pines and Berry 2007]. 
Postmenopausal women might demonstrate a greater response to exercise [Hagey and 
Warren 2008] since it was shown that even small increases in physical activity and exercise 
at the time of menopause can help prevent the atherogenic changes in lipid profiles and the 
weight gain experienced by menopausal women [Rainville and Vaccaro 1984]. 
Longitudinal and cross-sectional studies have shown that physical activity is associated 
with lower body fat and less central adiposity in postmenopausal women [Stevenson, Davy 
et al. 1995; Astrup 1999; Guo, Zeller et al. 1999; Irwin, Yasui et al. 2003; Sternfeld, Wang 
et al. 2004]. The results of a research by Hagberg et al. even indicated that numerous years 
of high-intensity endurance training had a greater effect on total and regional body fat 
values than HRT in postmenopausal women [Hagberg, Zmuda et al. 2000]. Furthermore, it 
has been shown that moderate-intensity exercise can result in improvements in 
coronary/metabolic risk factors such as insulin action in postmenopausal women [Ready, 
Drinkwater et al. 1995; Ready, Naimark et al. 1996; Asikainen, Miilunpalo et al. 2002; 
Asikainen, Miilunpalo et al. 2003; Frank, Sorensen et al. 2005]. Given that obesity is 
extremely prevalent and difficult to treat, prevention of weight gain during this time in a 
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women’s life is an important health goal. A successful model of weight gain prevention has 
yet to be established [Simkin-Silverman, Wing et al. 2003]. In a cross-sectional study by 
Hagmar et al., postmenopausal former elite endurance athlete women were investigated in 
terms of athlete’s heart being compared with age-matched sedentary controls. Authors 
suggested that intense training enhances cardiovascular performance in the aging female 
athlete [Hagmar, Hirschberg et al. 2005]. This may imply that previous exercise training 
(during the reproductive period) may be useful in the prevention of deleterious cardio-
metabolic effects of menopause. Taken together, it seems that postmenopausal women with 
high levels of physical activity have lower body fat and abdominal fat and are less likely to 
gain fat (total and abdominal) during menopause than those with low levels of physical 
activity [Astrup 1999].  
It has been shown that Ovx animal models can benefit from an exercise training 
program. In 1987, a reduction in fat gain with training has been reported [Richard, Rochon 
et al. 1987]. Then in 2002, Shinoda et al. showed that exercise training has a strong action 
upon reduction in body fat accumulation following a decrease in estrogen levels [Shinoda, 
Latour et al. 2002]. 8-wk endurance exercise training in the latter did not reduce overall 
weight gain and increased food intake brought about by an ovariectomy; suggesting a 
compensatory increase in muscle weight by training. On the other hand, although food 
restriction seems to prevent the Ovx-induced weight gain, this treatment suppresses muscle 
growth in Ovx rats [Fisher, Kohrt et al. 2000]. It appears that increase in body weight and 
organ weights including muscle mass subsequent to ovariectomy in rats [Booth and Tipton 
1969; Santidrian and Thompson 1981] may be a compensatory mechanism to protect the 
bone loss when the estrogen levels are low. For instance, it has been reported that freely 
eating Ovx rats suffered less bone loss than did food restricted Ovx animals; suggesting 
that freely eating Ovx animals were partially protected from bone loss by their greater body 
weight [Wronski, Schenck et al. 1987]. In this regard, it was shown that muscle tissue 
hypertrophy induced by a progressive loading exercise program has a stimulatory effect on 
bone mass in Ovx rats as there are many studies showing beneficial effects of exercise on 
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bone tissue in the postmenopausal estrogen-deficient state [Renno, Silveira Gomes et al. 
2007].  
Another concern of a reduction in estrogenic status is insulin resistance. It is well 
known that environmental factors such as aging and obesity are linked to the development 
of a state of insulin resistance and type 2 diabetes mellitus. The prevalence and progression 
of type 2 diabetes mellitus increase in postmenopausal women that is closely related to 
estrogen deficiency which leads to higher body weight and fat mass exacerbating insulin 
resistance [Choi, Jang et al. 2005]. Similarly, several studies have reported insulin 
resistance in experimental animals after Ovx, which can be reversed by HRT and exercise 
training, although the results have been somewhat conflicting [Latour, Shinoda et al. 2001; 
Yakar, Nunez et al. 2006]. In spite of well-documented influences of estrogens on insulin 
action, the exact mechanisms are not well described [Hansen, McCarthy et al. 1996]. The 
deterioration of insulin action in Ovx animals might be related to the central effects (i.e. 
increases in body fat) or to the ectopic effects of estrogen withdrawal (lower estrogen levels 
per se) or to a combination of both. Ropero et al. showed that estrogens in mouse 
pancreatic β-cells act synergistically with glucose to close KATP channels through a cGMP-
dependent phosphorylation process, consequently resulting in a calcium-mediated 
stimulation of insulin secretion [Ropero, Fuentes et al. 1999]. This might explain the 
ectopic and direct effects of estrogen at a molecular level in pancreatic β-cells suggesting 
that this could also be the case in other ectopic tissues such as muscle and liver.  
Exercise training and low-calorie diet have long been prescribed as part of the 
treatment in the management of type 2 diabetes. There are several studies reporting that 
food restriction and exercise training increases insulin sensitivity through loss of body fat 
[Ross, Dagnone et al. 2000; Greco, Mingrone et al. 2002; Shinoda, Latour et al. 2002]. In 
the study on Ovx diabetic rats, food restriction treatment was partially successful in 
reversing diabetes progression through body weight and fat reduction (reversing the central 
effects of estrogen withdrawal) [Choi, Jang et al. 2005]. However, the improvement could 
not be sustained since this treatment failed to improve pancreatic β-cells function and mass 
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(showing no ectopic effect of this treatment). On the other hand, regular exercise alone, 
regardless of estrogen replacement, had the most beneficial effects on insulin sensitivity 
and β-cell function and mass (reversing both central and ectopic effects of estrogen 
withdrawal) in Ovx diabetic rats, even though estrogen replacement alone also improved 
them. Moreover, Saengsirisuwan et al., showed that ovariectomy in female Sprague-
Dawley rats results in the development of a systemic metabolic condition representing 
characteristics of the metabolic syndrome including increased visceral fat content, 
abnormal serum lipid profile, impaired glucose tolerance, and defective insulin-mediated 
skeletal muscle glucose transport [Saengsirisuwan, Pongseeda et al. 2009]. In this study, 
new evidence was provided showing that whole-body and skeletal muscle insulin resistance 
is effectively corrected by endurance exercise training alone and estrogen replacement 
alone. Despite this, similarly to Choi et al., they could find no evidence that exercise 
training could additively modulate insulin action in Ovx animals that also received estrogen 
replacement; suggesting that endurance exercise training and estrogen may share common 
mechanisms to correct defects in ectopic tissues caused by estrogen deficiency [Choi, Jang 
et al. 2005]. This concept is supported by observations that transcripts encoding estrogen 
signaling in skeletal muscle, cardiac muscle, and liver are enhanced by regular exercise 
[Lemoine, Granier et al. 2002; Wiik, Gustafsson et al. 2005; Paquette, Wang et al. 2007]. 
 
Resistance training  
Weight loss achieved through restrictive diet often results in adverse effects on 
muscle mass [Villareal, Apovian et al. 2005]. In this regard, resistance training (RT) seems 
to be a logical choice considering its beneficial effects on muscular strength in 
postmenopausal women [Bemben, Fetters et al. 2000]. It has been demonstrated that RT 
exercise can be an effective substitute for hormone replacement therapy in preserving 
menopause related osteoporosis and sarcopenia [Maddalozzo, Widrick et al. 2007]. In 
addition to increasing muscle mass and improving muscle function, RT has been reported 
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to augment resting and total energy expenditure, and to induce decreases in total and 
abdominal fat [Maesta, Nahas et al. 2007]. On the other hand, there are studies that showed 
no reduction in fat tissue and Orsatti et al. suggest that this discrepancy might be related to 
the methods used to assess adiposity in postmenopausal women (measurements of skin fold 
thickness, indirect measurements such as waist circumference and body composition 
measurements, computerized tomography, dual-energy X-ray absorptiometry) [Orsatti, 
Nahas et al. 2008]. However, 8 weeks of low intensity, short duration RT program was not 
sufficient to produce significant alterations in body composition and blood lipid 
concentrations in postmenopausal women, although it produced substantial improvements 
in muscle strength [Elliott, Sale et al. 2002]. In obese, sedentary postmenopausal women, it 
has been suggested that RT has the potential to ameliorate/prevent the development of 
insulin resistance and may reduce the risk of glucose intolerance and non-insulin-dependent 
diabetes mellitus [Ryan, Pratley et al. 1996]. In these subjects, RT alone or in combination 
with weight loss program (diet) (RT+WL) improved muscular strength and insulin action 
and glucose homeostasis. However, the same authors in another study showed that body 
weight and fat mass did not change with RT alone, but decreased with RT+WL [Ryan, 
Pratley et al. 2000]. Nevertheless, RT and RT+WL both increased fat-free mass and resting 
metabolic rate and decreased percent fat in these postmenopausal women [Ryan, Pratley et 
al. 1995]. Considering the fact that subjects in the RT group were non-obese and subjects in 
RT+WL group were obese postmenopausal women, this research group suggests that RT 
may be a valuable component of an integrated weight management program in 
postmenopausal women. In general, it seems that data from human studies are suggestive of 
resistance training. 
In ovariectomized rats, Corriveau et al. have shown that an 8-wk program of 
resistance training in conjunction with a restrictive diet reduced intra-abdominal fat depot 
and plasma free fatty acid levels and prevented liver fat accumulation [Corriveau, Paquette 
et al. 2008]. They concluded that RT is an asset to minimize the deleterious effects of 
ovarian hormone withdrawal on abdominal fat and liver lipid accumulations in Ovx rats. 
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Leite et al. also recently indicated the potential benefits of resistance training as an 
alternative strategy to control the negative effects of ovariectomy [Leite, Prestes et al. 
2009]. Twelve-wk strength training in Ovx rats decreased fat content in the liver, skeletal 
muscle, and intra-abdominal adipose tissue and positively changed the lipid profile such as 
increasing HDL levels while decreasing total cholesterol and LDL levels. In both studies, 
the RT program consisted of climbing vertical grill with weights attached to the tail of rat. 
Although these studies did not investigate the mechanism of RT action on liver lipid 
content, based on evidences on the effects of exercise on AMP-activated protein kinase 
(AMPK) activation [Griffiths, Baker et al. 1993; Park, Kaushik et al. 2002; Dobrzyn, 
Dobrzyn et al. 2004; Lavoie and Gauthier 2006], they speculated that RT could induce 
AMPK activation with a decrease in the expression of transcription factors related to 
lipogenesis, improving liver fat oxidation and consequently reducing liver lipid content. 
Moreover, the notion that liver fat follows adipose tissue fat accumulation is always present 
(exercise has secondary effects on liver fat). 
 
Weight regain  
It seems that maintenance of weight loss is a core problem in the treatment of 
obesity and long term maintenance of weight loss remains a challenge. A common 
treatment for weight loss is food restriction or hypocaloric diet therapy. Although 
interventions aimed at weight loss are strongly supported [Scheen and Luyckx 2002], 
reductions in weight by dietary restriction are typically modest and are increasingly viewed 
as an unsustainable outcome of lifestyle modification [Shaw, Gennat et al. 2006; Hansen, 
Dendale et al. 2007]. It seems that there is a high rate of relapse after diet-induced weight 
loss [1992]. One of the main underlying problem in this matter appears to be the 
compensatory metabolic responses to weight reduction which results in a strong drive to 
regain lost weight [Corbett, Wilterdink et al. 1985; Hill, Thacker et al. 1988; Dulloo and 
Girardier 1990; Dulloo and Calokatisa 1991; MacLean, Higgins et al. 2004]. Such 
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responses including enhanced metabolic efficiency with a progressively increasing appetite 
along with interrelated alterations like improved insulin sensitivity and energetically 
favorable shifts in fuel utilization characterized by an increased preference for carbohydrate 
oxidation at the expense of lipid oxidation; may well explain why successful weight 
reduction is so hard to achieve [MacLean, Higgins et al. 2004]. MacLean et al. suggest that 
these compensatory adjustments in metabolism are part of an interrelated group of 
adaptations in the homeostatic feedback loop between the periphery and the central nervous 
system that controls body weight [MacLean, Higgins et al. 2006]. Their proposed metabolic 
state after weight-reduction in the context of the homeostatic feedback system that defends 
fat stores is summarized in Figure 3. It seems that this homeostatic feedback system 
defending body weight and adiposity is fundamental to the metabolic drive to regain lost 
weight [Levin and Dunn-Meynell 2000; MacLean, Higgins et al. 2006]. The good thing is 
that modification of this biological predisposition is possible. Interestingly, exercise 
training seems to positively alter this propensity and has been shown to be important to 
successful weight maintenance after weight loss programs [Klem, Wing et al. 1997; 
Wadden, Vogt et al. 1998]. Levin et al. reported that regular physical activity lowers the 
defended level of weight gain and adiposity without a compensatory increase in intake and 
with a favorable alteration in the development of the hypothalamic pathways controlling 
energy homeostasis as compared to calorically restricted rats [Levin and Dunn-Meynell 
2004; Patterson, Dunn-Meynell et al. 2008]. These authors suggested that exercise produces 
a different set of regulatory signals from caloric restriction that resets the homeostatic 
balance between energy intake and expenditure toward defense of a lower level of weight 
gain and adiposity. 
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Figure 3. Taken from [MacLean, Higgins et al. 2006] Metabolic state after weight-
reduction (A), early in relapse (B), and after relapse (C). The compensatory adaptations in 
the periphery, regarding 1) energy balance, 2) energetic cost of gain, 3) lipid accretion, and 
4) adiposity signals that facilitate rapid and efficient weight regain are summarized in the 
context of the homeostatic feedback system that defends peripheral fat stores. A: the 
metabolic state after weight reduction is diagrammed. The anabolic central nervous system 
profile promotes a large energy gap with an increased drive to eat and a suppressed 
expenditure of energy. The weight-reduced state is maintained only if intake is forcefully 
restricted to the level that energy expenditure is suppressed. Peripheral tissues are forced to 
be flexible with their use of fuels because of intermittent exogenous fuel availability. 
Adipose depots are stable, but depleted, and humoral adiposity signals are lower than 
would be expected for the level of peripheral fat. This blunted signal contributes to the 
adapted regulatory loop by lowering the sensitivity of neural control centers to hunger and 
satiety signals in a manner that promotes the overall anabolic output. B: with uncontrolled 
intake, the energy gap is realized. Excess fuels and the accompanying insulin excursions, in 
the context of insulin sensitive tissues that have the cellular infrastructure to suppress fat 
oxidation, promote a dramatic shift in fuel utilization whereby exogenous fat is 
preferentially diverted to storage depots. Ingested energy is rapidly and efficiently diverted 
toward the repletion of adipose stores. C: the pressures driving regain gradually resolve as 
the lost weight is regained. The metabolic state gradually shifts to one that attempts to 
prevent further weight gain. The energy gap is minimized at a higher overall energy flux, 
and peripheral tissues become resistant to insulin’s actions and metabolically inflexible. 
The energetic efficiency of further gain is elevated. The regulatory system achieves a level 
of equilibrium similar to what is seen before weight loss except that the adipose depots 
have increased their total capacity to store fat, an effect that may have implications on the 
continued progression of obesity. In the face of both hyperinsulinemia and hyperleptinemia, 
the neural control centers exhibit what would appear to be a selective resistance to 
regulating intake, as both intake and expenditure remain high.  
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Body weight and fat mass gain and regain following weight loss may be even more 
critical after menopause since physiological withdrawal of ovarian hormones, by itself, 
negatively affects the energy balance. Similarly to above discussion on weight regain, 
Nicklas et al. suggest that the poor success rate of food restriction treatment in 
postmenopausal women may be due in part to metabolic adaptations that occur in response 
to a long period of negative energy balance such as declined fat oxidation, resting 
metabolic rate, and adipocyte lipolytic responsiveness; which predispose to regain body 
weight [Nicklas, Rogus et al. 1997]. They showed that addition of endurance exercise to 
diet-induced weight loss program minimizes these negative metabolic adaptations in 
postmenopausal women. Another strategy, substituting a walking training with very-low-
energy diet in premenopausal obese women improved maintenance of losses in weight and 
waist circumference and prevented further clustering of metabolic risk factors [Fogelholm, 
Kukkonen-Harjula et al. 2000]. However, randomized controlled trials comparing different 
strategies such as diet and diet plus exercise in postmenopausal women are few and the 
results do not allow a firm conclusion as to whether physical activity may prevent or limit 
the gain of total and abdominal fat during menopause or whether it may be effective as part 
of an obesity treatment program [Astrup 1999].  
 
The specific case of liver fat accumulation and exercise training  
A fatty liver overproduces components of the metabolic syndrome (dyslipidemia, 
hyperglycemia) and new data imply that fat accumulation in the liver is a key player in the 
pathogenesis of insulin resistance and the metabolic syndrome which may distinguish who 
develop the syndrome from those who do not, even independently of obesity [Kotronen, 
Westerbacka et al. 2007; Kotronen, Seppala-Lindroos et al. 2008]. Despite growing 
evidence of the metabolic and cardiovascular impact of liver lipid infiltration, there are 
relatively few studies examining the effects of lifestyle intervention [Johnson, Sachinwalla 
et al. 2009]. Interventions which reduce hepatic triglyceride concentrations are often come 
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with significant improvements in metabolic function such as insulin resistance [Petersen, 
Dufour et al. 2005]. On the other hand, there is increasing evidence suggesting that physical 
activity and increased fitness can improve the metabolic syndrome even without weight 
loss [Ross, Dagnone et al. 2000; Cox, Burke et al. 2004; Ross, Janssen et al. 2004; Nassis, 
Papantakou et al. 2005]. Very recent experimental study showed that short-term 4-week 
aerobic exercise training results in a significant reduction in both hepatic lipids and visceral 
adipose tissue even in the absence of body weight reduction [Johnson, Sachinwalla et al. 
2009]. Moreover, concurrent exercise training in animals prevented high-fat-diet-induced 
intra-abdominal fat accumulation and hepatic steatosis [Gauthier, Couturier et al. 2003]. 
Therefore, it is very relevant to investigate the effects of exercise training in estrogen-
deficient states which is characterized with increased visceral adipose tissue and hepatic 
lipid accumulation. 
 
Pathogenic role of sub-acute systemic inflammation in obesity 
and insulin resistance 
 
Inflammation 
Inflammation is one of the first responses of the immune system to infection or 
irritation. It is stimulated by chemical factors, including specialized chemical mediators, 
called cytokines and ranges from a local to a systemic response to cellular injury 
[Moldoveanu, Shephard et al. 2001]. The local response to infections or tissue injury 
involves the production of cytokines that are released at the site of inflammation. Cytokines 
are small polypeptides, which were originally discovered to have immunoregulatory roles 
[Akira and Kishimoto 1992; Akira, Taga et al. 1993]. Some of these cytokines facilitate an 
influx of lymphocytes, neutrophils, monocytes, and other cells. The local inflammatory 
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response is accompanied by a systemic response known as the acute-phase response. This 
response includes the production of a large number of hepatocyte-derived acute phase 
proteins, such as C-reactive protein (CRP). The initial cytokines in the cytokine cascade are 
(named in order) tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, IL-1 
receptor antagonist (IL-1ra), and soluble TNF-α receptors (sTNF-R) [Petersen and Pedersen 
2005]. IL-1ra inhibits IL-1 signal transduction and sTNF-R represents the naturally 
occurring inhibitors of TNF-α [Dinarello 1991; Akira and Kishimoto 1992; Akira, Taga et 
al. 1993]. In response to an acute infection or trauma, the cytokines and cytokine inhibitors 
may increase several fold and decrease when the infection or trauma is healed. When 
inflammation overwhelms the whole organism, systemic inflammatory response syndrome 
(SIRS) is diagnosed. When it is due to infection, the term sepsis is applied.  
With the discovery of interleukins, another concept of systemic inflammation was 
developed. Although the processes involved are identical, this form of inflammation is not 
confined to a particular tissue but involves the endothelium (lining of blood vessels) and 
many other organ systems. During the last decade, it has become clear that inflammatory 
mechanisms are key players in pathological processes of several chronic diseases such as 
ischemic cardiovascular disease (CVD), insulin resistance,  type 2 diabetes (T2D), 
colorectal cancer, stroke, chronic obstructive pulmonary disease, and Alzheimer’s disease; 
which are among the most common causes of mortality in the Western world [Bruunsgaard 
2005]. At the same time, it has been recognized that cytokines are not only important 
signals in immune function, as they also represent important regulators of endocrine 
systems, the metabolism, the coagulation system, and the brain function [Febbraio and 
Pedersen 2002]. In addition, it has been discovered recently that circulating levels of 
cytokines in vivo are affected significantly by contributions of cells outside the immune 
system such as adipose tissue, skeletal muscle, and endothelial cells in healthy humans; 
e.g., 30% of IL-6 in plasma is derived from fat tissue [Mohamed-Ali, Goodrick et al. 1997]. 
The concept of regulatory adipokines has developed together with the discovery of fat 
tissue as an important endocrine organ, producing and secreting classical cytokines 
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including TNF-α, IL-6, IL-18, as well as a wide range of other new peptides [Kershaw and 
Flier 2004]. Moreover, it was demonstrated that working skeletal muscles produce and also 
release cytokines to the circulation [Febbraio and Pedersen 2002]. Therefore, cytokine 
production is not restricted to the context of infections.  
Systemic low-level inflammation is defined as two- to fourfold elevation in 
circulating levels of cytokines, natural occurring cytokine antagonists, and acute-phase 
proteins, as well as minor increases in counts of neutrophils and natural killer cells 
[Bruunsgaard and Pedersen 2003]. Although these increases are far from levels observed 
during acute/severe infections, systemic low-level inflammation is strongly associated with 
lifestyle factors such as obesity, and dietary patterns [Bermudez, Rifai et al. 2002; Esposito, 
Marfella et al. 2004]. Chronic low-grade inflammation accompanies aging as well as some 
chronic medical disorders and it is a strong, consistent, and independent predictor of all-
cause mortality and CVD-cause mortality in elderly populations [Harris, Ferrucci et al. 
1999; Yeh, Hafner et al. 2004]. Several reports investigating various markers of 
inflammation in different population groups have confirmed an association between low-
grade systemic inflammation on one hand and the metabolic syndrome, Type 2 diabetes, 
and atherosclerosis on the other [Barzilay, Abraham et al. 2001; Ford 2002; Duncan, 
Schmidt et al. 2003]. It seems that systemic low-grade inflammation is a cause as well as a 
consequence of pathological processes [Bruunsgaard 2005].  
 
Circulating inflammatory markers in metabolic syndrome 
In sepsis and experimental models of sepsis (the processes involved are identical as 
in low-level systemic inflammation), the cytokine cascade consists of TNF-α, IL-1β, IL-6, 
IL-1ra, sTNF-R, and IL-10 [Akira, Taga et al. 1993]. The first two cytokines in the 
cytokine cascade, that is, TNF-α and  IL-1β, along with IL-2, IL-8, and IL-15 are usually 
referred to as pro-inflammatory cytokines [Moldoveanu, Shephard et al. 2001]. While IL-
1ra, sTNF-R, IL-4, IL-10 and IL-13 are well-known anti-inflammatory cytokines 
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[Moldoveanu, Shephard et al. 2001]. TNF-α and IL-1 stimulate the production of IL-6, 
which has been classified as both a pro- and anti-inflammatory cytokine [Tilg, Dinarello et 
al. 1997] depending on the origin of its production such as adipose and liver tissue in 
obesity-originated versus muscles during exercise, respectively. IL-10 attenuates the cell 
surface expression of TNFRs and it inhibits the production of cytokines by monocytes and 
type 1 T cells [Kolling, Hansen et al. 2001]. However, circulating levels of cytokines work 
in a network, and their levels are found to inter-correlate, e.g., plasma levels of TNF-α were 
positively correlated with IL-6, sTNF-R, and CRP in centenarians [Bruunsgaard 2005; 
Petersen and Pedersen 2005].  
Cytokines such as IL-6, IL-1β, and TNF-α which are produced during and 
participate in inflammatory processes, are the chief stimulators of the production of acute-
phase proteins [Gabay and Kushner 1999]. The acute phase reaction is a nonspecific 
physiological response to tissue injury, infection, inflammation, and disease activity; whose 
functions include repairing tissue damage, containing infections, promoting wound healing 
and triggering host defense mechanisms such as the innate immune response [Chen 2006; 
Kalani, Judge et al. 2006]. As mentioned, this response is carried out by secretion of acute 
phase proteins coming mainly from hepatocytes including CRP, serum amyloid A (SAA), 
fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) [Gabay and Kushner 1999]. 
Among the acute phase markers, CRP that functions primarily to recognize and eliminate 
pathogens and damaged cells by activating the complement system and phagocyte cells 
[Volanakis 2001], is considered as an excellent pro-inflammatory biomarker, and received 
more attention due to its potential in predicting cardiovascular disease in several 
populations including postmenopausal women [Tracy, Lemaitre et al. 1997; Ridker, 
Hennekens et al. 2000]. Plasma CRP concentrations have also been reported to increase in 
the metabolic syndrome and diabetes [Danesh, Whincup et al. 2000]. Moreover, IL-6, 
another acute phase cytokine and the main stimulator of liver CRP production, has been 
implicated in developing the inflammatory response persistent in cardiovascular disease 
[Ridker, Cushman et al. 1997]. Elevated levels of circulating IL-6 have been associated 
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with several disorders and plasma concentrations of IL-6 and TNF-α have been shown to 
predict the risk of myocardial infarction in several studies [Ridker, Rifai et al. 2000]. It 
must be mentioned that although IL-6 is generally regarded as a pro-inflammatory 
cytokine, it can play a contrary role. For example, it is now well known that IL-6 is rapidly 
released into the circulation following exercise [Febbraio and Pedersen 2002] and it seems 
that when IL-6 is produced by working muscles independently of TNF-α/IL-1β, it exerts 
mainly anti-inflammatory activities [Bruunsgaard 2005]. Furthermore, other cytokines 
originating from adipocytes or other cells including TNF-α are also involved in this process 
[Maachi, Pieroni et al. 2004]. TNF-α is a pro-inflammatory cytokine produced by different 
tissues such as immune cells and adipocytes and it has been shown to play a role in obesity-
induced local and systemic insulin resistance [Bastard, Maachi et al. 2006]. There is 
accumulating data to suggest that TNF-α plays a direct role in the metabolic syndrome. 
TNF-α, together with IL-6 and other chemokines, mediates macrophage infiltration that 
causes adipose tissue inflammation in obesity leading to deregulated secretion of 
adipokines and insulin resistance [Schenk, Saberi et al. 2008]. Consequently, it is not 
surprising that patients with diabetes demonstrate high expression of TNF-α in plasma 
[Winkler, Salamon et al. 1998; Mishima, Kuyama et al. 2001] and in skeletal muscle 
[Saghizadeh, Ong et al. 1996], and it is likely that adipose tissue is the main source of the 
circulating TNF-α [Coppack 2001]. 
 Taken as a whole, Esposito and Giugliano report that elevated circulating levels of 
major pro-inflammatory cytokines including CRP, IL-6, TNF-α, and IL-1β along with low 
levels of anti-inflammatory cytokines such as IL-10 are associated with the metabolic 
syndrome [Esposito and Giugliano 2004].  
 
Cellular inflammatory responses in obesity and insulin resistance 
Weight gain and obesity are most important risk factors for diseases ranging from 
insulin resistance and T2DM to atherosclerosis and the sequelae of NAFLD [Shoelson, 
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Herrero et al. 2007]. In recent years, it has become clear that metabolic disturbances related 
to fat accumulation in adipocytes and ectopic tissues such as the liver, are associated to sub-
clinical inflammation [Esposito and Giugliano 2004; Bruunsgaard 2005]. Obesity is 
strongly associated with enhanced circulating TNF-α levels, whereas weight loss reduces 
systemic levels [Dandona, Weinstock et al. 1998]. Adipose tissue from obese individuals 
shows accumulation of macrophages, which provide the major cellular source of a 
concomitant, enhanced, local expression of the TNF-α and IL-6 proteins [Weisberg, 
McCann et al. 2003]. In fact, obesity is associated with accretion of lipids into adipocytes 
and expansion of adipose tissue which produce pro-inflammatory cytokines like TNF-α, IL-
6, resistin, MCP-1, and PAI-1; initiating an inflammatory signal that in turn, results in a 
state of local and systemic insulin resistance (Figure 4) [Shoelson, Herrero et al. 2007].  
A model on how inflammation leads to insulin resistance has been proposed by 
Chen that is illustrated in Figure 5 [Chen 2006]. It seems that adipokines such as TNF-α 
induces insulin resistance in experimental animal models by mechanisms that involve 
serine phosphorylation of the insulin receptor substrate 1 (IRS-1) [Hotamisligil, Peraldi et 
al. 1996]. This phosphorylation reduces insulin receptor tyrosine kinase activity in response 
to insulin and the ability of IRS-1 to associate with the insulin receptor and thereby 
interfering with downstream insulin signal transduction [Dandona, Aljada et al. 2005]. The 
responsible intracellular pathways involve activation of c-Jun N-terminal kinases 
(JNKs/stress activated protein kinases) [Hirosumi, Tuncman et al. 2002] and the inhibitor 
of кB kinase (IKKβ) [Arkan, Hevener et al. 2005] whereas activation of members in the 
suppressor of cytokine signaling (SOCS) family represents alternative intracellular stress 
pathways in cytokine-mediated inhibition of insulin signaling [Ueki, Kondo et al. 2004]. 
IKKβ activates nuclear factor of kappa B (NF-kB), a master regulator of inflammation and 
transcription factor that stimulates production of many inflammatory markers. It seems that 
IKKβ/NF-kB signaling pathway which is activated by pro-inflammatory cytokines is a key 
pathway in tissue inflammation [Chen 2006]. Increased free fatty acids (FFA) levels have  
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Figure 4. Taken from [Shoelson, Herrero et al. 2007] Potential mechanisms for obesity-
induced adipocyte inflammation. The accumulation of lipids in adipose tissue and the 
expansion of the fat mass lead to the initiation of an inflammatory process. This may be 
initiated through the production of pro-inflammatory cytokines and chemokines by the 
adipocytes, including TNF-α, IL-6, leptin, resistin, MCP-1, and PAI-1. Endothelial cells 
respond through the increased expression of adhesion molecules, which along with the 
chemokines serve to recruit immune cells including monocyte-derived macrophages to the 
adipose tissue. Together, the adipocyte-, immune cell-, and endothelial cell-derived 
substances create an inflammatory milieu that promotes insulin resistance locally. Similar 
pro-inflammatory and pro-atherogenic mediators enter the circulation to promote insulin 
resistance and increase the risk for atherosclerosis.  
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Figure 5. Taken from [Chen 2006] Hypothetical model of metabolic stress, cellular 
inflammatory responses and effects on insulin signaling pathway. Nutrient overload in 
adipose tissue leads to increased secretion of FFAs and pro-inflammatory adipokines, 
which activate resident macrophages. Activated macrophages in turn secrete cytokines and 
chemokines to recruit additional monocytes and macrophages into fat. The secreted FFAs, 
IL-6 and TNF-α cause insulin resistance in adipocytes through activation of several serine-
threonine kinase pathways that interfere with insulin signaling via serine phosphorylation 
and subsequent inactivation of IRS-1. In addition, IKKβ and JNK1 activate transcription 
factors which increase expression of cytokines and inflammatory genes. This vicious cycle 
amplifies inflammation and accentuates insulin action. Obesity-mediated metabolic stress 
also adds burden to cellular machineries, leading to ER stress or mitochondria oxidative 
stress, which again activate IKKβ/NF-kB and JNK1 inflammatory pathways. These same 
immune modulators similarly lead to impaired insulin action in other tissues like liver and 
muscle. FFAs: free fatty acids; DAG: diacylglycerol; ER: endoplasmic reticulum.  
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also been implicated as a causative factor in phosphorylation of IRS-1 [Dandona, Aljada et 
al. 2005] through increased intra-cellular fatty acyle-CoA and diacylglaycerol (DAG) 
concentrations and activation of pro-inflammatory kinase, protein kinase C-θ (PKC-θ) 
[Gao, Zhang et al. 2004]. Moreover, it has been shown that nutritional fatty acids, whose 
circulating levels are often increased in obesity, activate toll-like receptors (critical players 
of innate immune system) which in turn trigger pro-inflammatory pathways and induce 
cytokine expression in a variety of cell types [Shi, Kokoeva et al. 2006]. On the other hand, 
obesity-mediated metabolic stress (increased fatty acids and glucose metabolism and 
reactive oxygen species) also exerts a higher-than-normal load to cellular machineries 
leading to endoplasmic reticulum (ER) stress or mitochondria oxidative stress, which 
activate both IKKβ/NF-kB and JNK1 inflammatory pathways [Furukawa, Fujita et al. 
2004; Ozcan, Cao et al. 2004; Summers 2006]. 
Moreover, inflammatory markers and mediators such as CRP and IL-6 are 
synthesized in the liver, suggesting hepatic low-level inflammation most likely secondary 
to hepatic steatosis, might be involved in the development of insulin resistance and the 
metabolic syndrome. The findings of Cai et al. demonstrate that fat accumulation in the 
liver leads to sub-acute hepatic inflammation via IKKβ/NF-kB activation and downstream 
pro-inflammatory cytokine production including IL-6, TNF-α, and IL-1β [Cai, Yuan et al. 
2005] . This suggests that hepatocyte lipid accumulation (steatosis) might induce a sub-
acute inflammatory response in liver that is similar to adipose tissue inflammation. 
Alternatively, pro-inflammatory substances in the portal circulation, potentially produced in 
abdominal fat, might initiate hepatic inflammation [Shoelson, Lee et al. 2006]. In any case, 
it seems that NF-кB pathway is stimulated in hepatocytes, and cytokines including IL-6, 
TNF-α, and IL-1β, are overproduced in a fatty liver. The pro-inflammatory cytokines 
participate in the development of insulin resistance both locally in liver and systemically 
[Cai, Yuan et al. 2005].  
According to Shoelson et al., skeletal muscle is another major site of insulin 
resistance and a target of inflammation-induced insulin resistance as opposed to a site of 
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initiation (Figure 6) [Shoelson, Lee et al. 2006]. However, in contrast with this, a study by 
Boden et al. [Boden 2006] indicates that elevated plasma free fatty acid levels, either as a 
result of obesity or high-fat diet feeding, produces low-grade inflammation in skeletal 
muscle and liver through activation of NF-кB, as in adipose tissue, resulting in the releasing 
several pro-inflammatory and pro-atherogenic cytokines leading to insulin resistance. 
Finally, vascular inflammation is central in the pathology of atherosclerosis [Ross 1999] 
and inflammation (in adipose tissue and liver) might be a connecting link between obesity 
and many of its pathological metabolic disorders such as atherosclerosis by infiltrating the 
artery wall [Surmi and Hasty 2010] (Figure 6). Apart from the underlying mechanisms, the 
pro-inflammatory state that accompanies the metabolic syndrome associates with both 
insulin resistance and endothelial dysfunction, providing a connection between 
inflammation and metabolic processes which is highly deleterious for vascular functions 
[Esposito and Giugliano 2004].  
 
Physical activity and systemic low-level inflammation 
A recent number of papers have documented that self-reported physical activity or 
physical performance is correlated inversely with systemic low-level inflammation, 
although the lack of an association has also been reported (Table 5) [Bruunsgaard 2005]. 
However, the findings of cross-sectional studies demonstrating an association between 
physical inactivity and low-grade systemic inflammation in healthy subjects and in elderly 
people [McFarlin, Flynn et al. 2006] [King, Carek et al. 2003; McFarlin, Flynn et al. 2006] 
together with the results of longitudinal and prospective studies showing that regular 
training reduces CRP level, suggest that physical activity as such may suppress systemic 
low-grade inflammation [Mattusch, Dufaux et al. 2000; Kasapis and Thompson 2005]. 
Accordingly, a high level of physical activity has been shown to be associated with reduced 
levels of inflammatory mediators in the range of 20–60% compared with a sedentary 
lifestyle among apparently healthy middle-aged and older US  
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Figure 6. Taken from [Shoelson, Lee et al. 2006] Local, portal, and systemic effects of 
inflammation in insulin resistance and atherogenesis. Increasing adiposity activates 
inflammatory responses in fat and liver, with associated increases in the production of 
cytokines and chemokines. Immune cells including monocytes and macrophages are 
recruited and/or activated, and together, they cause local insulin resistance. Hepatic 
steatosis and/or portal delivery of abdominal fat–derived cytokines and lipids contribute to 
hepatic inflammation and insulin resistance. Pro-inflammatory and pro-atherogenic 
mediators are produced in adipose tissue and liver as well as associated immune cells. This 
creates a systemic inflammatory diathesis that promotes insulin resistance in skeletal 
muscle and other tissues and atherogenesis in the vasculature.  
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Table 5. Taken from [Bruunsgaard 2005] Self-reported physical activity and physical 
performance in relation to low-level inflammation in epidemiological studies 
 
SAA, Serum amyloid A; WBC, white blood cell count; HRT, hormone replacement 
therapy; MIP-1α, macrophage-inflammatory protein-1α; circulating levels, concentration in 
serum or plasma.  
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adults [Abramson and Vaccarino 2002]. In addition, several studies have reported that 
exercise intervention programs reduce systemic low-level inflammation in patients with 
coronary heart disease [Oberbach, Tonjes et al. 2006], claudicants [Tisi, Hulse et al. 1997], 
patients with chronic heart failure [Gielen, Adams et al. 2003], and also in healthy young 
adults [Mattusch, Dufaux et al. 2000]. Improved measures of chronic inflammation markers 
with exercise training in animal models has also been reported [Kalani, Judge et al. 2006; 
de Lemos, Reis et al. 2007]. 
Several studies have shown an anti-inflammatory effect of acute physical exercise, 
characterized through increased circulating concentrations of IL-10, IL-1 receptor 
antagonist (IL-1ra), soluble receptor of TNF (TNFRs) [Petersen and Pedersen 2005]. It 
seems that the cytokine response to exercise differs from that elicited by severe infections 
[Febbraio and Pedersen 2002]. An acute bout of exercise appears to mediate anti-
inflammatory effects in skeletal muscle and fat tissue [Ostrowski, Rohde et al. 1999; 
Febbraio and Pedersen 2002; Febbraio, Hiscock et al. 2004; Kelly, Keller et al. 2004; 
Petersen and Pedersen 2005]. The underlying mechanisms appear to involve IL-6- 
dependent [Petersen and Pedersen 2005] and –independent [van der Poll, Coyle et al. 1996; 
Kolling, Hansen et al. 2001; Keller, Keller et al. 2004] pathways. Muscle contractions 
induce a myokine response characterized by a large release of IL-6 from working muscles, 
independently of pro-inflammatory markers such as TNF-α; which is followed by 
elevations in circulating levels of well-known anti-inflammatory cytokines and cytokine 
inhibitors including IL-1ra, IL-10, and sTNFRs [Ostrowski, Rohde et al. 1999]. It has been 
suggested that the contraction-induced IL-6 expression in skeletal muscle is a specific 
biochemical phenomenon with the purpose of mobilizing substrate from fuel depots within 
the body to facilitate energy metabolism [Pedersen, Steensberg et al. 2003]. According to 
Pederson’s theory, contracting skeletal muscles release myokines, which work in a 
hormone-like fashion, exerting specific endocrine effects on visceral fat and other ectopic 
fat deposits while other myokines will work locally within the muscle via paracrine 
mechanisms, exerting their effects on signaling pathways involved in fat oxidation 
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[Pedersen 2009]. This may provide a conceptual basis to understand the mechanisms 
whereby exercise influences metabolism and exerts anti-inflammatory effects; playing an 
important role in the health-beneficial effects of exercise. For instance, even moderate 
physical activity is probably sufficient to induce the anti-inflammatory effects of exercise, 
as an increased transcription rate of the IL-6 gene is already detected after 30 min of two-
leg extensor exercise at 60% of the individual maximal power output [Keller, Steensberg et 
al. 2001]. Thus, only 30 min of moderate exercise on a regular basis probably has the 
power to facilitate an anti-inflammatory environment characterized by enhanced levels of 
IL-10, IL-1Ra, and sTNFRs between bouts of physical activity [Bruunsgaard 2005]. 
Although the exact link between acute and long-term effects yet to be known, regular 
exercise protects against diseases associated with chronic systemic low-grade 
inflammation; and this long-term effect might be ascribed to the anti-inflammatory 
response elicited by an acute bout of exercise [Petersen and Pedersen 2005]. In theory, a 
reduced local pro-inflammatory markers production could explain a part of the decline in 
systemic low-level inflammation together with the improvement in symptoms and risk 
factors (mainly decreased visceral and ectopic fat accumulation) associated with the 
metabolic syndrome, CVD, and T2DM in relation to regular exercise [Bruunsgaard 2005]. 
  
The importance of inflammatory cytokines in fatty liver and insulin 
resistance 
Obesity is associated with a chronic inflammatory response characterized by 
abnormal cytokine production and activation of inflammatory signaling pathways, which 
has been proposed to play a key role in the pathogenesis of obesity-related insulin 
resistance and NAFLD [Hotamisligil 2006]. The contribution of the adipose tissue versus 
the liver as the major sources of circulating and systemically active pro-inflammatory 
cytokines in these diseases remains unclear. However, once obesity leads to fatty liver, 
mostly observed in cases of obesity, the liver itself can become a major source of various 
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inflammatory mediators [Tilg and Moschen 2008; Fabbrini, Sullivan et al. 2010]. In fact, 
many inflammatory markers that have been associated with insulin resistance, T2DM, 
metabolic syndrome, and cardiovascular diseases such as CRP, PAI-1, and fibrinogen are 
liver proteins [Cai, Yuan et al. 2005]. Bruce and Byrne suggest that hepatic ectopic fat 
accumulation per se is associated with a pro-inflammatory state; together being central to 
the development of the metabolic syndrome [Bruce and Byrne 2009]. Accordingly, it has 
been shown that hepatic steatosis increased production of pro-inflammatory cytokines 
including IL-6 [Wieckowska, Papouchado et al. 2008], showing the strong link between 
NAFLD and increased cardiovascular risk [Alkhouri, Tamimi et al. 2009]. Similarly, in 
animal models, high-fat diet and genetically induced obesity resulted in hepatic steatosis, 
insulin resistance, and increased hepatic pro-inflammatory markers including NF-kB 
activity, IL-6, IL-1β, TNF-α [Samuel, Liu et al. 2004; Cai, Yuan et al. 2005]. Joshi-Brave 
et al. induced lipid accumulation in hepatocytes (rat and human primary hepatocytes) by 
exposing them to pathophysiologically relevant concentrations of palmitic acid to stimulate 
the excessive influx of fatty acids into hepatocytes [Joshi-Barve, Barve et al. 2007]. This 
was accompanied by hepatic steatosis (increased intracellular TAG) that induced hepatic 
inflammation (elevated pro-inflammatory IL-8) through activation of NF-kB and JNK1. 
Moreover, Cai and colleagues demonstrated that sub-acute hepatocellular activation of NF-
kB caused hepatic inflammation without steatosis and resulted in both hepatic and skeletal 
muscle insulin resistance notably through IL-6 since these animals increased hepatocyte 
expression of IL-6 and plasma IL-6 concentrations; and IL-6 neutralization (IL-6 antibody) 
restored insulin sensitivity in both hepatic and peripheral insulin resistance [Cai, Yuan et al. 
2005]. These findings suggest that steatosis can cause sub-acute hepatocellular 
inflammation by activating IKKβ/NF-kB pathway, which up-regulates the production of 
pro-inflammatory cytokines that mediate both local hepatic and systemic insulin resistance. 
The balance between various inflammatory mediators seems to play an important 
role in hepatic and systemic insulin action and also in the development of fatty liver disease 
[Tilg and Hotamisligil 2006]. For instance, it has been suggested that a proper balance 
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between IL-10 and TNF-α, rather than any of individual cytokines is of more physiological 
importance and IL-10/TNF-α ratio has been pointed out as an indicator of inflammatory 
status [Kaur, Sharma et al. 2006; Leonidou, Mouzaki et al. 2007]. TNF-α plays a central 
role in initiating and sustaining inflammation and has a pivotal role in the production of 
several cytokines [Ksontini, MacKay et al. 1998; Coppack 2001; Trayhurn and Wood 
2005]. Whereas, IL-10 demonstrates potent anti-inflammatory properties through 
restraining IKKβ/NF-kB signaling pathway and inhibiting the production of various pro-
inflammatory cytokines including IL-6 and TNF-α [Schottelius, Mayo et al. 1999; Bolger, 
Sharma et al. 2002]. Hashem et al. reported that IL-10/TNF-α ratio is a convenient 
predictive biomarker for investigation of fatty liver of different grades and suggests that 
modulation of this ratio in favor of increasing it may exert significant improvement 
[Hashem, Mahmoud et al. 2008]. However, considering the fact that IL-6 by itself is known 
to induce insulin resistance in hepatocytes [Kim, Higashimori et al. 2004] and according to 
their results on IL-6 as the strongest evidence of pathological involvement, Cai et al. state 
that ‘’many pieces of the pathogenic puzzle are still missing including how steatosis 
activates IKK-β and NF-κB and how IL-6 mediates hepatic insulin resistance’’ [Cai, Yuan 
et al. 2005]. 
 
Inflammation and menopause  
The increase in visceral adiposity along with deprivation of female ovarian sex 
hormones across the menopausal transition may result in the development of pro-
inflammatory cytokine changes, pointing to a role of cytokines and inflammation in 
metabolic disorders. In fact, it has been suggested that adipocytokines may be a link 
connecting postmenopausal hormonal changes, the excess of visceral fat and increased risk 
of cardiovascular disease [Sieminska, Cichon-Lenart et al. 2006]. There is now a large body 
of evidence suggesting that the decline in ovarian function with menopause increases pro-
inflammatory cytokines such as CRP, IL-1, IL-6, and TNF-α [Pfeilschifter, Koditz et al. 
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2002; Vural, Akgul et al. 2006; Georgiadou and Sbarouni 2009; Kireev, Tresguerres et al. 
2010]. Physiological concentrations of E2 have been shown to inhibit the spontaneous 
secretion of these pro-inflammatory cytokines [Rogers and Eastell 2001; Vural, Akgul et al. 
2006] suggesting that estrogens have anti-inflammatory and vasoprotective properties 
[Miller and Duckles 2008]. However, a review paper that recently outlined the effects of 
hormone replacement therapy on inflammatory biomarkers states that although animal and 
observational studies have shown beneficial effects of hormone replacement therapy in 
early periods of post-menopause, randomized trials in older women have not shown any 
benefit in the prevention of cardiovascular events; strongly supporting the current practice 
which is not to prescribe HRT [Georgiadou and Sbarouni 2009]. 
In rodents, it has been shown that serum IL-1β increases shortly after Ovx which 
precedes body mass and retroperitoneal fat mass increases; indicating the fact that the 
interplay between ovarian function and inflammatory cytokines may not be directly related 
to weight and fat gain per se [Percegoni, Ferreira et al. 2009]. Moreover, inflammatory 
responses of different tissues in animal models of menopause have been investigated. 
Estrogen-deficient rats were found to have increased production of IL-6 and IL-8 in adipose 
tissue [Bruun, Nielsen et al. 2003]. Hamilton et al. found an Ovx-induced increases in 
myocardial genes mediating inflammation including IL-6 and TNF-α [Hamilton, Lin et al. 
2008]. In the study by Kireev et al., inflammation (increased pro-inflammatory cytokines 
TNF-α, IL-1β, IL-6 and decreased anti-inflammatory cytokine IL-10) induced during aging 
in the liver were more marked in castrated than in intact old female rats [Kireev, 
Tresguerres et al. 2010]. Administration of hormonal replacement therapy was able to 
inhibit the induction of pro-inflammatory cytokines in different tissues in all of these 
studies. More interestingly, very recently, the research group of Greenburg in Tufts 
University showed that increased inflammation is an early event in the development of 
Ovx-induced obesity and identified, for the first time, distinct depot-specific inflammatory 
profiles that support a role for macrophages in Ovx-associated adipose tissue inflammation; 
highlighting the loss of ovarian function as a metabolic risk factor that can promote a 
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deleterious state of chronic inflammation even in the absence of dietary change [Rogers, 
Perfield et al. 2009]. Ovx-induced hepatic steatosis in this study was associated with the 
induction of hepatic TNF-α and osteopontin (a cytokine is implicated in the progressive 
pathophysiology of hepatic inflammation and cancer as well as the development of insulin 
resistance and atherosclerosis) (Figure 7). On the other hand, it is important to recall that 
physical activity mediates anti-inflammatory effects in skeletal muscle and fat tissue 
[Bruunsgaard 2005]. However, to our knowledge, currently the effects of exercise training 
on Ovx-induced hepatic inflammation are entirely unknown. In humans, exercise 
intervention has been shown to improve the metabolic and lipid profile and to reduce 
inflammatory and cell adhesion molecules in postmenopausal women [Wegge, Roberts et 
al. 2004].   
 
General objective of thesis and presentation of manuscripts 
The general objective of this thesis is to provide information on the treatment and 
prevention of estrogen withdrawal-induced fat mass increase and hepatic steatosis by 
lifestyle modifications including diet and exercise training in Ovx rat model of menopause. 
Following this objective, in this chapter the emergence of metabolic syndrome (intra-
abdominal fat) and hepatic steatosis in the postmenopausal hormonal state, and their 
treatment and prevention by lifestyle modifications such as exercise training have been 
reviewed. In addition, the review on the pathogenic role of sub-acute inflammation in 
obesity and insulin resistance was presented. In coming chapters (chapters 2-5) the 
experimental studies of this thesis will be presented. The first study was undertaken to 
evaluate the effect of resistance training protocol on body weight and fat mass in Ovx 
Sprague-Dawley rats following diet-induced weight loss. In line with approach, the aim of 
the second study was to investigate the effects of maintaining only one of the two 
components of a food restriction (FR) + resistance training (RT) regimen on the regain of 
body weight and fat mass (liver and adipocytes) in Ovx rats. The third study was conducted  
  
 
59
 
Figure 7. Taken from [Rogers, Perfield et al. 2009] Ovx mice display early hepatic 
steatosis and inflammation. A, Representative hematoxylin and eosin staining demonstrates 
more lipid droplet development in liver sections from OVX mice. B, Liver gene expression 
determined using quantitative real-time PCR. Error bars indicate SEM. n = 7–10. *, P 
<0.05; **, P< 0.01; ***, P< 0.001.  
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to determine whether a training state protects against the metabolically deleterious effects 
of ovariectomy on liver and adipocytes fat accumulation in rats. In continuation of this 
study, we hypothesized, in the fourth study that the reduction in liver fat accumulation 
known to occur with exercise training in Ovx rats is associated with reduced expression of 
genes involved in lipogenesis while favoring the expression of transcription factors 
regulating lipid oxidation. In this last study, we also tested the hypothesis that liver fat 
accumulation in Ovx rats is associated with an increased gene expression of several pro-
inflammatory markers and that exercise training would attenuate this response. 
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Abstract 
Objective: Fat mass gain and regain following weight loss is a major concern and 
may even be more critical after menopause. The present study was undertaken to evaluate 
the effect of resistance training protocol on body weight and fat mass in ovariectomized 
Sprague-Dawley rats following diet-induced weight loss.  
Design: Rats were randomly divided into ovariectomized (Ovx) and sham-operated 
(Sham) groups. Five weeks after ovariectomy, Ovx rats were subjected to a 26% food 
restriction (OvxFR) for 8 wk. Following this period, OvxFR rats went back to a normal ad 
libitum feeding and divided into two groups: either sedentary or undergoing a resistance 
training program for an additional 5 weeks, which consisted of climbing a 1.5-m vertical 
grill, 20-40 times, with progressively increasing load 4 times/week.  
Results: The food restriction program decreased (P < 0.01) body mass, fat pad 
weight (intra-abdominal and subcutaneous), and liver triacylglycerol (TAG) levels as 
compared to normally fed Ovx rats. Stopping the food restriction program over a 5-week 
period resulted in a partial regain in body weight and intra-abdominal fat pad weight (P < 
0.05), and in an almost complete regain in liver TAG compared to normally fed Ovx rats. 
On the other hand, no significant increases in these variables were noted when the food 
restriction was replaced by resistance training over the same 5-week period.  
Conclusion: These results indicate that a resistance training program could be 
useful in preventing body weight as well as adipose tissue and liver fat regain in Ovx rats, 
following diet-induced weight loss. It is suggested that alternating from a food restriction 
regimen to a resistance training program can be an interesting strategy to promote 
successful long-term weight reduction in postmenopausal women. 
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Introduction 
Menopause is associated with increased risks of developing obesity and its 
associated health problems such as dyslipidemia, diabetes and cardiovascular diseases.1 In 
recent years, fat accumulation in liver, often in conjunction with increased fat in intra-
abdominal depots, has been identified as an important factor in the development of insulin 
resistance and it is now considered as the hepatic component of the metabolic syndrome.2, 3 
Recent data in ovariectomized (Ovx) rats support the interpretation that the absence of 
estrogens contributes to liver lipid infiltration.4 There is also good evidence that menopause 
is in fact associated with the development of a state of hepatic steatosis.5 In a recent study 
that included 800 women aged 40-59 years, it was confirmed that the menopausal status is 
indeed associated with a state of hepatic steatosis.6 Therefore, information regarding fat 
accumulation in liver and adipocytes is needed to establish strategies to counteract the 
deleterious metabolic effects of increased body fat content in postmenopausal women. 
Weight loss achieved through lifestyle modifications (diet and exercise) may reduce 
the risks of developing obesity-induced disorders in post-menopausal women.7, 8 It has been 
reported that weight loss, as modest as 5 to 10%, can reduce obesity-related disorders.9 
However, long-lasting maintenance of weight loss is difficult to achieve and body weight 
relapse is a common feature after weight loss intervention.10-12 Strategies to improve the 
maintenance of weight loss and its associated metabolic changes are multiple but most of 
them involve changes in diet and higher levels of physical activity.13-15 Since weight loss 
achieved through restrictive diet has negative effects on muscle mass,16 some authors used 
a resistance training program in conjunction with energy restriction in postmenopausal 
women with 17 and without 18 beneficial effects on body weight and fat mass. In a recent 
study, an Ovx rat model was used to evaluate the effects of adding resistance training to a 
restrictive diet. In this study, it was found that the addition of resistance training to food 
restriction not only further reduced fat accumulation in the intra-abdominal depots, but 
completely abolished liver lipid accumulation in the Ovx rats.19 It is thus possible that 
resistance training may constitute an interesting adjunct therapy to food restriction to 
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maintain the beneficial effects of food restriction in estrogen-deficient animals and in 
postmenopausal women. In the present study, we used an Ovx rat model to test the 
hypothesis that substituting food restriction by resistance training after a period of weight 
loss would maintain the decrease in fat accumulation in liver and adipose tissue that occurs 
with weight loss.  
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Methods 
Animal care. Six-week-old Sprague-Dawley female rats, ranging in mass from 180 
to 200 g were purchased from Charles River (St-Constant, PQ, Canada) and maintained on 
a 12:12 h light-dark cycle, with lights on at 0600. The animals were housed individually 
throughout the study at 20-23°C ambient temperature. All rats received standard rat chow 
(12.5% fat; 63.2% carbohydrate; 24.3% protein; kJ, Agribrands Purina Canada, Woodstock, 
ON, Canada) and had free access to tap water. Rats were randomly divided into seven 
groups (n = 8 per group) that initially had similar mean body masses and were treated 
similarly in terms of daily manipulations. All experiments described in this report were 
conducted according to the guidelines of the Canadian Council on Animal Care after 
institutional approval. 
Surgery. Two days after their arrival to our laboratory, rats were randomly divided 
into ovariectomized (Ovx) and sham-operated (Sham) groups. Ovx was conducted 
according to the technique described by Robertson and colleagues.20 Animals were injected 
with antibiotics (Tribrissen 24%; 0.125cc/kg s.c.) for 3 days, beginning the day before 
surgery. We followed the surgery guidelines that have been described in the report of 
Shinoda and colleagues.21 Following surgery, body weight and food intake were monitored 
three times per week in all rats. 
Groups, food restriction and training protocol. A schematic representation of the 
experimental design is presented in Figure 1. Five weeks after ovariectomy, rats were first 
submitted to a food restriction regimen (OvxFR) for 8 weeks (weeks 6-13). Following this 
period, OvxFR rats went back to a normal ad libitum feeding while either remaining 
sedentary (OvxPostFR) or being submitted to a resistance training program 
(OvxPostFR+RT) for an additional 5 weeks (weeks 14-18). Subgroups of Sham and Ovx 
rats were sacrificed either after 13 or 18 weeks. The food restriction program consisted of a 
target 25% daily caloric reduction calculated from the daily energy intake average of the 2 
preceding weeks in normally fed rats. It turned out that the daily caloric reduction was 26% 
for the rats submitted to this program for 8 weeks (weeks 6-13). Resistance training was 
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conducted using a device similar to the one described by Murphy and colleagues.22 The 
resistance training program consisted of climbing on a 1.5-m vertical metal grill with a 
slope of 7°, four times a week with a progressively increasing load up to 50% of body 
weight attached to the tail. The number of repetitions increased progressively during the 
first 2 weeks from two sets of ten repetitions to four sets of ten repetitions. Each repetition 
lasted ~3-5 s with ~40 s rest between repetitions. Exercise animals were sacrificed 48 h 
after the last exercise session. 
Sacrifice. Rats were sacrificed between 09.00 and 12.00. Remaining food was 
removed from the animal’s cage at least 3 h before sacrifice. Immediately after complete 
anesthesia (pentobarbital sodium; 50mg/kg i.p.), the abdominal cavity was opened 
following the median line of the abdomen, and approximately 4 ml of blood were collected 
from the abdominal vena cava (<45s) into syringes pre-treated with 
ethylenediaminetetraacetic acid (15%, EDTA). Blood was centrifuged at 3000 rpm at 4°C 
for 12 min (Beckman GPR Centrifuge) and the plasma was kept for further analysis. 
Several organs and tissues were removed and weighed (Mettler AE 100) in the following 
order: liver, uterus, mesenteric, urogenital, retroperitoneal and subcutaneous fat deposits 
along with four skeletal muscles of the right hind-limb (soleus, plantaris, medial 
gastrocnemius and lateral gastrocnemius). All tissue samples were frozen in liquid nitrogen 
immediately after they were weighed. The liver median lobe was freeze-clamped and used 
for triacylglycerol (TAG) determination. Mesenteric fat was collected from the superficial 
area covering the alimentary tract, the spleen and the pancreas. Special care was taken to 
distinguish fat cells from pancreatic cells, based on color and texture differences. On the 
right side of the animal, the subcutaneous fat was removed from the region between the 
caudal border of the rib cage, the dorsal and ventral midlines of the body and the urogenital 
organs. All tissue and plasma samples were stored at -78°C until analyses were performed. 
All rats were visually inspected for presence or not of ovaries, and uteri were excised and 
weighed to confirm ovariectomy or sham surgery. 
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Analytical procedures. Plasma 17β-estradiol and insulin concentrations were 
determined with radioimmunoassay test kits distributed by ICN Biomedicals (Costa Mesa, 
CA, USA) and Medicorp Laboratories (Montreal, PQ, Canada), respectively. Plasma 
glucose concentrations were determined with the use of a glucose analyzer (Yellow Springs 
Instruments 2300, Yellow Springs, OH, USA). Plasma glucose and insulin values were 
used to calculate a homeostasis model assessment of insulin resistance (HOMA-IR) as 
followed: glucose (mmol/l) x insulin (mIU/ml)/22.5.23 Plasma free fatty acid (FFA) and TAG 
concentrations were determined with an enzymatic colorimetric assay available from Roche 
Diagnostics (Mannheim, Germany) and Sigma (Saint Louis, Missouri, USA), respectively. 
Liver TAG concentrations were estimated from glycerol released after ethanolic KOH 
hydrolysis by using commercial kit from Sigma (Saint Louis, Missouri, USA).  
Statistical analysis. Values are expressed as means ± standard error (SE). Statistical 
analyses were performed by one-way ANOVA for non-repeated measures design using 
treatment as a main effect. These analyses were conducted separately at two different times 
(13 and 18 weeks). Fisher’s post hoc test was used in the event of a significant (P < 0.05) F 
ratio. The effect of ovariectomy on food intake between weeks 1 and 5 was analyzed using 
unpaired t-test. 
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Results 
Final body weight and food intake. Ovariectomized as compared to Sham animals 
had higher body weight, measured either after 13 and 18 weeks (Figure 2a). Food 
restriction between weeks 5 and 13 led to significantly (P < 0.01) lower final body weight 
in Ovx rats than that observed in the free-feeding Ovx animals. In fact, body weight in 
OvxFR animals was not significantly different from that measured in Sham rats at 13 
weeks. Interrupting the food restriction treatment between weeks 13 and 18 resulted in 
body weight values that were still lower (P < 0.05) than values measured in free-feeding 
Ovx rats but higher (P < 0.01) than Sham rats (Figure 1a). This indicates a partial regain of 
body weight with the abandonment of the food restriction program. However, the final 
body weight in Ovx rats in which food restriction was substituted by resistance training 
between weeks 13 and 18 was not significantly different that of Sham rats but significantly 
lower than that observed in both OvxPostFR and Ovx (P < 0.01). 
As for body weight, food intake was higher (P < 0.01) in Ovx than in Sham rats 
during the first 5 weeks after surgery (Figure 2b). As designed, the 8-week food restriction 
program resulted in a lower (P < 0.01) food intake in OvxFR compared to ad libitum fed 
Ovx rats. However, all groups of animals had similar food intake from weeks 14 to 18.  
Uterus weight, plasma estradiol and muscle weight. All Ovx animals showed lower 
(P < 0.01) uterus weight and plasma estradiol concentrations than Sham rats, indicating 
total ovariectomy (Table 1). Ovx resulted in higher (P < 0.05) muscle weight compared to 
Sham animals and these higher values were maintained whether Ovx rats underwent the 
food restriction or the resistance training treatment. This relation was, however, abolished 
when the sum of muscle weight was divided by body weight. The gain in muscle weight 
with ovariectomy was observed only in conditions where body weight in Ovx rats was 
reduced, that is, after food restriction and when food restriction was substituted by 
resistance training.  
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Plasma glucose, insulin and free fatty acids concentrations. There was no 
difference in plasma glucose concentration after 13 weeks (Table 2). After 18 weeks, 
however, plasma glucose concentrations were higher (P < 0.01) in Ovx and OvxPostFR rats 
compared to Sham animals; this result was attenuated by substituting food restriction by 
resistance training (P < 0.05). The food restriction regimen and substitution of food 
restriction by resistance training in OvxFR and OvxPostFR+RT rats, respectively, led to 
lower plasmatic concentrations of insulin compared to Ovx rats. Calculation of the HOMA-
IR ratio indicated lower values in OvxFR compared to Ovx rats at week 13. Interestingly, 
the resistance training program in OvxPostFR+RT animals was associated with lower 
HOMA-IR ratio compared to Ovx and OvxPostFR rats. There were no inter-group 
differences in plasma free fatty acid levels (Table 2). 
Liver and plasma TAG concentrations. Ovarictomy resulted in significantly (P < 
0.01) higher levels of liver TAG measured either after 13 and 18 weeks (Figure 3a). Food 
restriction between weeks 5 and 13 significantly (P < 0.01) attenuated liver lipid infiltration 
in Ovx rats such that no significant differences were found compared to Sham rats. 
Abandoning the food restriction regimen between weeks 13 and 18 resulted in a regain in 
liver fat levels that were midway between those measured in Sham and Ovx animals. 
However, substituting food restriction by resistance training kept liver TAG levels in 
OvxPostFR+RT rats to the level of Sham rats. Similar findings were observed for plasma 
TAG levels (Figure 3b). Plasma TAG levels were not significantly different between Ovx 
and Sham rats after 13 weeks but were lower in Ovx than in Sham animals after 18 weeks. 
The FR regimen significantly (P < 0.01) reduced plasma TAG accumulation in Ovx rats 
(week 13). Plasma TAG levels returned to the level of normally fed Ovx rats 5 weeks after 
abandoning the food restriction treatment. Interestingly, however, substituting food 
restriction by resistance training prevented the re-increase in plasma TAG levels. 
Intra-abdominal and subcutaneous fat pad weights. The sum of three intra-
abdominal fat pad weight and subcutaneous fat depots were higher in Ovx than in Sham 
rats either after 13 (P < 0.01) or 18 weeks (P < 0.05) (Figure 4). Similarly to what we 
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observed for liver TAG levels, food restriction significantly (P < 0.01) reduced fat depots 
in adipose tissues in Ovx rats. Interrupting of the food restriction regimen during 5 weeks 
did not result in a pronounced regain of fat mass such that fat pad weights were still lower 
(P < 0.05) than what was measured in Ovx rats. However, substituting food restriction by 
resistance training largely lowered (P < 0.01) fat mass accumulation. 
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Discussion 
In this study, we sought to determine the efficacy of resistance training in 
attenuating the regain of adiposity and liver fat after the cessation of a prolonged food 
restriction leading to weight loss in Ovx rats. Results of this experimental approach indicate 
that substitution of resistance training favored the maintenance of a lower body weight and 
adiposity in this animal model. These data support the concept that resistance training may 
provide a successful alternative to chronic food restriction to avoid relapse of body weight 
and lipid accumulation in Ovx rats. 
Body weight. As previously reported, body weight was higher in Ovx than in Sham 
rats.24, 25 The ~ 25% FR in OvxFR animals resulted in a reduction of body weight to the 
level of Sham animals (Figure 2a, week 13). Considering that food intake in OvxFR 
animals was lower than in Sham rats, one would have expected a larger reduction in body 
weight. This suggests a decrease in energy expenditure in the OvxFR rats. As expected, the 
abandonment of the food restriction regimen resulted in a regain of body weight, but not 
completely since body weight in OvxPostFR rats was still lower than in Ovx animals. 
Nevertheless, this partial regain in body weight was significantly attenuated by substituting 
resistance training for food restriction. These changes in body weight can hardly be 
attributed to differences in food intake since food intake was similar in all groups after the 
abandonment of the food restriction program (Figure 2b, weeks 14-18). It is well 
documented that weight-reduced rats show a profound drive to regain lost weight when 
they are allowed free access to food.26, 27 A large body of evidence now suggests that a 
homeostatic feedback system defending body weight and adiposity is fundamental to this 
metabolic drive to regain lost weight.28-30 Interestingly, it has also been reported that 
exercise lowers the defended level of weight gain and adiposity.31 These authors suggested 
that exercise resets the homeostatic balance between energy intake and expenditure toward 
defense of a lower level of weight gain and adiposity. It seems that exercise produces a 
different set of regulatory signals from caloric restriction that lowers the defended level of 
weight gain and adiposity.31 In a recent study,32 the same authors showed that early-onset 
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exercise, as opposed to early caloric restriction, may favorably alter the development of the 
hypothalamic pathways controlling energy homeostasis during brain development. It may, 
therefore, be inferred that the introduction of the resistance training program initiated a new 
set of regulatory signals that contributes to the maintenance and even the lowering of the 
defended body weight gain and adiposity after cessation of the food restriction regimen.  
Liver TAG and adiposity. The main objective of the present study was to determine 
whether substituting food restriction by resistance training would help to maintain the 
decreased liver lipid infiltration that is likely to occur with food restriction in Ovx rats. The 
importance of this information has been highlighted in recent years by the recognition of 
hepatic steatosis as the hepatic component of the metabolic syndrome.33 Ovx in the present 
study resulted in ~ 50-55% higher fat accumulation in the livers of our rats (Figure 3a). 
Food restriction resulted in a complete resorption of liver fat accumulation to the level of 
that in Sham rats (week 13), along with an important reduction in plasma TAG. In a recent 
study,19 only a partial reduction of liver TAG levels was found after 8 weeks of food 
restriction in Ovx rats. The discrepancy between the two studies may be due to a better 
control of the food restriction regimen in the present study. The abandonment of the food 
restriction resulted in regains of liver and plasma TAG that were significantly attenuated by 
the introduction of the resistance training program. It was previously reported that the 
adjunct of a resistance training program to a food restriction regimen largely contributed to 
the reduction of fat accumulation in liver of Ovx rats.19 The present data complement this 
finding by indicating that a food restriction regimen may be adequately replaced by a 
resistance training program to maintain low liver fat accumulation in Ovx animals. 
Although the present study did not address mechanisms involved in these responses, it is 
likely that the mechanisms of action are different for the food restriction than for the 
resistance training treatment. Food intake reduction in the present Ovx rats was important, 
reaching food intake levels lower than what was ingested in Sham rats. This must have 
substantially reduced the amount of substrate taking up by the liver and consequently 
resulted in a progressive resorption of accumulated lipids. A return to a normal diet would 
increase the amount of substrate available, thus causing a regain of liver fat accumulation. 
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The introduction of resistance training  after cessation of food restriction would, on the 
other hand, control liver fat accumulation by stimulating lipid oxidation inside the liver 
itself, in addition of increasing energy expenditure. This interpretation is supported by the 
observation that the introduction of the resistance training program after cessation of the 
food restriction regimen not only prevented the relapse in fat accumulation in adipose 
tissues, but reduced fat mass to levels lower than those measured in Ovx animals. Since 
changes in liver fat accumulation paralleled changes in adipose tissue fat mass following 
food restriction and resistance training in Ovx rats, one may reach the conclusion that liver 
fat accumulation is strictly related to adipose tissue fat accumulation or relapse. Although 
this is probably correct to a certain point, it must be kept in mind that estrogens can act 
intrahepatically as a protective tool against liver lipid infiltration. Estrogens are known to 
have a role in regard to several regulatory aspects of hepatic lipid metabolism, including 
very low density lipoprotein synthesis.34, 35 The absence of estrogens as such could 
therefore favor liver fat accumulation. If, on one hand, food restriction would most likely 
reduce the amount of lipids taken up by the liver, on the other hand, it is possible that 
resistance training may stimulate metabolic pathways in liver common to estrogens, thus 
favoring a reduction in hepatic fat accumulation. In this regard, endurance training in Ovx 
rats has been recently reported to have beneficial effects similar to those of estrogens on the 
heart of Ovx rats.36 
Food restriction in Ovx rats was associated with lower plasma insulin levels 
compared to ad libitum fed Ovx rats. However, this effect was not observed anymore after 
cessation of food restriction, indicating an increase in insulin levels. Plasma glucose levels 
were also higher with cessation of food restriction as compared to values in Sham rats. 
Most interestingly, it is with the introduction of the resistance training program that the 
lower plasma glucose and insulin values were observed. Although our rats were not in an 
overnight fasted state (3-h fast or more), we calculated HOMA-IR to obtain an index of 
insulin sensitivity. This index indicates a deterioration of insulin sensitivity with Ovx (week 
13), which was improved by the food restriction regimen and even more by the resistance 
training program. Although insulin sensitivity in the present context should be measured 
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using more sophisticated techniques, the present data suggest that, in addition to attenuating 
fat accumulation resulting from cessation of a food restriction regimen, the introduction of 
a resistance training program in Ovx animals may also be an adjunct in attenuating the 
metabolic deleterious effects associated with the withdrawal of ovarian hormones. 
The appropriateness of present resistance training program in Ovx animals needs to 
be addressed. It is difficult to use a RT program in rats without mobilizing several muscle 
groups. Taken into account the very short active time (~ 3-5 s) interspersed by a relatively 
long period of rest (~ 40 s), we feel confident that the nature of the present training program 
is closely related to resistance training. In the present resistance training program, rats were 
trained four times a week with a maximal load attached to the tail of the rats of 50% body 
weight, compared to five times a week with a maximal load of 75% body weight in a 
previous study.19 It was thought that these limitations make the program more suitable to 
Ovx rats. Both of these resistance training programs did not result in higher muscle mass 
compared to Ovx. This may be explained by the fact that ovariectomy itself resulted in an 
increased muscle mass, attributed to increased body weight.25 Accordingly, there was no 
difference in muscle mass/body weight between Sham and Ovx rats. The abandonment of 
the food restriction regimen resulted in a tendency (P < 0.09) to lower relative muscle mass 
values (0.73 vs 0.65). However, substituting food restriction by resistance training resulted 
in the maintenance of the relative muscle mass (0.73 vs 0.71). This may be taken as an 
indication that the present resistance training program had an effect on muscle mass. 
In summary, results of the present study show that the cessation of food restriction 
regimen aimed at lower body weight and fat accumulation in Ovx rats may be 
advantageously substituted by a resistance training program, without causing any 
appreciable regain of body weight and fat in liver and adipose tissue. The resistance 
training program was even associated with a lowering of fat accumulation in adipocytes to 
levels lower than measured in Sham rats.  
While it is still unclear whether the menopause transition itself brings about weight 
gain,37 there is good evidence that menopause is associated with weight gain and changes in 
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fat distribution that increase the risk of cardiovascular diseases.38, 39 There is also recent 
evidence that withdrawal of estrogens results in rapid fat accumulation in liver of 
postmenopausal women.6 Postmenopausal women are, therefore, often confront with the 
undertaking of lifestyle modifications (nutrition and exercise) that are so hard to maintain 
in practice. Results of the present study suggest that changing from a food restriction 
regimen to a resistance training program may prove to be an interesting strategy to promote 
successful long-term weight reduction in postmenopausal women. 
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Table 1. Uterus weight, estradiol levels, and sum of weight of four muscles measured after 
13 and 18 weeks in the following groups of rats: Sham (sham-operated), Ovx 
(ovariectomized), OvxFR (5-week ovariectomized + 8-week food restriction), OvxPostFR 
(5-week ovariectomized + 8-week food restriction + 5-week interruption of food 
restriction), and OvxPostFR+RT (5-week ovariectomized + 8-week food restriction + 5-
week resistance training). Values are given as mean ± standard error with n = 8 rats in each 
group 
 
 
Significantly different from Ovx group, bP < 0.01; significantly different from Sham group, 
cP < 0.05, dP < 0.01; significantly different from OvxFR group, eP < 0.01; significantly 
different from OvxPostFR group, fP < 0.01, gP < 0.01 
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Table 2. Plasma concentrations of glucose, insulin, HOMA-IR, and free fatty acids 
measured after 13 and 18 weeks in the following groups of rats: Sham (sham-operated), 
Ovx (ovariectomized), OvxFR (5-week ovariectomized + 8-week food restriction), 
OvxPostFR (5-week ovariectomized + 8-week food restriction + 5-week interruption of 
food restriction), and OvxPostFR+RT (5-week ovariectomized + 8-week food restriction + 
5-week resistance training). Values are given as mean ± standard error with n = 8 rats in 
each group 
 
 
Significantly different from Ovx group, aP < 0.05, bP < 0.01; significantly different from 
Sham group, cP < 0.05, dP < 0.01; significantly different from OvxPostFR group, fP < 0.05 
HOMA-IR, homeostatic model assessment of insulin resistance (glucose (mmol/l) × insulin 
(mIU/ml)/22.5; 3-h fasted state) 
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Legends 
 
Figure 1.  Schematic representation of the experimental design. The tip of the arrow 
indicates the time of sacrifice. Sham, sham-operated; Ovx, ovariectomized; FR, food 
restriction; RT, resistance training 
 
Figure 2. Body weight (a) and average daily food intake (b) measured after 5, 13 
and 18 weeks in the following groups of rats: Sham (sham-operated), Ovx 
(ovariectomized), OvxFR (5-week ovariectomized + 8-week food restriction), OvxPostFR 
(5-week ovariectomized + 8-week food restriction + 5-week interruption of food 
restriction), and OvxPostFR+RT (5-week ovariectomized + 8-week food restriction + 5-
week resistance training). Values are given as mean ± standard error with n = 8 rats in each 
group. Significantly different from Ovx group, aP < 0.05, bP < 0.01; significantly different 
from OvxFR group, eP < 0.01; significantly different from OvxPostFR group, gP < 0.01  
 
Figure 3. Liver triacylglycerol (TAG) concentrations (a) and plasma concentrations 
of TAG (b) measured after 13 and 18 weeks in the following groups of rats: Sham (sham-
operated), Ovx (ovariectomized), OvxFR (5-week ovariectomized + 8-week food 
restriction), OvxPostFR (5-week ovariectomized + 8-week food restriction + 5-week 
interruption of food restriction), and OvxPostFR+RT (5-week ovariectomized + 8-week 
food restriction + 5-week resistance training). Values are given as mean ± standard error 
with n = 8 rats in each group. Significantly different from Ovx group, aP < 0.05, bP < 0.01; 
significantly different from Sham group, dP < 0.01; significantly different from OvxFR 
group, eP < 0.01; significantly different from OvxPostFR group, fP < 0.05, gP < 0.01 
 
Figure 4. Sum of weights of three intra-abdominal (mesenteric, urogenital and 
retroperitoneal) fat depots (a) and subcutaneous fat depot weight (b) measured after 13 and 
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18 weeks in the following groups of rats: Sham (sham-operated), Ovx (ovariectomized), 
OvxFR (5-week ovariectomized + 8-week food restriction), OvxPostFR (5-week 
ovariectomized + 8-week food restriction + 5-week interruption of food restriction), and 
OvxPostFR+RT (5-week ovariectomized + 8-week food restriction + 5-week resistance 
training). Values are given as mean ± standard error with n = 8 rats in each group. 
Significantly different from Ovx group, aP < 0.05, bP < 0.01; significantly different from 
Sham group, dP < 0.01; significantly different from OvxPostFR group, gP < 0.01  
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Abstract 
Objective: The aim of the present study was to investigate the effects of 
maintaining only one of the two components of a food restriction (FR) + resistance training 
(RT) regimen on the regain of body weight and fat mass (liver and adipocytes) in 
ovariectomized (Ovx) rats.  
Methods: Five week Ovx rats were submitted to a weight loss program consisting 
of a 26% FR combined with RT (OvxFR+RT) for 8 weeks. RT consisted of climbing a 1.5 
m vertical grid with a load attached to the tail, 20-40 times with progressively increasing 
loads 4 times/week. Following this weight loss intervention, OvxFR+RT rats were sub-
divided into 3 groups for an additional 5 weeks: 2 groups went back to a normal ad libitum 
feeding with or without RT and the other group kept only FR.  
Results: Combined FR+RT program in Ovx rats led to lower body mass gain, liver 
triacylglycerol (TAG) levels, and fat mass gain compared to sedentary normally fed Ovx 
rats (P < 0.01). Stopping both FR and RT over a 5-week period resulted in the regain of 
body weight, intra-abdominal fat pad weight and liver TAG (P < 0.01). When only FR was 
maintained, the regain of body and fat pad weight as well as liver and plasma TAG 
concentrations was completely prevented. However, when only RT was maintained, regain 
in the aforementioned parameters was attenuated but not prevented (P < 0.05).  
Conclusion: It is concluded that following a FR+RT weight loss program, 
continuation of only RT constitutes an asset to attenuate body weight and fat mass regain in 
Ovx rats; although the impact is less than the maintaining FR alone. These results suggest 
that, in post-menopausal women, RT is a positive strategy to reduce body weight and fat 
mass relapse.  
 
Key words: Food restriction, exercise, liver triacylglycerols, plasma lipid profile, 
body weight relapse. 
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1. Introduction 
Menopause in women is associated with an increased risk of incidence of several 
deleterious metabolic effects which may compromise quality of life. There is clear evidence 
that the prevalence of all individual components of the metabolic syndrome increases in 
women after menopause [1]. The tendency for weight gain is one of the most frequently 
observed sign after menopause [2] and increases the risk of obesity-related diseases 
including coronary heart diseases and type 2 diabetes in post-menopausal women [3]. 
Although therapies aimed at preventing these changes in women include hormone 
replacement therapy (HRT) [4], the risks associated with HRT have prompted extensive 
studies for other preventive or therapeutic alternatives such as diet and exercise [5].  
It is well established that ovariectomy (Ovx) in animals leads to increased food 
intake and body weight [6] thus resulting in increased adipose tissue and liver fat accretion 
[7,8]. The increase in liver fat infiltration is of special interest since recent evidences 
suggest that the deficiency in estrogens in rat directly contributes to liver fat accumulation 
[9,10]. Fatty liver is now considered as a hepatic component of the metabolic syndrome that 
is known to significantly enhance the risk of developing cardiovascular disease and/or type 
2 diabetes [11]. Moreover, recent data suggest that ectopic fat in the liver may be more 
important than visceral fat in characterization of metabolically benign obesity in humans 
[12]. It is thus of importance to investigate non-pharmacological interventions that may 
influence the accumulation of adipose tissue and/or lipids in liver following estrogen 
withdrawal. 
Resistance training (RT) may constitute an interesting adjunct to food restriction 
(FR) to control body weight and fat accumulation in post-menopausal women [13]. 
However, it is a common observation that long-lasting maintenance of weight loss is 
difficult to achieve and body weight relapse is a common feature [14-16]. We recently 
reported, using an animal model, that a FR+RT program was effective to attenuate the 
ovariectomy-induced increase in body fat, especially in liver [17]. In line with this 
approach, the present study investigates the effect of maintaining RT or FR on body weight 
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regain, fat mass, and liver lipid infiltration in estrogen deficient animals previously 
submitted to a FR+RT weight loss program. 
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2. Methods 
2.1. Animal care 
Female Sprague-Dawley strain rats (n = 64) weighing 180-200g (6 weeks of age) 
were obtained from Charles River (St-Constant, PQ, Canada) and were housed individually. 
The 12:12-h light-dark cycle started at 6:00 AM and the room temperature was maintained 
at 20-23°C. All rats received usual pellet rat chow, referred to as the standard diet (SD; 
12.5% fat; 63.2% carbohydrate; 24.3% protein; kcal, Agribrands Purina Canada, 
Woodstock, ON) and had free access to tap water. The experiments described in this report 
were conducted according to the directives of the Canadian Council on Animal Care after 
institutional approval. 
2.2. Surgery 
Two days after their arrival to our laboratory, rats were randomly divided into 
ovariectomized (Ovx) and sham-operated (Sham) groups. Ovx was conducted according to 
the technique described by Robertson et al. [18]. Animals were injected with antibiotics 
(Tribrissen 24%; 0.125cc/kg, sc) for three days, beginning the day before surgery. Details 
of the surgery have been previously described [19]. Following surgery, body weight and 
food intake were monitored three times per week in all rats. 
2.3. Groups, food restriction and training protocol 
Rats were randomly divided into 8 groups (n = 8/group) that had similar initial 
mean body mass and were treated similarly in terms of daily manipulations. A schematic 
representation of the experimental design is presented in Fig. 1. Rats that had been 
ovariectomized for 5 weeks were first submitted to a program of weight loss consisting of a 
FR regimen combined with a program of RT (OvxFR+RT) for 8 weeks (weeks 6-13). 
Following this period, OvxFR+RT rats were sub-divided into 3 groups for an additional 5 
weeks (weeks 14-18): One group stopped both RT and FR (Ovx[postFR-RT]), one group 
continued FR while stopping RT (Ovx[contFRw/oRT]), and the last group went back to a 
normal ad libitum feeding while continuing RT (Ovx[contRTw/oFR]). Subgroups of Sham 
  
 
96
and Ovx rats were either sacrificed after 13 or 18 weeks. The FR program consisted in a 
target 25% daily caloric reduction calculated from the daily energy intake average of the 2 
preceding wk in normally fed rats. It turned out that the daily caloric reduction was 26% for 
the rats submitted to this program. RT was conducted using a device similar to the one 
described by Murphy et al. [20]. The resistance training program consisted of climbing on a 
1.5 m metal grill with a slope of 7° from the wall, 4 times a week with a progressively 
increasing load up to 50% of body weight attached to the tail. The climbing grid (0.6-cm 
mesh) was divided into six 15-cm lanes. The animals were placed at the bottom of the grid 
(approximately 60 cm from the floor), head up, and climbed to the top where they could 
rest on a platform. The number of repetitions increased progressively during the first 2 
weeks from 2 sets of 10 repetitions to 4 sets of 10 repetitions. Each repetition lasted ~3-5 s 
with ~40 s rest between repetitions. Exercise animals were sacrificed 48 h after the last 
exercise session. 
2.4. Sacrifice 
Rats were sacrificed between 09:00 and 12:00 AM. Remaining food was removed 
from the animal’s cage at least 3 h before sacrifice. Immediately after complete anesthesia 
(pentobarbital sodium; 50mg/kg, ip), the abdominal cavity was opened following the 
median line of the abdomen and approximately 4 mL of blood was collected from the 
abdominal vena cava (<45s) into syringes pre-treated with ethylenediaminetetraacetic acid 
(15%; EDTA). Blood was centrifuged (3000 rpm; 4°C; 12 min; Beckman GPR Centrifuge) 
and the plasma was kept for further analysis. Several organs and tissues were removed and 
weighed (Mettler AE 100) in the following order: liver, uterus, mesenteric, urogenital, 
retroperitoneal, and subcutaneous fat deposits along with 4 skeletal muscles of the right 
hindlimb (soleus, plantaris, medial gastrocnemius, and lateral gastrocnemius). All tissue 
samples were frozen in liquid nitrogen immediately after they were weighed. The liver 
median lobe was freeze-clamped and used for triacylglycerol (TAG) determination. 
Mesenteric fat was collected from the superficial area covering the alimentary tract, the 
spleen and the pancreas. Special care was taken to distinguish fat cells from pancreatic cells 
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based on color and texture differences. On the right side of the animal, the subcutaneous fat 
was removed from the region between the caudal border of the rib cage, the dorsal and 
ventral midlines of the body and the urogenital organs. All rats were visually inspected for 
presence or not of ovaries, and uteri were excised and weighed to confirm ovariectomy or 
sham surgery. All tissue and plasma samples were stored at -78° C until analyses were 
performed.  
2.5. Analytical procedures 
Plasma 17β-estradiol and insulin concentrations were determined with 
radioimmunoassay test kits distributed by ICN Biomedicals (Costa Mesa, CA) and 
MEDICORP Laboratories (Montreal, PQ, Canada) respectively. Plasma glucose 
concentrations were determined with the use of a glucose analyzer (Yellow Springs 
Instruments 2300, Yellow Springs, OH). Plasma glucose and insulin values were used to 
calculate a homeostasis model assessment of insulin resistance (HOMA-IR) as followed: 
glucose (mmol/l) x insulin (mIU/ml)/22.5 [21]. Plasma free fatty acid (FFA) and TAG 
concentrations were determined with an enzymatic colorimetric assay available from Roche 
Diagnostics (Mannheim, Germany) and SIGMA (Saint Louis, Missouri, USA), 
respectively. Liver TAG concentrations were estimated from glycerol released after 
ethanolic KOH hydrolysis by using commercial kit from SIGMA (Saint Louis, Missouri, 
USA).  
2.6. Statistical analysis 
Values are expressed as means ± S.E. Statistical analyses were performed by one-
way ANOVA for non-repeated measures design using treatment as a main effect. These 
analyses were conducted separately at two different times (13 and 18 weeks). Fisher’s post 
hoc test was used in the event of a significant (P < 0.05) F ratio. Ovx effects on body 
weight change and food intake between weeks 1 and 5 were analyzed using unpaired t-test.  
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3. Results 
3.1. Final body weight, body weight change and food intake 
Ovx resulted in higher body weight measured either after 13 and 18 weeks (Table 
1). The FR+RT program significantly (P < 0.01) reduced final body weight in Ovx animals 
to the level measured in Sham rats. Stopping both FR and RT treatments between weeks 13 
and 18 re-established body weight values back to those of Ovx animals (Table 1). This 
regain in body weight was, however, completely prevented by maintaining FR while 
stopping RT. Continuing only RT resulted in body weight values that were midway 
between those measured in corresponding Sham and Ovx animals. The extents of these 
body weight changes are illustrated in Fig. 2A. These data first show that the gain in body 
weight following Ovx was mainly observed during the first 5-week post-surgery. These 
data also show the attenuation of body weight regain when FR or RT was maintained. 
Food intake measured throughout the experiment follows a pattern similar to body 
weight changes (Fig. 2B). Food intake was higher (P < 0.01) in Ovx than in Sham rats 
between weeks 1-5 but not between weeks 6-13 and weeks 14-18. As planned, the FR 
program resulted in a lower (P < 0.01) food intake in OvxFR+RT (weeks 6-13) and 
Ovx[contFRw/oRT] (weeks 14-18) compared to all other ad libitum fed animals. 
Abandoning FR also led to increased (P < 0.01) food intake (weeks 14-18).  
3.2. Uterus weight, plasma estradiol, and sum of 4 leg muscles weight. 
All Ovx animals showed lower (P < 0.01) uterus weight and plasma estradiol 
concentrations than Sham rats confirming total ovariectomy (Table 1). The sum of 4 
muscles weight was significantly (P < 0.01) increased in Ovx compared to Sham rats. The 
FR+RT program, however, decreased (P < 0.01) muscle mass to the level measured in 
Sham rats (Table 1). The abandon of both of the FR+RT components along with the 
selective continuation of RT or FR maintained muscle mass to the level of Ovx animals. 
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3.3. Plasma glucose, insulin, and free fatty acids concentrations 
Plasma glucose concentrations were higher in Ovx compared to almost all other 
groups (week 18) (Table 2). The FR+RT regimen between weeks 6-13 in OvxFR+RT and 
continuing either FR or RT (weeks 14-18) in Ovx[contFRw/oRT] and Ovx[contRTw/oFR], 
led to lower plasmatic concentrations of insulin compared to corresponding Ovx rats. On 
the other hand, stopping both FR and RT treatments between weeks 13 and 18 
(Ovx[postFR-RT]) increased the plasma insulin concentrations to the levels observed in 
Ovx rats (week 18). Calculation of the HOMA-IR score indicates lower values following 
the FR+RT program and the maintenance of either FR or RT of this program. There were 
no inter-group differences in plasma free fatty acid levels at week 13, but 
Ovx[contFRw/oRT] rats had lower (P < 0.05) plasma FFA concentrations compared to 
Sham, Ovx, and Ovx[postFR-RT] animals at week 18 (Table 2).  
3.4. Liver and plasma TAG concentrations 
Ovx resulted in significantly (P < 0.01) higher levels of liver TAG measured either 
after 13 and 18 weeks (Fig. 3A). FR+RT between weeks 5 and 13 significantly (P < 0.01) 
reduced liver lipid infiltration in Ovx rats to the levels of Sham rats. Abandoning both FR 
and RT between weeks 13 and 18 resulted in an increase in liver fat to the levels measured 
in Ovx animals. Interestingly, continuing either FR or RT kept liver TAG levels to the level 
measured in Sham rats.  
Plasma TAG levels were not significantly different between Ovx and Sham rats 
after 13 weeks but were lower in Ovx than in Sham after 18 weeks (Fig. 3B). The FR+RT 
weight loss program reduced (P < 0.05) plasma TAG accumulation in Ovx rats (week 13). 
Plasma TAG concentrations returned to higher levels than normally fed Ovx rats (P < 0.05) 
5 weeks after interrupting both FR and RT between weeks 13 and 18. Similarly to liver 
TAG, continuing either FR or RT prevented the increase in plasma TAG (week 18). 
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3.5. Intra-abdominal and subcutaneous fat pads 
The sum of 3 intra-abdominal (mesenteric, urogenital, and retroperitoneal) fat pads 
weight and subcutaneous fat depots were higher in Ovx than in Sham rats either after 13 or 
18 weeks (Fig. 4). FR+RT significantly (P < 0.01) reduced fat depots in Ovx rats. Stopping 
FR+RT in Ovx animals during 5 weeks resulted in a pronounced regain of fat to the levels 
of normally fed Ovx rats. On the other hand, maintenance of FR or RT largely prevented 
the fat regain although this effect was more pronounced when FR was maintained. 
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4. Discussion 
Weight loss achieved through lifestyle interventions such as diet and exercise may 
be beneficial in reducing the risks of developing obesity and associated metabolic disorders 
in post-menopausal women [22,23]. Several strategies have been put forward to improve 
maintenance of weight loss in which, most involve changes in diet and increased levels of 
physical activity [24-26]. In recent years, our research group used an ovariectomized rat 
model to show that the addition of RT to a FR treatment synergistically reduced abdominal 
fat deposition and completely prevented liver lipid infiltration [17]. Results of the present 
study confirm the efficiency of the FR+RT program in reducing body weight as well as 
liver and adipocytes fat accretion in Ovx rats. The efficiency of the present FR+RT 
program is further supported by the subsequent relapse in all measured metabolic 
parameters in rats that were removed from the program for 5 weeks. In a recent study [27] 
we also observed that RT may be successfully substituted to a FR regimen to avoid body 
weight and fat mass regain. In line with this, the present study sought to determine if 
keeping the RT component of the FR+RT weight loss program would be successful in 
avoiding the relapse of body weight and fat mass. Results of the present study indicate that, 
although maintaining FR was more efficient than maintaining RT alone, the latter was 
successful in reducing the relapse in body weight, fat mass, and plasma TAG 
concentrations.   
Liver lipid infiltration is known to increase in Ovx rats [28] and to a certain extend 
in post-menopausal women [29]. The present effect of RT on preventing liver TAG re-
increase follows a pattern similar to that found for intra-abdominal fat accumulation. Both 
of these responses could, therefore, be simply associated with increased energy expenditure 
with the maintenance of the RT program. However, in recent studies, we reported 
observations suggesting that liver fat accumulation in Ovx animals may be regulated 
differently than adipocytes fat accumulation. For instance, we observed that adding RT to a 
program of FR is more successful in preventing fat accumulation in liver than FR alone 
[17]. These observations are in line with recent findings that the absence of estrogens alters 
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gene expressions in liver favoring a reduction in lipid oxidation and an increase in 
lipogenesis [10]. We previously suggested that RT may specifically regulate the levels of 
fat accumulation in liver by, for instance, maintaining the level of fat oxidation in spite of 
estrogen deficiency [17]. Although the present study does not provide any molecular and/or 
enzymatic evidence to support this interpretation, it does indicate that liver fat 
accumulation in Ovx rats is not solely regulated by an increased food intake. 
Although maintenance of RT attenuated the relapse of body weight and fat 
accumulation in the present study, body weight, and fat mass regain was better preserved 
with the maintenance of the FR regimen. This indicates that the FR component of the 
FR+RT program is more important than the RT component. Nevertheless, the contribution 
of the RT component cannot be considered as non-significant since its maintenance 
attenuated the relapse. In a recent study [27], we observed that substituting FR by RT 
resulted in a large attenuation of body weight and fat regain. This suggests that a RT 
program might have a larger impact on maintaining body weight and fat loss when it is 
newly introduced into a program of weight loss than when it is already part of a FR weight 
loss program. It is likely that the biological interactions between FR and RT upon reducing 
body weight and fat accumulation are dominated by the FR intervention. Cessation of FR 
would therefore have a larger impact on fat regain than training cessation, as observed in 
the present study. This interpretation means that the impact of a RT program on body 
weight and fat mass reduction and/or maintenance is different when pursued in conjunction 
or in substitution of a FR program. Although identification of regulatory mechanisms are 
beyond the aim of the present study, it is possible on a speculative point of view, that gene 
expression and activity of key enzymes involved in metabolic pathways that may have an 
impact on body weight and fat accumulation are activated to a different extent whether RT 
is conducted simultaneously or substituted to a FR regimen.  
Exercise training and FR may both affect peripheral insulin sensitivity. Although 
the rats in the present study were not in an overnight fasted state (3 h fast or more), we 
calculated HOMA-IR to obtain an index of insulin sensitivity. This index indicates a 
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deterioration of insulin sensitivity with Ovx, which was improved by the FR+RT program. 
Interestingly, maintenance of either FR or RT contributed similarly to the maintenance of 
low levels of HOMA-IR score. Although insulin sensitivity in the present context should be 
measured using more sophisticated techniques, the present data suggest that RT may be an 
asset in maintaining gain in insulin sensitivity after withdrawal of ovarian hormones.  
As previously reported, Ovx resulted in an increase in muscle mass most likely 
secondary to an increase in body weight [17,30]. Accordingly, muscle mass was 
significantly decreased following the FR+RT program and re-increased after the total 
abandon of the program. It is likely, as it is the case for body weight and fat mass 
accumulation, that these changes in muscle mass are related more to the FR than to the RT 
component of the weight loss program. The incapacity of the RT program to maintain 
muscle mass when combined to FR program might be due to the substantial food restriction 
(26%) used in the present study. It is difficult to determine the real impact of the RT 
program on muscle mass in this study due to the confounding effect of the FR program.  
In summary, results from the present study show that body weight and fat mass 
regain after the cessation of a weight loss program consisting of FR and RT in Ovx rats is 
minimized by the maintenance of FR regimen. Maintenance of RT program also constitutes 
an asset to attenuate body weight and fat mass regain, although the impact is less than 
maintaining FR alone. On a clinical point of view, the present results suggest that the 
maintenance of only one component of a FR+RT weight loss program constitutes a positive 
strategy to reduce body weight and fat mass relapse in post-menopausal women. 
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Table 1. Final body weight (Wt.), uterus Wt., plasma estradiol, and sum of 4 leg muscles 
Wt. measured after 13 and 18 weeks. 
 
Values are mean ± SE. Sham: sham-operated; Ovx: ovariectomized; FR: food restriction; 
RT: resistance training; cont: continued; w/o: without. 5 week Ovx rats were first submitted 
to a program of weight loss consisting of a FR regimen combined with a program of RT 
(OvxFR+RT) for 8 weeks (weeks 6–13). Following this period, OvxFR+RT rats were sub-
divided into 3 groups for an additional 5weeks (weeks 14–18): One group stopped both RT 
and FR (Ovx[postFR-RT]), one group stopped only RT (Ovx[contFRw/oRT]), and the last 
group stopped only FR (Ovx[contRTw/oFR]). 
a Significantly different from Ovx[contFRw/oRT], P < 0.05. 
aa P < 0.01. 
bb Significantly different from Ovx[contRTw/oFR], P < 0.01. 
** Significantly different from Ovx[postFR-RT], P < 0.01. 
§§ Significantly different from Ovx, P < 0.01. 
++ Significantly different from OvxFR+RT, P < 0.01.  
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Table 2. Plasma concentrations of glucose, insulin, HOMA-IR, and free fatty acids (FFA) 
measured after 13 and 18 weeks. 
 
Values are mean ± SE. HOMA-IR: homeostatic model assessment of insulin resistance 
[(glucose: mmol/l × insulin: mlU/ml)/22.5] (3 h fasted state). Abbreviations and groups are 
described in Table 1. 
aa Significantly different from Ovx[contFRw/oRT], P < 0.01. 
b Significantly different from Ovx[contRTw/oFR], P < 0.05. 
bb P < 0.01. 
§ Significantly different from Ovx, P < 0.05. 
§§ P < 0.01. 
* Significantly different from Ovx[postFR-RT], P < 0.05. 
** P < 0.01.  
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Legends 
 
Fig. 1. Schematic representation of the experimental design. The tip of the arrow 
indicates the time of sacrifice. Sham: sham-operated, Ovx: ovariectomized, FR: food 
restriction, and RT: resistance training. 
 
Fig. 2. Body weight change (A) and average daily food intake (B) during weeks 0–
5, weeks 6–13, and weeks 14–18. Values are mean ± SE. §§ Significantly different from 
Ovx, P < 0.01. ++Significantly different from OvxFR+RT, P < 0.01. *Significantly 
different from Ovx[postFR-RT], P < 0.05, **P < 0.01. aa: Significantly different from 
Ovx[contFRw/oRT], P < 0.01. bb: Significantly different from Ovx[contRTw/oFR], P < 
0.01. Abbreviations and groups are described in Table 1.  
 
Fig. 3. Liver triacylglycerol (TAG) concentration (A) and plasma concentration of 
TAG (B) measured after 13 and 18weeks. Values are mean ± SE. § Significantly different 
from Ovx, P < 0.05, §§P < 0.01. +Significantly different from OvxFR+RT, P < 0.05, ++P 
< 0.01. *Significantly different from Ovx[postFR-RT], P < 0.05, **P < 0.01. aa: 
Significantly different from Ovx[contFRw/oRT], P < 0.01. bb: Significantly different from 
Ovx[contRTw/oFR], P < 0.01. Abbreviations and groups are described in Table 1.  
 
Fig. 4. Sum of 3 intra-abdominal (mesenteric, urogenital, and retroperitoneal) fat 
depots weight (A) and sub-cutaneous fat pad weight (B) measured after 13 and 18 weeks. 
Values are mean ± SE. § Significantly different from Ovx, P < 0.05, §§P < 0.01. 
++Significantly different from OvxFR + RT, P < 0.01. **Significantly different from 
Ovx[postFR-RT], P < 0.01. a: Significantly different from Ovx[contFRw/oRT], P < 0.05, 
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aa: P < 0.01. bb: Significantly different from Ovx[contRTw/oFR], P < 0.01. Abbreviations 
and groups are described in Table 1. 
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ABSTRACT 
Objective: To determine whether a training state protects against the metabolically 
deleterious effects of ovariectomy on liver and adipocytes fat accumulation in rats.  
Design: Female rats were randomly assigned to each group (n = 8 rats/group). The 
animals were first either exercise trained (Tr) for 6 weeks or kept sedentary (Sed) before 
being sham operated (Sham), ovariectomized (Ovx), or Ovx with 17 β-estradiol 
supplementation (OvxE2). Following surgery, sedentary rats either remained sedentary 
(Sed-Sed) or undertook exercise training for 6 weeks (Sed-Tr) while exercise-trained rats 
either became sedentary (Tr-Sed) or resumed exercise training (Tr-Tr).  
Results: Body weight and energy intake along with intra-abdominal and 
subcutaneous fat pad weights and homeostasis model assessment of insulin resistance 
(HOMA-IR) were significantly (P < 0.01) increased in the Ovx group compared to the 
Sham and OvxE2 groups. Rats kept in a sedentary state after surgery showed the higher (P 
< 0.05) values for all of these variables whether they were trained or not before surgery 
(Sed-Sed and Tr-Sed), indicating no protective effect of a previous exercise-trained state. 
On the other hand, training conducted after surgery resulted in a lowering of fat mass and 
HOMA-IR whether rats had been trained or not before surgery (Sed-Tr and Tr-Tr), 
indicating the effectiveness of exercise training even initiated after surgery. These 
responses were independent of surgery. Interestingly, liver triacylglycerol concentrations 
followed a pattern of responses identical to fat mass with the exception that all of the 
responses were observed only in the Ovx group (P < 0.05).  
Conclusion: There is no protective effect of a previous exercise-training state on 
ovariectomy-induced liver and adipocytes fat accumulation if rats remain sedentary after 
ovariectomy. However, training conducted concurrently with estrogen withdrawal has 
protective effects, especially on liver fat accumulation, whether or not rats were previously 
trained. 
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INTRODUCTION 
Cardiovascular disease risk factors, such as lipid profile deterioration, become more 
pronounced after menopause,1 making coronary heart disease a leading cause of death 
among postmenopausal women.2 A large proportion of women after menopause gain 
weight, especially in the abdominal region, resulting in several metabolic 
disturbances.3,4(for a review, see reference 5)  Recent evidence also suggests that 
menopause is associated with the development of a state of hepatic steatosis.6,7  Excessive 
fat accumulation in hepatocytes has been shown to play an important role in the 
development of insulin resistance8 and is even considered as a hepatic component of the 
metabolic syndrome.9,10  The importance of the phenomenon is highlighted by recent data 
suggesting that ectopic fat in liver may be even more important than visceral fat in 
characterization of metabolically benign obesity in humans.11 Liver fat accumulation with 
estrogen withdrawal is also well documented in animals in which ovariectomy leads to 
increased adipose tissue and liver fat accretion.12-15 Considering the consequences of 
ectopic fat accumulation in liver, there is an important need to establish strategies to 
counteract this effect in postmenopausal women. 
Although results from animal and human studies have shown a decrease in body 
weight and abdominal fat accumulation following estrogen replacement,16-18 long-term 
estrogen supplementation in postmenopausal women could increase several health risks, 
such as cancer, and their utilization is still under debate.19,20 Lifestyle modifications (diet 
and physical activity), therefore, constitute an interesting alternative to circumvent 
metabolic problems arising with menopause. Cross-sectional and randomized controlled 
trials studies indicate that physical activity can be an effective intervention to improve body 
fat and/or metabolic risks variables in overweight/obese postmenopausal women.21-23 On 
the other hand, recent reviews6,24 of lifestyle modifications on liver lipid infiltration in 
humans indicate a paucity of specific information on liver lipid infiltration associated with 
menopause. In animals, we recently reported that resistance training prevents liver fat 
accumulation in ovariectomized rats.12,25 There is, however, no information to our 
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knowledge on the effects of an endurance training program on the prevention of liver fat 
accumulation with estrogen withdrawal. 
An interesting question related to exercise and estrogen withdrawal is whether 
women who exercise regularly during their reproductive period are protected against the 
deleterious metabolic effects of menopause. In the only study conducted in women that 
addressed this question, cross-sectional comparisons indicated that there was no difference 
in percent body fat between premenopausal and postmenopausal trained runners.26 There 
are, however, no randomized controlled trial studies on the effects of exercise on body fat 
and abdominal fat throughout menopause that would allow a firm conclusion on whether 
physical activity may prevent or limit the gain of total fat and abdominal fat during 
menopause. In the present study, we addressed this question using an animal model that 
allowed us to test a complete design of trained and untrained animals before and after 
withdrawal of estrogens. 
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METHODS 
Animal care 
Female Sprague-Dawley strain rats weighing 180-200 g (8-week-old) were obtained 
from Charles River (St-Constant, PQ, Canada) and were housed individually. The 12 : 12-h 
light-dark cycle started at 06:00 and the room temperature was maintained at 20-23°C. All 
rats received usual pellet rat chow, referred to as the standard diet (SD; 12.5% fat; 63.2% 
carbohydrate; 24.3% protein; kcal, Agribrands Purina Canada, Woodstock, ON) and had 
free access to tap water. Rats were randomly sequentially assigned to each group (n = 8 
rats/group) that had initial similar mean body mass and were treated similarly in terms of 
daily manipulations. The experiments described in this report were conducted according to 
the directives of the Canadian Council on Animal Care after institutional approval. 
Groups, surgery and post-surgery treatment 
A schematic representation of the experimental design is presented in Figure 1. Rats 
were first submitted to an endurance training (Tr) program, or remained sedentary (Sed) for 
6 weeks. Exercise training consisted of continuous running on a motor-driven rodent 
treadmill (Quinton Instruments, Seattle, WA), 5 times/week. The rats progressively ran 
from 15 min/day at 15 m/min, 0% slope, up to 60 min/day at 26 m/min, 10% slope, for the 
last 4 weeks. At the end of this first 6-week period, two groups (n = 8/group) of Sed and Tr 
animals were sacrificed. All other rats were ovariectomized (Ovx), sham-operated (Sham), 
or Ovx with 17β-estradiol supplementation (OvxE2). 
Ovariectomy was conducted according to the technique described by Robertson et 
al.27 Animals were injected with antibiotics (Tribrissen 24%; 0.125cc/kg, subcutaneously) 
for 3 days, beginning the day before surgery. For surgery, rats were anesthetized with a 
mixture of ketamine-xylazine (61.5-7.6 mg/kg, intraperitoneally). In OvxE2 rats, a small 
17β-estradiol pellet (0.72 mg; 0.012 mg/d) with a biodegradable carrier binder efficient for 
60 days (catalog no. SE-121; Innovative Research of America, Sarasota, FL) was placed 
subcutaneously between the shoulder blades. El-Mas and Abdel-Rahman28 previously 
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showed that this estrogen regimen produces physiological levels of the hormone. A placebo 
60-day pellet containing the binding carrier only was used in all other rats (catalog no. SC-
111).  
One week (7th week) was provided for surgery and recovery in all rats. During this 
time, all rats were only submitted to a habituation running protocol (10-15 min/day) in the 
last 3 days. Thereafter, sedentary rats either remained sedentary (Sed-Sed) or started 
training (Sed-Tr) after surgery and trained rats either stopped (Tr-Sed) or resumed training 
(Tr-Tr) after surgery (Figure 1). Training resumed for rats assigned to training groups the 
next week for 5 more weeks. This second program of training was adjusted to be the same 
for all training rats and to be close to the training program used before surgery. The post-
surgery exercise-trained rats progressively ran from 15 min/day at 15 m/min, 0% slope, up 
to 60 min/day at 26 m/min, 10% slope, for the last 3 weeks. Body weight and food intake 
were monitored every other day. Rats were sacrificed at the end of this second treatment 
(week 12). Exercise animals were sacrificed 48 h after the last exercise bout. 
Blood and tissue sampling 
Rats were sacrificed between 09:00 and 12:00. Remaining food was removed from 
the animal’s cage at least 3 h before sacrifice. Immediately after complete anesthesia 
(pentobarbital sodium; 50mg/kg, intraperitoneally), the abdominal cavity was opened 
following the median line of the abdomen and approximately 4 ml of blood was collected 
from the abdominal vena cava (<45s) into syringes pre-treated with 
ethylenediaminetetraacetic acid (15%; EDTA). Blood was centrifuged (3000 rpm; 4°C; 12 
min; Beckman GPR Centrifuge) and the plasma was kept for further analysis. Several 
organs and tissues were removed and weighed (Mettler AE 100) in the following order: 
liver, uterus, mesenteric, urogenital, retroperitoneal, and subcutaneous fat deposits along 
with four skeletal muscles of the right hind limb (soleus, plantaris, medial gastrocnemius, 
and lateral gastrocnemius). All tissue samples were frozen in liquid nitrogen immediately 
after they were weighed. The liver median lobe was freeze-clamped and used for 
triacylglycerol (TAG) determination. Mesenteric fat pad consisted of adipose tissue 
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surrounding the gastro-intestinal tract from the gastro-oesophageal sphincter to the end of 
the rectum, with special care taken in distinguishing and removing pancreatic cells. 
Urogenital fat pad included adipose tissue surrounding the kidneys, ureters and bladder as 
well as ovaries, oviducts and uterus. Retroperitoneal fat pad was taken as that distinct 
deposit behind each kidney along the lumbar muscles. For subcutaneous fat deposit 
measurement, a rectangular piece of skin was taken on the right side of each animal, from 
the median line of the abdomen to the spine and the right hip to the first rib as described by 
Krotkiewski and Bjorntorp.29 All rats were visually inspected for presence or not of ovaries, 
and uteri were excised and weighed to confirm ovariectomy or sham surgery. All tissue and 
plasma samples were stored at -78°C until analyses were performed.  
Biochemical analyses 
Plasma insulin concentrations were determined with radioimmunoassay test kit 
distributed by LINCO Research (St. Charles, Missouri, USA). Plasma glucose 
concentrations were determined with the use of a glucose analyzer (Yellow Springs 
Instruments 2300, Yellow Springs, OH). Plasma glucose and insulin values were used to 
calculate a homeostasis model assessment of insulin resistance (HOMA-IR) as follows: 
glucose (mmol/l)  insulin (mIU/L)/22.5.30 Plasma free fatty acid (FFA) and TAG 
concentrations were determined with an enzymatic colorimetric assay available from Roche 
Diagnostics (Mannheim, Germany) and SIGMA (Saint Louis, Missouri, USA), 
respectively. Liver TAG concentrations were estimated from glycerol released after 
ethanolic KOH hydrolysis by using commercial kit from SIGMA (Saint Louis, Missouri, 
USA).  
Statistical analysis 
Values are expressed as means ± standard error. Statistical analyses were performed 
by two-way ANOVA for non-repeated measures design using surgery and training as main 
effects. Fisher’s post hoc test was used in the event of a significant (P < 0.05) F ratio. 
Comparisons between Sed and Tr rats at week 6 were conducted using unpaired t-test. 
  
 
124
RESULTS 
All Ovx animals showed lower (P<0.01) uterus weight than Sham and OvxE2 rats, 
indicating total ovariectomy (Table 1). Moreover, uterus weight of OvxE2 rats was higher 
(P<0.01) compared to Sham rats, suggesting hyperestrogenic state in OvxE2 animals. The 
6-week pre-surgery training increased (P<0.05) muscle weight compared to the weights in 
the sedentary group. Ovariectomy resulted in higher (P<0.01) muscle weight and plasma 
glucose concentrations compared to Sham and OvxE2 rats (Table 1). Estrogen replacement 
in OvxE2 led to lower plasma glucose concentrations than in Sham rats (P<0.01). There 
was no treatment effect on the sum of weights of the four leg muscles and plasma glucose 
concentrations. 
Body weight (Figure 2a), energy intake (Figure 2b), intra-abdominal and 
subcutaneous fat pad weights (Figure 3), plasma insulin concentrations (Table 1), and 
HOMA-IR values (Figure 4) show a similar pattern of responses to the treatments.  All of 
these parameters were significantly (P<0.01) increased in the Ovx compared to the Sham 
and OvxE2 groups. Body weight and HOMA-IR values were also significantly (P<0.01) 
reduced in OvxE2 compared to Sham rats (Fig. 2a and 4). Endurance exercise training 
conducted after the surgery decreased all of these variables in all groups whether rats have 
been trained or not before the surgery (Tr-Tr and Sed-Tr) (P<0.05). This also implies that 
rats kept sedentary after surgery had the higher values whether they were trained or not 
before surgery (Sed-Sed and Tr-Sed).  
Liver TAG concentrations follow a similar response pattern to fat mass with the 
exception that the responses were seen only in the Ovx group (Figure 5). More specifically, 
Ovx-induced liver fat accumulation was reduced in trained rats independently of whether 
the rats were trained or not before surgery. As a rule, the higher values of liver fat 
accumulation were found if the rats that were kept sedentary after the ovariectomy, whether 
they were trained or not before surgery.  
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The only exceptions to the response patterns observed for all above-mentioned 
variables were plasma TAG and FFA. There were no effects of ovariectomy with and 
without E2 replacement on plasma TAG levels (Table 1). When rats were trained, either 
before or after surgery or both, plasma TAG concentrations show lower (P<0.01) values 
compared to rats continuously maintained in the sedentary state (Sed-Sed). On the other 
hand, the 6-week pre-surgery training decreased the plasma FFA levels (P<0.01) compared 
to the levels in sedentary animals (Table 1, week 6). Opposite to liver TAG, ovariectomy 
resulted in lower (P<0.01) plasma FFA concentrations than in Sham and OvxE2 in all 
treatment groups. Lower (P<0.01) plasma FFA values were found in Sed-Tr condition 
compared to Sed-Sed and Tr-Sed groups. 
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DISCUSSION 
As previously reported13,31,32 body weight, energy intake, adipose tissue mass, and 
muscles weights were higher in Ovx compared to Sham rats. These effects of ovariectomy 
were reversed in E2-supplemented rats. The present results also confirm recent 
observations that ovariectomy leads to liver TAG accretion in rats12-15,33-35 that is prevented 
by E2 treatment.13,35 E2 supplementation in Ovx rats has been reported to counteract the 
effects of estrogens withdrawal by lowering food intake, decreasing lipoprotein lipase 
activity, and increasing adipose tissue lipolysis and energy expenditure.36 Similar to 
estrogen supplementation, the present results indicate that endurance exercise training 
conducted concurrently with the induction of ovariectomy significantly attenuated liver and 
adipocytes fat accumulation. However, an endurance exercise training state acquired before 
ovariectmoy does not provide any protective effects against ovariectmoy-induced fat 
accumulation if exercise is discontinued after the ovariectmoy.  
Training before Ovx 
Results of the present study indicate that there is no protective effect of a previous 
endurance exercise training state on ovariectmoy-induced liver and adipocytes fat 
accumulation in rats. The 6-week pre-surgery training resulted in decreased intra-
abdominal fat and plasma FFA levels and increased muscle weight in comparison to 
animals kept sedentary, indicating that this endurance exercise training program was 
successful. In spite of this, fat accumulation in liver and adipocytes 6 weeks after 
ovariectmoy was increased to a similar extent in rats kept sedentary, whether they were 
trained or not before surgery (Sed-Sed vs Tr-Sed). The increased food intake observed in 
the Tr-Sed group to the level of the Sed-Sed group may have contributed to the higher fat 
accretion. Linked to this observation, it is important to consider that, in addition to the 
estrogen withdrawal, rats in the Tr-Sed group were also submitted to an exercise training 
cessation stimulus. Regular exercise has been reported to lower body weight and adiposity 
level in rats.37 This has been shown to predispose to a rapid weight and fat regain upon 
cessation of a regular exercise training program.38 Increased lipid storage after cessation of 
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exercise training has been attributed to multiple factors including increased tissue 
sensitivity to insulin, increased lipoprotein lipase activity, and reduced resting and exercise-
induced energy expenditure.39-42 In a previous study38 it was found that endurance exercise 
training had no protective effect on fat accumulation following the initiation of a high-fat 
diet upon training cessation. Similar to these findings, the present study indicates that 
exercise training has no protective effect on fat accumulation following estrogens 
withdrawal upon training cessation. The only exception is the plasma TAG levels, which 
seem to be protected by a previous training state. Indeed, plasma TAG levels were lower in 
Tr-Sed than in Sed-Sed animals.  
Training after Ovx   
Training did have a significant metabolic impact when conducted concurrently with 
the induction of estrogens withdrawal. This first confirms what has been observed in 
previous animal studies,12,25 that exercise training is a lifestyle modification that has an 
important metabolic impact to circumvent the deleterious effects of estrogen withdrawal. 
The present study adds to these reports by specifying that training must be pursued 
concurrently to the ovariectmoy to be effective. Although concurrent exercise training had 
a significant impact on fat mass in Ovx animals, it is important to consider that the effects 
of training on body weight, energy intake, fat mass, and HOMA-IR were not limited to the 
Ovx animals since Sham and OvxE2 rats also benefited from these adaptations if training 
was pursued between weeks 7 and 12. This suggests that training offers a protection against 
fat accumulation not only against estrogens withdrawal but also against fat accumulation in 
Sham and OvxE2 animals. In addition, endurance training initiated before the period of 
observation (weeks 0 to 6) did not seem to offer any supplementary protection since there 
were no significant differences between rats in Sed-Tr and Tr-Tr groups. However, the fact 
that rats had to stop training after surgery and slowly resumed training thereafter may 
explain the absence of additive effects of training in the Tr-Tr compared to the Sed-Tr rats. 
The present study was not aimed at studying the underlying mechanisms involved in the 
protective effect of endurance exercise training on fat accumulation in Ovx animals. 
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However, based on the present data, it is clear that the mechanisms involved in the training 
effects (i.e. increased energy expenditure) must be maintained to be effective.  
The special case of liver fat accumulation with Ovx 
One of the tissues that is particularly affected by fat accumulation in Ovx animals12-
15 as well as in postmenopausal women6,7 is the liver. In the present study, the fact that liver 
fat accumulation was the only measured parameter in which the training and detraining 
status affected only the Ovx animals (not the Sham and OvxE2 groups), is of particular 
interest. Molecular and physiological results from recent studies conducted by our group 
indicated that liver lipid infiltration in Ovx animals may be related to reduced hepatic lipid 
oxidation and increased lipogenesis.35,43 Results from these studies provided some support 
to the concept that estrogens act intrahepatically as a protective tool against liver lipid 
infiltration. Subsequently, we observed that lipid accumulation in liver following estrogen 
deprivation is hardly reversible by diet changes in this hormonal context, thus supporting 
the concept that fat accumulation in liver of Ovx animals is not only linked to increased 
energy intake.34 In this context, it is particularly interesting to observe that training 
conducted concurrently with ovariectmoy largely reduced liver fat accumulation. This 
suggests that endurance exercise training could induce metabolic adaptations in liver 
similar to estrogen. Since liver fat accumulation has been shown to play an important role 
in the development of insulin resistance,8 the present data support the importance of 
endurance exercise training to prevent liver lipid infiltration in postmenopausal women.  
Metabolic consequences of fat accumulation in Ovx rats 
To get an insight into the possibility that exercise training may overcome the 
metabolic consequences of fat accumulation in Ovx rats, we calculated the HOMA-IR as an 
index of insulin sensitivity. As previously observed,12 ovariectomy was associated with a 
deterioration of insulin sensitivity. Although insulin sensitivity in the present context 
should be measured with more sophisticated techniques, it is revealing that training 
conducted concurrently with the induction of ovariectmoy resulted in the same pattern of 
positive effects as those observed for liver and adipocytes fat accumulation. This 
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observation is a further indication that training conducted concurrently with estrogen 
withdrawal is an asset not only to reduce liver and adipocytes fat accumulation, but also to 
attenuate the metabolic consequences associated with it. 
In conclusion, results of the present study indicate that training has a significant 
impact on reducing fat accumulation in liver and adipocytes, as well as increasing insulin 
sensitivity based on HOMA-IR index, in Ovx rats if conducted concurrently with the 
initiation of the estrogen withdrawal. In addition, training conducted before the 
ovariectmoy does not provide any protection against the metabolic deleterious effects of 
ovariectmoy if endurance exercise training is not pursued after ovariectmoy. From a 
clinical point of view, these observations suggest that sedentary women who undertake an 
endurance exercise training program during the menopause transition will benefit from it 
even though they have not been training before. Although further clinical randomized 
studies in women are warranted, the present results also emphasize the recommendation 
that trained women should keep on training after menopause. 
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Table 1. Uterus weight, sum of weights of four leg muscles and plasma glucose, insulin, 
triacyglycerol (TAG), free fatty acid (FFA) concentrations in sedentary (Sed) and training 
(Tr) rats for 6 weeks before surgery and subsequently divided into groups of sham-operated 
(Sham) and ovariectomized rats without (Ovx), and with 17β-estradiol replacement 
(OvxE2) evaluated 6 weeks after surgery (total 12 weeks). Pre-surgery sedentary rats either 
remained sedentary (Sed-Sed) or started training (Sed-Tr) after surgery while pre-surgery 
trained rats either stopped (Tr-Sed) or kept on training (Tr-Tr) after surgery. Values are 
mean ± standard errors; n = 8 rats/group  
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a, Significantly different from Tr group, P < 0.05, aa, P < 0.01; b, surgery effect: 
significantly different from Sham and OvxE2 groups, P < 0.05; c, surgery effect: 
significantly different from Sham group, P < 0.05; d, treatment effect: significantly 
different from Sed-Sed groups, P < 0.05, dd, P < 0.01; e, treatment effect: significantly 
different from Tr-Sed groups, P < 0.05, ee, P < 0.01 
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LEGENDS 
 
Figure 1. Schematic representation of the experimental design. The tip of the arrow 
indicates the time of sacrifice. Sham, sham-operated; Ovx, ovariectomized; OvxE2, 
ovariectomized þ 17β-estradiol replacement. Pre-surgery sedentary (Sed) rats either 
remained sedentary (Sed-Sed) or started training (Sed-Tr) after surgery while pre-surgery 
training (Tr) rats either stopped (Tr-Sed) or kept on training (Tr-Tr) after surgery (n = 8 
rats/group) 
 
Figure 2. Final body weight (a) and daily energy intake (b) in sedentary (Sed) and 
training (Tr) rats for 6 weeks before surgery and subsequently divided into groups of sham-
operated (Sham) and ovariectomized rats without (Ovx) and with 17 β-estradiol 
replacement (OvxE2) evaluated 6 weeks after surgery (total 12 weeks). Pre-surgery Sed 
rats either remained sedentary (Sed-Sed) or started training (Sed-Tr) after surgery while 
pre-surgery Tr rats either stopped (Tr-Sed) or kept on training (Tr-Tr) after surgery. Values 
are mean ± standard error, n = 8 rats/group. *, Surgery effect: significantly different from 
Sham and OvxE2 groups, P < 0.01; #, surgery effect: significantly different from Sham 
group, P < 0.01; ++, treatment effect: significantly different from Sed-Sed groups, P < 
0.01; §§, treatment effect: significantly different from Tr-Sed groups, P < 0.01 
 
Figure 3. Sum of the weights of three intra-abdominal fat pads (a) and 
subcutaneous fat pad weight (b) in sedentary (Sed) and training (Tr) rats for 6 weeks before 
surgery and subsequently divided into groups of sham-operated (Sham) and ovariectomized 
rats without (Ovx) and with 17β-estradiol replacement (OvxE2) evaluated 6 weeks after 
surgery (total 12 weeks). Pre-surgery Sed rats either remained sedentary (Sed-Sed) or 
started training (Sed-Tr) after surgery while pre-surgery Tr rats either stopped (Tr-Sed) or 
kept on training (Tr-Tr) after surgery. Values are mean ± standard error, n = 8 rats/group. a, 
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Significantly different from Tr group, P < 0.05; * surgery effect: significantly different 
from Sham and OvxE2 groups, P < 0.01; ++, treatment effect: significantly different from 
Sed-Sed groups, P < 0.01; §§; treatment effect: significantly different from Tr-Sed groups, 
P < 0.01 
 
Figure 4. HOMA-IR values in sedentary (Sed) and training (Tr) rats for 6 weeks 
before surgery and subsequently divided into groups of sham-operated (Sham) and 
ovariectomized rats without (Ovx) and with 17β-estradiol replacement (OvxE2) evaluated 6 
weeks after surgery (total 12 weeks). Pre-surgery Sed rats either remained sedentary (Sed-
Sed) or started training (Sed-Tr) after surgery while pre-surgery Tr rats either stopped (Tr-
Sed) or kept on training (Tr-Tr) after surgery. Values are mean ± standard error, n = 8 
rats/group. *, Surgery effect: significantly different from Sham and OvxE2 groups, P < 
0.01; #, surgery effect: significantly different from Sham group, P < 0.01; +, treatment 
effect: significantly different from Sed-Sed groups, P < 0.05, ++ P < 0.01; §§, treatment 
effect: significantly different from Tr-Sed groups, P < 0.01. HOMA-IR, homeostatic model 
assessment of insulin resistance [glucose (mmol/l) x insulin (mIU/l)/22.5], (3-h fasted state) 
 
Figure 5. Liver triacylglycerol (TAG) concentrations in sedentary (Sed) and 
training (Tr) rats for 6 weeks before surgery and subsequently divided into groups of sham-
operated (Sham) and ovariectomized rats without (Ovx) and with 17β-estradiol replacement 
(OvxE2) evaluated 6 weeks after surgery (total 12 weeks). Pre-surgery Sed rats either 
remained sedentary (Sed-Sed) or started training (Sed-Tr) after surgery while pre-surgery 
Tr rats either stopped (Tr-Sed) or kept on training (Tr-Tr) after surgery. Values are mean ± 
standard error, n = 8 rats/group. *, Surgery effect; significantly different from Sham and 
OvxE2 groups, P < 0.01; +, treatment effect: significantly different from Sed-Sed groups, P 
< 0.05; §, treatment effect: significantly different from Tr-Sed groups, P < 0.05 
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Abstract 
Objective: We hypothesized that the reduction in liver fat accumulation known to 
occur with exercise training in ovariectomized rats is associated with reduced expression of 
genes involved in lipogenesis while favoring the expression of transcription factors 
regulating lipid oxidation. We also tested the hypothesis that liver fat accumulation in Ovx 
rats is associated with an increased gene expression of several pro-inflammatory markers 
and that exercise training would attenuate this response.  
Methods: Sprague-Dawley female rats (14 wk of age) were randomly divided into 
four groups of sedentary sham-operated (Sham), ovariectomized (Ovx), and Ovx with 17β-
estradiol supplementation (OvxE2), and one group of endurance exercise trained Ovx 
(OvxTr). Endurance exercise training consisted of continuous running on a motor-driven 
rodent treadmill 5 times/wk for 5 wk.  
Results: Fat accumulation in liver as well as in adipose fat depots was higher (P < 
0.01) in Ovx than in Sham rats. This response was prevented in OvxE2 and OvxTr animals. 
Liver gene expressions of sterol regulatory element-binding protein 1-c (SREBP-1c), 
stearoyl coenzyme A desaturase 1 (SCD-1), carbohydrate response element binding protein 
(ChREBP), and acetyl-CoA carboxylase (ACC) were increased with estrogens withdrawal 
(P < 0.01). These responses were corrected with E2 supplementation alone as well as with 
training alone. Conversely, hepatic peroxisome proliferator-activated receptor α (PPAR-α) 
mRNA levels were lower (P<0.01) after estrogen removal compared to Sham rats. The 
lower hepatic PPAR-α mRNA levels in Ovx rats were re-increased by E2 replacement or 
by exercise training. Gene expression of pro-inflammatory cytokines including inhibitor-
kappaB kinase β (IKKβ) and interleukin-6 (IL-6) as well as protein content of nuclear 
factor-kappa B (NF-кB) was higher (P < 0.01) in Ovx than in Sham animals. As for the 
metabolic markers, E2 supplementation or exercise training prevented the expression of the 
pro-inflammatory markers.  
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Conclusion: It is concluded that exercise training, similarly to estrogens reduces fat 
accumulation in liver of Ovx rats possibly through regulation of key molecules involved in 
lipogenesis and lipid oxidation. Exercise training also acts as estrogens in properly 
regulating the expression of inflammatory bio-markers in liver of Ovx rats. 
 
Key words: Physical activity, Fatty liver, Estrogens, Lipogenesis, Lipid oxidation, 
hepatic inflammation, Menopause.  
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Introduction 
Menopause is associated with the development of a state of hepatic steatosis (1, 2). 
The importance of this phenomenon is enlightened by the fact that excessive fat 
accumulation in liver plays an important role in the development of insulin resistance (3). 
Recent findings even indicate that ectopic fat in liver may be more important than visceral 
fat in characterization of metabolically benign obesity in humans (4, 5). Hepatic and 
adipocytes fat accumulation is also well documented in animal models of menopause (6-9). 
Ovariectomized (Ovx) rats as well as aromatase receptor knockout mice exhibit hepatic fat 
accumulation that seems to be triggered by changes in expression of genes that increase 
lipid synthesis and reduce lipid oxidation in liver (10, 11). There is also recent 
physiological evidence that fatty acid oxidation is reduced in liver of Ovx rats (12). An 
alternative to counteract liver fat accumulation with estrogen withdrawal might be exercise 
training. It was reported that exercise training prevents fat accumulation in liver of high-fat 
fed rats (13, 14). Specifically in Ovx rats, there is some evidence that resistance training in 
conjunction with food restriction reduces liver fat accumulation (15, 16). Recently, we 
reported that endurance exercise training when conducted concurrently with estrogen 
withdrawal prevented liver fat accumulation in Ovx rats (17). These studies, however, did 
not provide any mechanistic information on the action of exercise training in preventing 
liver fat accumulation in Ovx animals. The first aim of the present study was to test the 
hypothesis that exercise training reduces the expression of key molecules involved in lipid 
synthesis while favoring the expression of molecules involved in fat oxidation. 
In recent years, it has become clear that metabolic disturbances related to fat 
accumulation in adipocytes and ectopic tissues, such as liver, are associated with sub-
clinical inflammation (18, 19). For instance, Cai et al. showed that inflammatory gene 
expression increases in liver of both transgenic and high-fat fed mice with increasing 
adiposity (20). Regardless of the causes, the nuclear factor-kappa B (NF-кB) is activated in 
hepatocytes and pro-inflammatory cytokines including tumor necrosis factor α (TNF-α) and 
interleukin 6 (IL-6) are overproduced in fatty liver (21). As such, it is relevant to 
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investigate if liver lipid accumulation resulting from estrogens deficit in Ovx rats leads to 
sub-acute hepatic inflammation and if it is so, whether exercise training attenuates this 
response as it does for fat accumulation. Consequently, the second objective of the present 
study was to investigate the effects of ovariectomy and exercise training on gene expression 
of inflammatory bio-markers in the liver. 
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Methods 
Animal care. Female Sprague-Dawley strain rats (Charles River, St-Constant, PQ, 
Canada), weighing 180-200g upon their arrival were housed individually and had ad 
libitum access to food and tap water. All rats received usual pellet rat chow, referred to as 
the standard diet (SD; 12.5% fat; 63.2% carbohydrate; 24.3% protein; kcal, Agribrands 
Purina Canada, Woodstock, ON). Their environment was controlled in terms of light 
(12:12-h light-dark cycle starting at 6:00 AM), humidity and room temperature (20-23°C). 
The experiments described in this report were conducted according to the directives of the 
Canadian Council on Animal Care after institutional approval. 
Groups. 6 weeks after their arrival to our laboratory, rats were randomly divided 
into sedentary sham-operated (Sham), sedentary ovariectomized (Ovx), sedentary Ovx with 
17β-estradiol supplementation (OvxE2), and Ovx rats that underwent endurance exercise 
training (OvxTr) groups (n = 6-8 rats / group). Body weight and food intake were 
monitored three times per week. All animals were sacrificed 6 weeks after the surgical 
manipulations. 
Surgery. Ovariectomy surgery was conducted according to the technique described 
by Robertson et al. (22). Animals were injected with antibiotics (Tribrissen 24%; 
0.125cc/kg, SC) for three days, beginning the day before surgery. For surgery, rats were 
anesthetized with a mixture of ketamine-xylazine (61.5-7.6 mg/kg, IP). In OvxE2 rats, a 
small 17β-estradiol pellet (0.72 mg; 0.012 mg/d) with a biodegradable carrier binder 
efficient for 60 days (catalog no. SE-121; Innovative Research of America, Sarasota, FL) 
was placed SC between the shoulder blades. El-Mas and Abdel-Rahman previously showed 
that this estrogen regimen produces physiological levels of the hormone (23). A placebo 
60-day pellet containing the binding carrier only was used in all other rats (catalog no. SC-
111). 
Exercise protocol. One week (7th wk) was provided for surgery and recovery in all 
rats. During this time, all animals were submitted to a habituation running protocol (10-15 
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min/day) in the last 3 days of the week. Exercise training (Tr) consisted of continuous 
running on a motor-driven rodent treadmill (Quinton Instruments, Seattle, WA), 5 times per 
week for the duration of the experiment (5 weeks after recovery). OvxTr rats progressively 
ran from 15 min/day at 15 m/min, 0% slope, up to 60 min/day at 26 m/min, 10% slope for 
the last 3 wk. All Tr animals were restrained from training 48 h before sacrifice. 
Blood and tissue sampling. Rats were sacrificed between 09:00 and 12:00 AM. 
Food was removed from the animal’s cage at least 3 h before sacrifice. Immediately after 
complete anesthesia (pentobarbital sodium; 50mg/kg, IP), the abdominal cavity was opened 
following the median line of the abdomen and approximately 4 mL of blood was collected 
from the abdominal vena cava (<45s) into syringes pre-treated with 
ethylenediaminetetraacetic acid (15%; EDTA). Blood was centrifuged (3000 rpm; 4°C; 12 
min; Beckman GPR Centrifuge) and the plasma was kept for further analysis. The liver was 
excised and the median lobe was immediately snap-frozen and was used for triacylglycerol 
(TAG) determination, mRNA extraction and quantification, and Western blotting. The 
uterus, mesenteric and retroperitoneal fat pads along with 4 skeletal muscles of the right 
hind limb (soleus, plantaris, medial gastrocnemius, and lateral gastrocnemius) were, 
thereafter, rapidly excised and weighed. All tissue and plasma samples were stored at -78° 
C until analyses were performed. Finally, the right femur wet weight was obtained 
following a short boiling period in a 10% KOH solution in order to remove the surrounding 
tissue. 
Biochemical analyses. Plasma insulin and leptin concentrations were determined 
with radioimmunoassay test kit distributed by LINCO Research (St. Charles, Missouri, 
USA). Plasma glucose concentrations were determined with the use of a glucose analyzer 
(Yellow Springs Instruments 2300, Yellow Springs, OH). Plasma glucose and insulin 
values were used to calculate a homeostasis model assessment of insulin resistance 
(HOMA-IR) as follows: glucose (mmol/l)  insulin (mIU/L)/22.5 (24). Plasma CRP 
concentrations were measured with Synchron LX Systems (Beckman Coulter) using Alpco 
Diagnostics kit (cat. no 41-CRPRT-E01). Liver TAG concentrations were estimated from 
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glycerol released after ethanolic KOH hydrolysis by using commercial kit from SIGMA 
(Saint Louis, Missouri, USA).  
Isolation of RNA and quantitative real-time (RT) polymerase chain reaction 
(PCR): RNA extraction and cDNA preparation. Quick-frozen tissue samples of the liver 
were powdered with cold mortar and pestle, and approximately 100 mg was used for the 
isolation of RNA. Total RNA was extracted by the guanidine thiocyanate method and 
mRNA purified using PureLink RNA Mini Kit (Invitrogen) according to the 
manufacturer’s instruction.  Total RNA were reverse transcribed in a final volume of 100 
μL using the High Capacity cDNA Reverse Transcription Kit with random primers 
(Applied Biosystems, Foster City, CA) as described by the manufacturer. Reverse 
transcribed samples were stored at -20°C. A reference RNA (Human reference total RNA, 
Stratagene, Ca) was also transcribed in cDNA. 
qPCR Reactions- ABI Gene Expression Assay – Endogenous controls. Gene 
expression level was determined using primer and probe sets from Applied Biosystems 
(ABI Gene Expression Assays, http://www.appliedbiosystems.com). PCR reactions for 384 
well plate formats were performed using 2 µl of cDNA samples (20-50 ng), 5 µl of the 
Express qPCR SuperMix (Invitrogen), 0.5 µl of the TaqMan® Gene Expression Assays 
(20X) and 2.5 µl of water in a total volume of 10 µl. The following pre-developed 
TaqMan® assays were used as endogenous control: GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase). 
TaqMan reactions using Universal Probe Library. Gene expression level was also 
determined using primer and probe sets from Universal ProbeLibrary from Roche, a fast, 
specific and flexible format for quantitative real-time PCR (https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp). PCR reactions for 384 well plate formats were 
performed using 2 µl of cDNA samples (50 ng), 5 µl of the Express qPCR SuperMix 
(Invitrogen), 2 µM of each primer and 1 µM of the Universal TaqMan probe in a total 
volume of 10 µl. The primer sets served to generate amplicons are presented in Table 1.  
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Detection and analysis. The ABI PRISM® 7900HT Sequence Detection System 
(Applied Biosystems) was used to detect the amplification level and was programmed 
FAST with an initial step of 3 min at 95˚C, followed by 45 cycles of 5 seconds at 95˚C and 
30 seconds at 60˚C. All reactions were run in triplicate and the average values were used 
for quantification. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as 
endogenous control. The relative quantification of target genes was determined using the 
UUCT method. Briefly, the Ct (threshold cycle) values of target genes were normalized to 
an endogenous control gene (GAPDH) (UCT = Ct target – Ct GAPDH) and compared with a 
calibrator: UUCT = UCt Sample - UCt Calibrator. Relative expression (RQ) was calculated 
using the Sequence Detection System (SDS) 2.2.2 software (Applied Biosystems): RQ = 2-
UUCT.  
Western blot analysis. 100 mg of liver was homogenized in TPER containing 
protease inhibitors (10 μl/ml pepstatin, and 1 mM phenylmethanesulfonyl fluoride and 
100U Trasylol) using a polytron and centrifuged at 12000g, 4°C for 10 min. The infranatant 
was collected with a blunt-tipped Pasteur pipette and stored at −80°C until protein 
determination. SCD-1 and NFκB contents in the liver were determined by Western blotting. 
All samples (10μg of proteins) were separated on a SDS-polyacrylamide gel and electro-
transferred onto Hybond-Cextra nitrocellulose membranes (Amersham). Membranes were 
blocked overnight in Tris-buffered saline containing 0.05% Tween 20 (TBST 0.05%) and 
5% nonfat dry milk at 4°C. The blot was then incubated with specific primary antibodies: 
SCD-1 (kindly provided by Dr. J. Ozols, University of Connecticut Health Center, Storrs, 
CT) and NFκB p65 (sc-109, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. 
After two washes in TBST (0.05%) and two washes in TBST (0.05%) containing 0.5% 
nonfat dry milk, the membrane was incubated for 30 min with a horseradish peroxidase-
conjugated anti-rabbit/anti-mouse IgG (Bm chemiluminescence Western Blotting Kit, cat. 
no. 11520709001, Roche Diagnostics) at room temperature. Then the membrane was 
washed four times for 20 min each time in TBST (0.05%) before a chemiluminescence 
substrate (cat. no. 11520709001, Roche Diagnostics) was applied to the membrane. The 
resulting signal was detected on scientific imaging films (Amersham). Densitometric 
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measurement of the bands was performed using Image J software and expressed as 
arbitrary units. Equal protein loading was determined using mouse anti-β-actin primary 
antibodies (Sigma, Saint Louis, Missouri, USA). 
Statistical analysis. Values are expressed as mean ± S.E. Statistical analyses were 
performed using one-way ANOVA for non-repeated measures. Fisher’s PLSD post-hoc test 
was used in the event of a significant (P < 0.05) F ratio.  
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Results 
Ovariectomy in rats, as compared to Sham operation resulted in higher body weight 
(P<0.05), daily energy intake, mesenteric and retroperitoneal fat depots weights (P<0.01) 
as well as higher plasma concentrations of insulin (P=0.059), glucose, leptin, and HOMA-
IR index (P < 0.01; Table 2). Furthermore, Ovx resulted in lower femur (14%; P<0.05) and 
uterus weight (80%; P<0.01) indicating physiological effects of ovariectomy. As a rule, 
almost all changes induced by ovariectomy were prevented either by 17β-estradiol 
supplementation or endurance exercise training (Table 2). The exceptions were uterus 
weight and an increase in plasma glucose concentrations in OvxTr rats. On the other hand, 
the higher uterus weight (29%; P<0.01) in OvxE2 compared with Sham rats suggests that 
17β-estradiol supplementation was slightly supraphysiological. There was no significant 
difference between Sham and Ovx rats in relative muscle weight (Table 2). However, 
exercise training and 17β-estradiol supplementation in Ovx rats increased leg muscles 
weight (P<0.01). 
Liver TAG levels were 71% higher (25.1±2.7 vs 14.6±1 mg/g; P<0.01) in Ovx than 
in Sham rats (Fig. 1A).  The ovx-induced hepatic fat accumulation was prevented either by 
17 β-estradiol replacement or exercise training. Quantitative real-time polymerase chain 
reaction (RT-PCR) analysis showed higher (P<0.01) gene expression of hepatic lipogenic 
transcription factors sterol regulatory element-binding protein 1-c (SREBP-1c) (57%; Fig. 
1B), stearoyl coenzyme A desaturase 1 (SCD-1) (87%; Fig. 2A), and carbohydrate response 
element binding protein (ChREBP) (63%; Fig. 2C), as well as acetyl-CoA carboxylase 
(ACC)  (68%; Fig. 2D) mRNA levels in Ovx than in Sham rats. Protein quantification by 
Western blot analysis confirmed results obtained by RT-PCR for SCD-1. We found greater 
SCD-1 (40%; P<0.01; Fig. 2B) protein abundance in the liver of Ovx rats. These Ovx-
induced higher lipogenic gene expressions and protein content were totally prevented either 
by E2 replacement or by endurance training. Conversely, the hepatic oxidative transcription 
factor peroxisome proliferator-activated receptor α (PPAR-α) mRNA was lower (31%; 
P<0.01) in Ovx than in Sham rats while hepatic peroxisome proliferator-activated receptor-
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γ coactivator 1α (PGC-1α) mRNA showed the same trend, although the differences did not 
reach significant statistical levels (Fig. 3). Again, lower PPAR-α mRNA levels were re-
established in OvxE2 animals and Ovx trained rats. 
To get an insight into how estrogen withdrawal and endurance exercise training 
affect the hepatic inflammatory response, we measured gene expression of several 
inflammatory markers in liver. Ovx, as compared to Sham rats, resulted in higher (P<0.01) 
hepatic pro-inflammatory IL-6 (37%) and inhibitor of kappa B kinase beta (IKKB) (35%) 
mRNA expressions (Fig. 4). Moreover, we found higher NF-кB (51%; P<0.01; Fig. 4C) 
protein level in liver of Ovx rats than in Sham control. Likewise the metabolic markers, 
Ovx-induced changes of inflammatory markers were totally prevented with estrogen 
replacement as well as with endurance training. TNF-α and interleukin 10 (IL-10) mRNA 
were not significantly changed by the ovariectomy (Fig. 5). Nevertheless, TNF-α gene 
expression was significantly (P<0.05) lower in OvxE2 and OvxTr rats compared to Ovx 
animals. Interestingly, the ratio IL-10/TNF-α was higher (P<0.05) in OvxE2 and OvxTr 
animals compared to Ovx group indicating better inflammatory status under these 
physiological conditions (E2 supplementation and exercise training) (Fig. 5).  
Opposite to the other inflammatory markers, we found that plasma C reactive 
protein (CRP) level as well as hepatic CRP mRNA expression were significantly lower 
(P<0.01) in Ovx rats than in Sham animals (Fig. 6).  These responses were re-increased 
when E2 replacement was provided. On the other hand plasma CRP remained decreased in 
OvxTr and hepatic CRP mRNA level in this group was midway between Ovx and OvxE2 
groups at the Sham group’s level.  
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Discussion 
The present observation that liver TAG content was 71% higher in Ovx than in 
Sham rats is consistent with previous findings showing that estrogen withdrawal results in a 
state of hepatic steatosis (7, 9, 25). We also confirmed previous reports that 17β-estradiol 
supplementation as well as endurance exercise training prevents the accretion of lipids in 
the liver of Ovx rats (10, 12, 17). This indicates that endurance exercise training has an 
important estrogenic-like effect on the prevention of hepatic steatosis in Ovx animals. It is 
important to recall that pair-feeding in Ovx rats does not completely prevent fat 
accumulation in liver ((26) and unpublished data from our lab). Consequently, Ovx-induced 
hepatic fat accumulation cannot be totally attributed to the increased food intake. To shed 
some light on possible mechanisms involved in the metabolic action of exercise training in 
liver of Ovx rats, we analyzed the expression of influential genes that regulate hepatic fat 
accumulation.  
Kinetic studies in human subjects indicate that ~26% of hepatic TAG accumulation 
can be accounted for by de novo lipogenesis (27). Therefore, it has been assumed that the 
enhancement of de novo lipid synthesis is a primary disorder in hepatic steatosis which is 
tightly stimulated by lipogenic molecules such as the transcription factor SREBP-1c and 
the ACC downstream enzyme (28). Similarly, SCD-1 is an enzyme that represents a pivotal 
control point in lipid homeostasis by catalyzing a rate-limiting step in the biosynthesis of 
monounsaturated fats, which are required for TAG synthesis (29, 30). On the other hand, 
the transcription factor ChREBP also plays an essential role in the regulation of gene 
expression of enzymes (i.e. ACC and fatty acid synthase (FAS)) involved in lipogenesis 
derived from glucose metabolism (31). Recently, it was reported that ovariectomy 
increased SREBP-1c and SCD-1 gene expressions (10). The present results complement 
these previous findings by showing that the gene expression of transcription factor 
ChREBP and the important downstream ACC enzyme are also elevated in Ovx rats. The 
main contribution of the present study, however, is the original finding that endurance 
exercise training, similarly to E2 supplementation, counteracted these hepatic molecular 
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disturbances by cancelling the increase in SREBP-1c, SCD-1, ChREBP, and ACC 
transcripts in Ovx rats. This effect was confirmed at the protein level for SCD-1. These 
molecular responses strongly suggest that endurance training depressed lipogenesis in liver 
of Ovx rats, thus constituting a possible mechanism that contributes to the decrease in liver 
fat accumulation. 
In addition to increased lipogenesis, recent data indicate that fatty acid oxidation is 
reduced in the liver of estrogen-deficient animals (10-12). The present decrease in gene 
expression of PPAR-α in liver of Ovx rats, which is re-increased in OvxE2 animals, is in 
agreement with this finding. PPAR-α is the key transcriptional regulator of peroxisomal, 
mitochondrial, and microsomal fatty acid oxidation systems in the liver (32, 33). Although 
less pronounced, PPAR-α transcript was also higher in OvxTr than in Ovx rats. This 
suggests that in addition to suppression of higher rates of liver lipogenesis, a re-increase in 
lipid oxidation in exercise trained Ovx rats, may also contribute to the prevention of liver 
lipid accumulation in Ovx rats. 
The fact that exercise training acts similarly as estrogen supplementation in 
changing gene expression of key molecules involved in fat metabolism in the liver of Ovx 
rats raises the question if both of these actions take place through a similar pathway. The 
molecular and biological mechanisms underlying the metabolic actions of estrogen in liver 
are weakly understood. Estrogen (E2) is a steroid hormone whose actions are 
predominantly mediated by genomic mechanisms of E2 action through its nuclear receptors 
(ER) α or β (34). E2 has also been shown to have rapid non-genomic biological actions 
through membrane bound subpopulations of ER (35-37). D`Eon et al. recently reported that 
E2 treatment decreases gene expression of SREBP-1c and its target genes FAS and ACC in 
liver (38). It is possible that E2 directly regulates SREBP-1c which contains an estrogen 
response element (ERE) in its promoter region (39). On the other hand, D`Eon et al. 
showed that E2 rapidly activates AMP-activated protein kinase (AMPK) in skeletal muscle 
(38). Since SREBP-1c expression is down-regulated by AMPK (40), they suggested that 
the decreased expression of SREBP-1c in muscle reflects AMPK activation by non-
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genomic action of E2 (38). Because physical exercise has been reported to activate AMPK 
in liver (41), it is thus possible that the decreased expression of SREBP-1c and its 
downstream targets (SCD-1 and ACC) by exercise training may be mediated through the 
AMPK pathway. Important increases in hepatic ERα mRNA levels have also been found in 
endurance-trained rats (42). Although further work is needed to clarify the precise 
mechanism, the present data support the contention that both E2 and exercise training act 
on hepatic expression of the same target genes to reduce de novo lipogenesis while favoring 
fat oxidation.  
An additional support to the interpretation that exercise training acts similarly as 
estrogen supplementation is the finding that exercise training had similar effects as E2 
supplementation in reducing peripheral fat accumulation and plasma leptin levels, as well 
as peripheral insulin resistance (as measured from HOMA-IR index) in the present Ovx 
rats. These results are in line with the recent report of Saengsirisuwan et al. who showed 
Ovx-induced features of the insulin resistance syndrome are largely attenuated by 
endurance exercise training alone and estrogen replacement alone (43). On the whole, the 
present results suggest that exercise training in Ovx rats acts similarly as estrogen 
supplementation in regulating not only liver fat but also peripheral fat accumulation and its 
metabolic consequence, the insulin resistance.  
The second objective of the present study was to investigate if gene expressions of 
some important inflammatory biomarkers were increased in liver of Ovx rats and the 
impact of exercise training on this response. Regardless if the cause is the liver fat 
accumulation or the pro-inflammatory substances in the portal circulation; pro-
inflammatory cytokines such as IL-6 and TNF-α are overproduced in fatty liver (21). Two 
main signaling pathways have been linked to inflammation associated with obesity: the NF-
κB pathway, activated by IKKB; and the c-Jun NH2-terminal kinase (JNK) pathway (44). 
In recent years, it was found that the NF-κB and IKKB signaling pathway activated by pro-
inflammatory cytokines is a key modulator of inflammation and insulin resistance (45). Cai 
et al. (20) demonstrated that lipid accumulation in liver (induced either by high-fat diet or 
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by transgenic expression of IKKB in mice) leads to sub-acute hepatic inflammation and 
downstream cytokine production, IL-6 showing the strongest evidence of pathological 
involvement. In the present study, mRNA levels of IL-6 and IKKB as well as protein 
content of NF-κB increased in liver of Ovx rats. E2 replacement neutralized these elevated 
gene expressions indicating that estrogens contribute to maintenance of low expression 
level of these inflammatory biomarkers in the liver. This is in line with results of Kireev et 
al. (46) and Hamilton et al. (47) who reported an increase in IL-6 and TNF-α gene 
expression in liver and heart of Ovx rats, respectively, that was corrected by 17β-estradiol 
replacement. To our knowledge, the present study is the first to report that endurance 
exercise training acts like estrogens in neutralizing increased gene expression of IL-6, 
IKKB, and NF-κB in liver of Ovx rats.  Although this effect of exercise training in liver 
might be solely linked to the reduction of fat accumulation, it is important to recall that 
physical activity mediates anti-inflammatory effects in skeletal muscle and fat tissue (18). 
Regular exercise protects against diseases associated with chronic low-grade systemic 
inflammation and the long-term effect of exercise training may be ascribed to the anti-
inflammatory response elicited by an acute bout of exercise (48).  
TNF-α plays a central role in initiating and sustaining inflammation (49), while IL-
10 demonstrates potent anti-inflammatory properties through inhibiting the production of 
various pro-inflammatory cytokines including IL-6 and TNF-α  (50). In fact, Kaur et al. 
(51) showed that a proper balance between IL-10 and TNF-α rather than any of these 
individual cytokine responses is of physiological importance. Hashem et al. (52) reported 
that IL-10/TNF-α ratio is a convenient predictive biomarker for investigation of fatty liver 
of different grades including steatohepatitis and nonalcoholic fatty liver disease. The 
present increase in gene expression ratio of IL-10/TNF-α with E2 replacement as well as 
with endurance exercise training in Ovx animals, therefore, indicates an improvement in the 
status of the liver in both of these conditions.  
An intriguing response related to inflammatory biomarkers in the present study is 
the observation that plasma CRP as well as CRP mRNA levels in liver decreased in Ovx 
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animals and re-increased with E2 replacement. A number of investigations have reported 
that hormone replacement therapy increases plasma CRP levels (53-55) especially in 
response to oral conjugated estrogens (56). Although it has been argued that rats are not an 
appropriate model to investigate the relationship between estrogen and CRP, Yang et al. 
showed that ovariectomy in rat reduces plasma CRP and that estrogen replacement raises 
the plasma CRP levels (57). It has been suggested that E2-mediated increase in CRP may 
not represent an up-regulation of pro-inflammatory response mediated by upstream 
cytokines but rather are related to a secondary mechanism (56). Nevertheless, in the present 
study, plasma and liver mRNA expression of CRP did not increase in endurance exercise 
trained Ovx rats. This indicates that whatever the clinical significance of the action of E2 
on increasing CRP levels, this is not carried out in exercise trained rats. 
In summary, results of present study indicate that exercise training acts as estrogen 
supplementation in properly regulating gene expressions of molecular markers involved in 
liver fat accumulation and bio-markers of sub-clinical inflammation in Ovx rats. On a 
clinical point of view, the present results reiterate the importance of exercise training as a 
tool to alleviate some of the metabolic consequences of low estrogenic status in post-
menopausal women. 
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Table 1. Oligonucleotide primers used for quantitative real-time polymerase chain reaction. 
Genes Accession no Sense primer (5′-3′) Antisense primer (5′-3′) 
SREBP-1c XM_213329 TACAGCGTGGCTGGGAAC GGCTGAGCGATACAGTTCAA 
SCD-1 NM_139192 GCCCTGTACGGGATCACA CCCAGGGCACTGATAAGGTA 
ChREBP NM_133552 AATCCCAGCCCCTACACC CTGGGAGGAGCCAATGTG 
ACC NM_022193 ACAGAGATGGTGGCTGATGTC GATCCCCATGGCAATCTG 
PPAR-α NM_013196 TCGGAGGGCTCTGTCATC CATCTGTACTGGTGGGGACA 
PGC-1α NM_031347 GAAGCGGGAGTCTGAAAGG GTAAATCACACGGCGCTCTT 
CRP NM_017096 CTTCTCTCAGGCTTTTGGTCA GCTTCCAGTGGCTTCTTTGA 
IKKB NM_053355 GAGAGCGTCAGCTGTGTCC CCCCACACTTTCCTCATCTG 
IL-6 NM_012589 CCCTTCAGGAACAGCTATGAA ACAACATCAGTCCCAAGAAGG 
TNF-α NM_012675 GCCTCTTCTCATTCCTGCTC GAGCCCATTTGGGAACTTCT 
IL-10 NM_012854 GCTCAGCACTGCTATGTTGC AATGGCCTTTGCTGGTCTT 
GAPDH NM_017008 CCCTCTGGAAAGCTGTGG AGTGGATGCAGGGATGATG 
 
SREBP-1c: sterol regulatory element-binding protein-1c; SCD-1: stearoyl CoA desaturase-
1; ChREBP: carbohydrate response element-binding protein; ACC: acetyl-CoA 
carboxylase; PPAR-α: peroxisome proliferator activated receptor-α; PGC-1α: Peroxisome 
proliferator-activated receptor-γ coactivator 1α; CRP: C-reactive protein; IKKB: inhibitor 
of kappa B kinase beta; IL-6: interleukin 6; TNF-α: tumor necrosis factor-α; IL-10: 
interleukin 10; GADPH: glyceraldehyde-3-phosphate dehydrogenase. 
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Table 2. Effects of ovariectomy, estrogen replacement, and exercise training on 
anthropometric and physiological parameters. 
 Sham Ovx OvxE2 OvxTr 
Body weight (g) 345±13 388±12abb 314±5 357±13b 
Energy intake (kj/day) 333±11 378±11aabbc 331±9 341±9 
Mesenteric fat weight (g) 9.52±0.9 13.6±1.2aabbcc 8.72±0.6 7.83±0.5 
Retroperitoneal fat weight (g) 5.69±0.8 8.69±1aabbcc 5.67±0.6 5.0±0.4 
Uterus weight (mg) 602±51 123±9aabb 774±64aa 123±8aabb 
Leg muscles weight (g/100gBW) 0.62±0.02 0.6±0.02bbcc 0.67±0.02 0.71±0.02aa 
Femur weight (g/100gBW) 0.21±0.007 0.18±0.01abbcc 0.24±0.009aa 0.22±0.007 
Plasma insulin (pM) 263±22 387±52 (abc)* 231±34 250±50 
Plasma glucose (mM) 8.62±0.3 10.5±0.4aabb 6.83±0.3aacc 9.59±0.3a 
HOMA-IR (mIU/l) 16.8±1.5 29.8±4.5aabbc 11.9±1.8 17.7±3.7 
Plasma Leptin (ng/ml) 8.85±1.1 13.6±1.3aabbcc 8.81±0.9 6.63±0.8 
 
a Significantly different from Sham, P < 0.05, aa P < 0.01. b significantly different from 
OvxE2, P < 0.05, bb P < 0.01. c significantly different from OvxTr, P < 0.05, cc P < 0.01. 
(abc)*: (P = 0.059). Values are mean ± S.E., n = 6-8 rats/group. 
Sham: sham-operated; Ovx: ovariectomized; OvxE2: ovariectomized with 17β-estradiol 
supplementation; OvxTr: ovariectomized + endurance exercise training. 
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Figure legends 
Figure 1. Liver triacyleglycerol (TAG) (A) and sterol regulatory element-binding 
protein-1c (SREBP-1c) mRNA (B) in sham-operated (Sham), ovariectomized (Ovx), 
ovariectomized with 17β-estradiol supplementation (OvxE2), and ovariectomized + 
endurance exercise training (OvxTr) rats. aa Significantly different from Sham, P < 0.01. b 
significantly different from OvxE2, P < 0.05, bb P < 0.01. c significantly different from 
OvxTr, P < 0.05, cc P < 0.01. Values are mean ± S.E., n = 6-8 rats/group. 
 
Figure 2. Hepatic lipogenic mRNA and protein abundance in sham-operated 
(Sham), ovariectomized (Ovx), ovariectomized with 17β-estradiol supplementation 
(OvxE2), and ovariectomized + endurance exercise training (OvxTr) rats. aa Significantly 
different from Sham, P < 0.01. b significantly different from OvxE2, P < 0.05, bb P < 0.01. 
cc significantly different from OvxTr, P < 0.01. Values are mean ± S.E., n = 6-8 rats/group. 
SCD-1: stearoyl CoA desaturase-1; ChREBP: carbohydrate response element-binding 
protein; ACC: acetyl-CoA carboxylase.  
 
Figure 3. Hepatic lipid oxidative mRNA abundance in sham-operated (Sham), 
ovariectomized (Ovx), ovariectomized with 17β-estradiol supplementation (OvxE2), and 
ovariectomized + endurance exercise training (OvxTr) rats. aa Significantly different from 
Sham, P < 0.01. bb significantly different from OvxE2, P < 0.01. c significantly different 
from OvxTr, P < 0.05. Values are mean ± S.E., n = 6-8 rats/group. 
PPAR-α: peroxisome proliferator activated receptor-α; PGC-1α: Peroxisome proliferator-
activated receptor-γ coactivator 1α.  
 
Figure 4. Hepatic gene expression of interleukin 6 (IL-6) (A), inhibitor of kappa B 
kinase beta (IKKB) (B), and the protein abundance of nuclear factor-kappa B (NF-кB) (C) 
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in sham-operated (Sham), ovariectomized (Ovx), ovariectomized with 17β-estradiol 
supplementation (OvxE2), and ovariectomized + endurance exercise training (OvxTr) rats. 
a Significantly different from Sham, P < 0.05, aa P < 0.01. bb significantly different from 
OvxE2, P < 0.01. c significantly different from OvxTr, P < 0.05, cc P < 0.01. Values are 
mean ± S.E., n = 6-8 rats/group. 
 
Figure 5. Hepatic gene expression of tumor necrosis factor-α (TNF-α) (A), 
interleukin 10 (IL-10) (B), and IL-10/TNF-α ratio (C) in sham-operated (Sham), 
ovariectomized (Ovx), ovariectomized with 17β-estradiol supplementation (OvxE2), and 
ovariectomized + endurance exercise training (OvxTr) rats. b significantly different from 
OvxE2, P < 0.05. c significantly different from OvxTr, P < 0.05. Values are mean ± S.E., n 
= 6-8 rats/group.  
 
Figure 6. Plasma C-reactive protein (CRP) levels (A) and hepatic gene expression 
of CRP (B) in sham-operated (Sham), ovariectomized (Ovx), ovariectomized with 17β-
estradiol supplementation (OvxE2), and ovariectomized + endurance exercise training 
(OvxTr) rats. aa Significantly different from Sham, P < 0.01. bb significantly different from 
OvxE2, P < 0.01. cc significantly different from OvxTr, P < 0.01. Values are mean ± S.E., n 
= 6-8 rats/group. 
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Figure 2. 
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Figure 3. 
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Figure 4.  
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6A
OvxTrOvxE2OvxSham
aabbc
IL
-6
 m
RN
A 
(a
rb
itr
ar
y 
un
its
)
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8B
O vxTrO vxE2O vxSham
abbc
IK
KB
 m
RN
A 
(a
rb
itr
ar
y 
un
its
)
 
 
  
 
178
Figure 5. 
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Figure 6. 
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Chapter 6: General discussion and conclusion 
The general objective of the studies presented in this thesis was to provide 
information regarding treatment and prevention of hepatic steatosis development and 
adipocyte fat accumulation in the estrogen deficient animals using lifestyle modifications 
(i.e. exercise training) as an alternative strategy for hormone replacement therapy. Since 
prospective studies assessing the physiological and biochemical effects of exercise in 
humans is difficult to carry out in controlled settings [de Lemos, Reis et al. 2007], we used 
an ovariectomized animal model that provided us with an appropriate research tool to 
mimic the postmenopausal hormonal state. If confirmed in human studies, the observations 
in the presented studies would be clinically relevant to the growing menopausal population 
in a society defined by energy overconsumption. However, we acknowledge the fact that 
the conclusions of our studies are limited to the employed experimental model. Human 
aging/onset of menopause implies a continuum of estrogen changes. Our model of 
ovariectomy is an aggressive method of estrogen withdrawal and may result in changes in 
metabolic profile and gene expression that may differ from those imposed by menopause in 
humans. Nevertheless, given that the risk of all causes of mortality associated with surgical 
ovariectomy in women younger than 45 year-old is increased [Rocca, Grossardt et al. 
2006], we believe that our model and experiments still provide information reasonably 
relevant to basic research on estrogen related changes in metabolic profile and gene 
expression. In support of this, Barlet et al. and Kalu reported that the ovariectomized rat 
model is suitable for studying problems that are relevant to postmenopausal bone loss [Kalu 
1991; Barlet, Coxam et al. 1994].  
All Ovx animals in the four studies showed lower uterus weight and higher food 
intake, body weight and fat pads weight than Sham rats indicating typical morphologic 
changes associated with ovariectomy [Lemieux, Picard et al. 2003; Paquette, Shinoda et al. 
2007] thus confirming quality of total ovariectomy in our studies. Moreover, E2 
supplementation in the last two studies totally prevented these Ovx-induced changes 
confirming that the observed effects in Ovx rats were indeed related to estrogen shortage. 
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The four original studies presented in this thesis provided information regarding the 
treatment and prevention of ovariectomy-induced fat accumulation in adipocytes and 
hepatocytes by lifestyle modifications including restrictive diets and physical activity in the 
form of resistance and endurance exercise training. Since in recent years hepatic steatosis 
was recognized as a hepatic component of the metabolic syndrome, we focused on liver 
lipid accretion after ovariectomy. The data from the first two studies support the concept 
that resistance training might provide a successful alternative or complement to chronic 
restrictive diet for preventing body weight gain, peripheral fat accumulation, and liver lipid 
infiltration following estrogen withdrawal and for avoiding their relapse in Ovx rats. This 
positive effect of resistance training on liver TAG followed the changes in fat mass 
accumulation in Ovx rats. Therefore, it is reasonable to conclude that liver fat infiltration is 
largely associated to adipose tissue fat accumulation; highlighting the dominant central 
properties of estrogen withdrawal compared to intra-hepatic effects. In this regard, food 
restriction in ovariectomized animals would most probably reduce the amount of lipids 
taken up by the liver. On the other hand, resistance training can increase the energy 
expenditure counteracting the central effects of estrogen withdrawal. Nevertheless, it is 
possible that resistance training act intra-hepatically invigorating metabolic pathways in 
liver common to estrogens such as stimulating lipid oxidation inside the liver itself, in 
addition to increasing energy expenditure. As mentioned in the first study, the 
appropriateness of the present resistance training program needs to be addressed. Since it is 
difficult to use a resistance training program in rats without mobilizing several muscle 
groups, one may discuss that our results in the first two studies might be partially originated 
from aerobic adaptations of employed exercise program. In humans, a 6-month resistance 
training program in relatively healthy postmenopausal subjects did not contribute to 
improving the metabolic profile [Brochu, Malita et al. 2009]. Although the comparison 
between animal and human studies is difficult, the discrepancy between the two studies 
may be due to the intensity of employed programs and the better control of the training 
regimen in our animal studies. 
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We conducted our third study in an attempt to address the question whether women 
who exercise regularly during their reproductive period of life are protected against the 
deleterious metabolic effects of menopause. Contrary to our first two studies, we addressed 
this question using endurance exercise training. Using the Ovx animal model, we were able 
to test a complete design of trained and untrained animals before and after withdrawal of 
estrogens. The data from this study 1) confirmed our previous observations that 
ovariectomy leads to increased adipose tissue mass and liver TAG accretion that was 
prevented in E2-supplemented rats; 2) showed that there is no protective effect of a 
previous exercise-training state on ovariectomy-induced liver and adipocyte fat 
accumulation if rats remain sedentary after ovariectomy; 3) similarly to estrogen 
supplementation, endurance exercise training conducted concomitantly with estrogen 
induction has protective effect on ovariectomy-induced liver and adipocytes fat 
accumulation, whether or not rats were previously trained. Our observation that endurance 
exercise training has a strong influence on lowering body fat accumulation following a 
decrease in estrogen levels was recently confirmed by a research group in Germany [Zoth, 
Weigt et al. 2010]. Again, it is likely that mechanisms involved in exercise effects 
counteracted the central effects of estrogen withdrawal (increased energy expenditure) and 
induced intra-hepatic metabolic adaptations (decreased lipogenesis and increased hepatic 
lipid oxidation). More importantly, in this study we found that the liver lipid infiltration 
was the only measured parameter in which the training status affected only the 
ovariectomized rats (not the Sham and OvxE2 animals) increasing our interest about the 
intra-hepatic effects of estrogens and exercise training in Ovx rats. The role of estrogen in 
the regulation of energy homeostasis in females is well recognized. On the other hand, it is 
also well acknowledged that exercise training has beneficial effects on the metabolic 
syndrome. Considering the fact that pair-feeding in Ovx rats does not completely prevent 
fat accumulation in liver [unpublished data from our lab], we hypothesized that Ovx-
induced hepatic fat accumulation cannot be totally attributed to the central effects of 
estrogen withdrawal and our data in the fourth study open a new avenue for the 
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investigation of potential mechanisms that might explain benefits of exercise in 
postmenopausal women.   
Supporting the recent reports of Paquette et al. [Paquette, Wang et al. 2008; 
Paquette, Chapados et al. 2009], data of the fourth study confirms that withdrawal of 
estrogen affects hepatic pathways of lipid synthesis and oxidation. We showed that mRNA 
levels of SREBP1-c and ChREBP which are known as the two major transcription factors 
in hepatic lipogenesis and the gene expression of their downstream enzyme proteins SCD-1 
and ACC are up-regulated in Ovx animals; while gene expression of PPAR-α, the key 
transcriptional regulator of lipid oxidation in liver of Ovx rats was decreased. In this last 
study, we provided important information regarding the similar effects of exercise training 
and estrogen replacement therapy in ovariectomized animals. Our original findings show 
that endurance exercise training, similarly to E2 supplementation, counteracted these 
hepatic molecular disturbances by cancelling the increase in SREBP-1c, SCD-1, ChREBP, 
and ACC transcripts; while re-increasing gene expression of PPAR-α in Ovx rats. These 
observations suggest that exercise training acts as estrogen supplementation in properly 
regulating gene expressions of molecular markers involved in liver fat accumulation in 
ovariectomized rats. The moderately short duration of our endurance exercise training 
program (5 weeks) may be a limitation of our study. To comprehend the full effect of 
exercise training on Ovx-induced liver lipid accumulation, future studies should consider 
extending exercise training for longer periods and controlling the central effects of estrogen 
withdrawal such as using pair-feeding model. Moreover, the intensity of exercise training 
used in the present studies can be considered as substantial. Moderating the intensity of 
exercise training program in future studies will allow relating the results to the clinical 
researches in postmenopausal women. 
Since in recent years metabolic consequences of increased ectopic fat are associated 
with sub-clinical inflammation, we hypothesized that gene expressions of hepatic 
inflammatory bio-markers would be changed in Ovx animals. Results of our fourth study 
showed that mRNA levels of IL-6 and IKKB as well as protein content of NF-κB were 
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increased in liver of Ovx rats. As for metabolic markers, E2 supplementation alone or 
exercise training alone neutralized these elevated gene expressions. Moreover, we observed 
an increase in the ratio of IL-10/TNF-α gene expressions with E2 supplementation as well 
as with exercise training in Ovx rats. Although we are the first, to our knowledge, to put 
forward the concept that exercise training has an estrogenic-like effect on the improvement 
of pre-clinical inflammatory status in the liver of Ovx rats, it seems that further research is 
warranted to reach firm conclusion on the effect of exercise training on Ovx-hepatic-
steatosis-induced sub-clinical inflammation in postmenopausal hormonal state. 
Taken together, our results introduce the concept that exercise training can 
compensate estrogenic actions in the estrogen deficit context, at least to a certain extent of 
metabolic consequences. However, identification of mechanisms such as activation of 
estrogen receptors and downstream pathways stimulated by exercise training will permit to 
explore more details concerning this concept. As indicated by the results of this thesis, it 
seems that similarly to estrogen supplementation, exercise training prevents lipid 
accumulation in the liver of Ovx rats possibly through proper regulation of key intra-
hepatic molecules implicated in lipogenesis and lipid oxidation; and/or through its 
secondary effects on lowering lipid storage in adipocytes (Table 6).  
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Table 6. Estrogenic-like effects of exercise training on metabolic and inflammatory bio-
markers in Ovx rats. 
Intra-hepatic Effects  Secondary Effects 
Decreased lipogenesis  
• SREBP-1c mRNA 
• ChREBP mRNA 
• SCD-1  
• ACC mRNA 
 
Increased lipid oxidation 
• PPAR-α mRNA 
 
Improved inflammatory bio-markers 
• IL-6 mRNA 
• IKKB mRNA 
• NF-κB 
• TNF-α mRNA 
• IL-10/ TNF-α mRNA 
 
 Most possibly increased energy 
expenditure 
 
Improved insulin sensitivity and 
lipid profile  
 
Decreased intra-abdominal and 
subcutaneous fat pads 
 
See list of abbreviations for meaning of acronyms.  
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Conclusion 
The results of the studies presented in this thesis complement previous findings 
regarding the central (increased intra-abdominal fat) and intra-hepatic effects (pathways of 
liver lipogenesis and lipid oxidation) of estrogen withdrawal favoring the accumulation of 
TAG in hepatocytes of Ovx rats. Our results clearly indicate that exercise training (either in 
the form of resistance or endurance) has a significant impact on ovariectomy-induced 
deleterious metabolic effects including reducing fat accumulation in liver and adipocytes. 
In addition, we showed for the first time that exercise training in Ovx rats seems to 
stimulate estrogenic-like effects on the expression of genes involved in lipid accumulation 
and sub-clinical inflammation in the liver. This is of importance knowing the fact that two-
thirds of postmenopausal women are overweight and since utilization of hormone 
replacement therapy is under debate. Moreover, this thesis opens new avenue in designing 
clinical studies in women by promoting physical activity. 
From a clinical point of view, results of this PhD work confirm the recommendation 
of The Study of Women’s Health Across the Nation which suggests that ‘‘not only do 
women who enter menopause transition (midlife) with higher level of physical activity and 
maintain that level weigh less to begin with and gain less weight over time, but women who 
increase their level of activity in midlife, regardless of where they start from, also gain less 
weight’’ [Sternfeld, Wang et al. 2004]. Moreover, the results of the first two studies suggest 
that the application of resistance training can play a role to minimize the deleterious effects 
of menopause and may constitute a positive strategy to reduce body weight and fat mass 
relapse in postmenopausal women. These results are promising for health care staff 
providing advice to postmenopausal women for lifestyle changes that reduce the risks of 
insulin resistance, cardiovascular and coronary heart disease, and diabetes [Frank, Sorensen 
et al. 2005]. From a systemic review of randomized controlled exercise trials in 
postmenopausal women, it was recommended that early postmenopausal women could 
benefit from 30 minutes of daily moderate walking in one or three bouts combined with a 
resistance training program twice a week [Asikainen, Kukkonen-Harjula et al. 2004]. This 
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review indicates that such exercise training is likely to preserve normal weight and increase 
cardiovascular capacity, and improve disorders of lipid and carbohydrate metabolism. 
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